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Abstract 
Lipoprotein VLPs, known also as lipid-envelope VLPs, are expressed intracellularly in 
yeast, localised on the host endoplasmic reticulum (ER). The main challenge in production lies 
in  the  complexity  of  the  recovery  and  purification  process.  Using  the  Hepatitis  B  surface 
antigen (HBsAg) as the VLP model, strategies for exploiting the full potential of primary 
recovery operations to raise the overall process efficiency and throughput were investigated.  
Detergent-mediated liberation of HBsAg from the host endoplasmic reticulum is a 
critical step which influences product quality and yield and defines the characteristics of the 
resulting  process  stream.  Screening  studies  established  that  Triton  X-100  gave  superior 
performance if concentrations were maintained within the range of 0.2% v/v to 0.5% v/v. 
Concentrations  above  this  threshold  led  to  HBsAg  delipidation  and  loss  of  antigenicity. 
Increased  levels  of  co-liberated  host  protein  and  of  lipid  contamination  which  resulted  in 
poorer ultrafiltration performance were also observed.  
PEG and ammonium sulphate precipitations were investigated to reduce the level of 
host protein and lipid contaminants. In each case, although significant product enrichment was 
achieved, product loss of up to 50% was incurred owing to the difficulty of PEG precipitate 
recovery and resolubilisation and the lack of selectivity of the ammonium sulphate agent. A 
novel  selective  product  recovery  methodology  was  developed  in  which  an  additional 
centrifugation step was introduced post-cell disruption but prior to the addition of detergent. 
HBsAg  associated  with  the  ER  was  pelleted  allowing  bulk  cytosolic  contaminants  in  the 
supernatant to be eliminated. This approach was further enhanced by the use of moderate 
homogenisation pressures in the region of 400 bar. Recovery of active HBsAg improved by 
~20% under lower shear conditions and a further ~40% reduction in the level of host lipid 
contaminants  was  observed.  The  benefits  of  the  proposed  process  on  a  downstream 
chromatography step include better product capture and improved step yield.   
The  scalability  of  the  selective  recovery  method  relies  on  the  dewatering  and 
clarification  performance.  A  CARR  tubular  type  centrifuge  was  identified  to  be  the  most 
suitable equipment type for this purpose. Ultra scale-down centrifugation experiments were 
employed  to  predict  suitable  operating  conditions  for  a  pilot-scale  process  which  was 
subsequently carried out and successfully verified that the selective recovery methodology 
remained feasible upon scale-up.  
Overall, this study has demonstrated how the adoption of a rational approach to the 
design of primary purification operations can lead to significant improvements of downstream 
purification performance.     4 
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Chapter 1: Introduction 
Introduction    
 
 
1.1 Background and motivation to the project 
This study investigates  new strategies for improving the primary purification 
process for future generation lipid envelope virus-like particle (VLP) vaccines using the 
recombinant  hepatitis  B  surface  antigen  (HBsAg)  expressed  in  Saccharomyces 
cerevisiae as the VLP model. The findings presented in this study would benefit process 
design  for  novel  VLPs  bearing  similar  lipid-envelope  structures  and  chimeric  VLPs 
constructed on a HBsAg platform.  
VLPs are assemblies of virus capsid or envelope proteins mimicking the native 
viral structure but in the absence of the viral genome. In the form of VLPs, vaccine 
proteins  are  presented  in  their  natural  conformations  and  trigger  powerful  immune 
responses. Lacking viral DNA or RNA, VLPs offer a safe and effective vaccination 
approach compared to traditional vaccines which suffer from risks of viral reversion, 
recombination  or  re-assortment.  VLP  vaccines  against  hepatitis  B  and  human 
pappilomavirus (HPV) have been licenced while others are at different stages of the 
development pipeline (Grgacic and Anderson, 2006).  
Virus-like particles can be categorised broadly as simple non-envelope VLPs 
and  lipid-envelope  VLPs  (Noad  and  Roy,  2003).  The  lipid-envelope  subclass  is  of 
specific  interest  in  this  study  since  viruses  causing  many  diseases  including  HIV, 11 
 
dengue fever and hepatits B and C exist in envelope structures in the natural state (Bisht 
et al., 2001; Yao et al., 2000; Baumert et al., 1998; Betenbaugh et al., 1995). The lipid 
environment  is  important  for  the  correct  folding  and  presentation  of  the  antibody 
neutralising epitopes (Greco et al., 2007) however the re-creation of the virion lipid-
envelope is often difficult (Grunder et al., 2002). The lipoprotein structure of the pre-
established HBsAg particle can be used as a platform for the display of foreign epitopes 
which are otherwise difficult to reconstruct de novo (Netter et al., 2001; Bisht et al., 
2001; Michel et al., 2007; Greco et al., 2007).  
In  spite  of  the  obvious  merits  of  VLP  vaccines,  it  is  recognised  that  their 
potential has yet to be fully realised (Pattenden et al., 2005). One of the main reasons 
for this is the higher costs of production (Boisgerault et al., 2002). VLP vaccines require 
sophisticated and expensive technologies for production and characterisation compared 
to those in the production of live attenuated vaccines. The stricter regulatory oversight 
(Buckland, 2005) derived from the fact that vaccines are to be administered to healthy 
individuals impact every step in the manufacturing cycle and further contribute to the 
high  costs  of  production.  From  a  manufacturing  perspective,  changes  in  the  VLP 
microenvironment during processing could have significant impact on its biophysical 
attributes (Shi et al., 2005) and the process of producing the VLPs has been described as 
what defines the end product (Buckland, 2005).     
This project aims to address some of the challenges discussed above from the 
perspective of the VLP manufacturing process. It is well recognised that downstream 
processing is the main cost contributor in the manufacturing of VLPs. It is thus not 
surprising that process development efforts are centred on these operations. Primary 
purification  which  could  be  equally  critical  in  setting  the  backdrop  for  downstream 
operations and in determining the overall process performance is often overlooked. It is 12 
 
the target of this thesis to address some of the disparities in process design. Specific 
emphases in this study are on improving the performance of primary purification and 
optimising  primary  and  downstream  process  interactions  so  as  to  increase  overall 
process efficiency and throughput.        
Since the process defines the product, it is vital that the intrinsic physiochemical 
properties of the VLPs are taken into account at all stages of processing. Specifically for 
lipid-envelope  VLPs  such  as  the  HBsAg,  the  detergent  step  which  facilitates  VLP 
recovery  from  associated  membranous  organelles  could  present  a  hidden  challenge. 
Although high yield is important, equally so is the VLP potency. Hence, it is critical 
that the use of detergent does not have negative consequences on the conformation or 
composition of the VLP. High concentrations of detergent would favour VLP recovery 
based on reaction kinetics. Excess detergent, however, could detrimentally affect the 
VLP lipid constituents leading to reduced immunogenicity (Gavilanes et al., 1990). In 
this respect, the benefits of improved VLP recovery need to be traded-off with the risks 
of VLP activity loss when identifying the optimal operating range for the detergent step.  
Like most protein recovery operations, the cost in VLP production is dominated 
by the expensive and low throughput chromatographic operations (Przybycien et al., 
2004). Although alternatives to chromatography such as membrane filtration, aqueous 
two-phase  extractions,  crystallisation  and  membrane  chromatography  have  been 
proposed,  it  is  unlikely  that  the  use  of  chromatography  can  be  excluded  entirely. 
Nevertheless, the ability to reduce the reliance on chromatography and to improve its 
throughput is highly attractive (Leser and Asenjo, 1992; Tsoka et al., 2000; Przybycien 
et al., 2004). One means of achieving this is by maximising the potentials of the initial 
recovery and purification stage to attain significant levels of reduction in contaminants 
such  as  host  lipids  and  proteins,  higher  product  enrichment  and  lower  processing 13 
 
volumes entering the higher resolution downstream operations. This study proposes a 
two-tier strategy for this purpose: (1) by reducing the levels of host lipids and proteins 
which  are  co-released  into  the  process  stream  during  detergent-mediated  VLP 
liberation, and (2) by selectively removing lipid and protein contaminants in the process 
stream via the introduction of a bulk separation or fractionation step. 
Although  the  bulk  of  contaminants  from  S.cerevisiae  originate  from  the  cell 
cytosol, membranous organelles such as the endoplasmic reticulum (ER), golgi bodies 
and plasma membrane are also rich in proteins and lipids. It is likely that during the 
VLP liberation step by detergent, significant proportions of membrane associated lipids 
and proteins are co-released. VLP yield and the contamination levels would both vary 
as a function of the detergent concentration but could have different rates of release. 
Optimisation studies could be performed to identify a suitable operating range for the 
detergent  step  where  high  yields  of  VLP  are  achieved  without  the  expense  of  high 
contamination levels. The release rates of VLPs and contaminants during the detergent 
step could also be influenced by the degree of cell disruption and size of debris formed. 
Extensive  cell  disruption  could  improve  VLP  recovery  however  the  smaller  debris 
particulates formed would create larger surface area for the extraction of membrane 
lipids and proteins by detergent. Likewise, a trade-off study would be useful here to 
determine the suitable operating range.                     
    Different approaches are possible for improving the effectiveness of eliminating 
host-derived contaminants during primary purification. Precipitation using polyethylene 
glycol  (PEG)  or  ammonium  sulphate  is  commonly  employed  to  achieve  selective 
fractionation of VLP prior to downstream purification (Tsoka et al., 2000; Huang et al., 
2007, Wijnendaele et al., 1987). Although the use of PEG and ammonium sulphate 
precipitation has been demonstrated in the purification of the blood-derived HBsAg 14 
 
vaccine (Einarsson, 1983; Peterson et al., 1981), their application for the recombinantly 
expressed  HBsAg  vaccine  is  limited.  Since  recombinantly  expressed  VLPs  are  not 
completely  identical  to  the  blood-derived  ones,  the  precipitation  conditions  and 
performance may differ.  
Unique VLP compartmentalisation characteristics of membrane-envelope VLPs 
such as the localisation of HBsAg on the yeast endoplasmic reticulum (ER) can also be 
exploited  for  the  purpose  of  selective  product  release.  For  example,  following  cell 
disruption but prior to VLP liberation by detergent, a solids-liquid separation step by 
centrifugation could be employed to sediment VLPs which are still compartmentalised 
within the associated membranous organelle allowing the supernatant containing bulk 
contaminants originating from the cytosol to be eliminated. When the solids fraction is 
later treated with detergent, the VLP product would be released into a process stream 
with minimal cytosolic contaminants. Application of such selective product release for 
VLP purification has been demonstrated at a laboratory scale (Chi et al., 1994) but the 
study had been limited to the protein class of contaminants. 
  Scale-up considerations are crucial from the onset of process design since once a 
process is in place, any corrective actions would be expensive and could take years for 
approval from the regulatory authorities (Buckland, 2005). Process development efforts 
at  laboratory  scale  can  lead  to  inefficient  process  design  as  some  of  the  putative 
processes may indeed prove difficult or costly to scale up and not be amenable to late-
stage  bioprocess  modifications  (Pattenden  et  al.,  2005).  Scale-down  bioprocess 
technologies  are  highly  attractive  in  this  light  as  they  allow  the  development  and 
prediction of scalable processes with minimal developmental time and costs (Titchener-
Hooker  et  al.,  2008).  Successful  scale-down  of  commonly  employed  downstream 
operations such as homogenisation (Hetherington et al., 1971), centrifugation (Higgins 15 
 
et  al.,  1978),  precipitation  (Boychyn  et  al.,  2000)  and  chromatography  (Janson  and 
Dunhill, 1978) have been demonstrated. These scale-down techniques are invaluable 
here to ensure that the primary purification processes developed at laboratory scale are 
equally effective upon scale-up (Boychyn et al., 2000; Pattenden et al., 2005).  
  This thesis describes how a systemic approach can be adopted in designing an 
efficient primary purification process. This would take into account the different factors 
discussed for the development of an improved primary purification process for future 
generation  lipid-envelope  VLP  vaccines.  The  strategy  employed  here  places  great 
significance on understanding the expression system and the physiochemical attributes 
of VLPs, as well as the process interactions and engineering factors which together 
determine process performance. The next section provides the background to virus-like 
particles and the challenges facing its production and purification while the specific 
aims of the project are detailed in Section 1.6.  
 
 
1.2 Introduction to virus-like particles 
Virus-like particles (VLPs) are recombinant virus capsid or enveloped proteins 
(Grgacic and Anderson, 2006) self-assembled  in a host cell in the absence of viral DNA 
and RNA genome (Noad and Roy, 2003). The VLPs consist of highly repetitive and 
ordered  structures  mimicking  the  native  structure  and  antigenic  properties  of  the 
parental virus which can trigger potent humoral and cellular responses (Boisgerault et 
al.,  2002).    The  VLPs  are  devoid  of  viral  genetic  material  which  ensures  that  any 
recipient  bears  no  risks  of  infection.  From  this  perspective,  VLPs  hold  a  major 
advantage over traditional vaccines based on inactivated or attenuated viruses which 
suffer from risks of viral reversion, recombination or re-assortment (Noad and Roy, 16 
 
2003).  Additional  benefits  of  VLP  vaccines  include  higher  efficiency  in  eliciting  a 
protective  response  and  lower  dosage  requirements  relative  to  subunit  vaccines,  in 
particular, which are based on purified antigen rather than the whole organism.  
There is increasing interest in the production of recombinant VLPs as vaccine 
candidates. The hepatitis B VLP, Recombivax HB
®, from Merck which was the first of 
such  vaccines,  licensed  for  human  use  in  1984  (Hilleman,  2001;  Hilleman,  2003; 
McAleer et al., 1984;  Valenzuela  et al., 1982). Recently,  VLP vaccines against the 
human pappilomavirus (HPV), Gardasil
® and Cerevix
® by Merck and GlaxoSmithKline 
(GSK), respectively were licenced (Andrawiss, 2007; Schiller and Lowly, 2006). VLP 
based  vaccines  for  over  30  viral  diseases  affecting  humans  and  animals  have  been 
developed hitherto and are at different stages of the development pipeline (Noad and 
Roy, 2003; Grargic and Anderson, 2006). 
VLPs  can  be  broadly  categorised  as  simple  non-enveloped  VLPs  and  lipid-
envelope VLPs. The HPV vaccine is an example of a simple non-enveloped VLP. Such 
VLPs  are  assembled  from  one  or  two  major  capsid  proteins  of  viruses  which  are 
relatively simple in structure and do not have a lipid envelope. The hepatitis B vaccine 
is an example of the latter category. The VLPs are assembled as envelope proteins bud 
from cellular compartments such as the ER, plasma membrane of lipid rafts taking with 
them  cellular  lipid  organised  to  form  lipoprotein  particles  (Grargic  and  Anderson, 
2006). Production of lipid-envelope VLPs has been reported to be the more challenging 
of  the  two.  Additional  technical  issues  for  consideration  for  lipid-envelope  VLPs 
include the choice of the expression system which would directly affect the envelope 
which is host-derived (Betenbaugh et al., 1995; Buonaguro et al., 2005) and the need to 
prevent interference of the envelope structure with the presentation of the immunogenic 
viral components (Yamshchikov et al., 1995; Baumert et al, 1998).   17 
 
In addition to the direct immunogenicity of VLPs, they have also been shown to 
be efficient in  stimulating cellular and humoral responses (Schirmbeck et al., 1996; 
Paliard et al., 2000; Murata et al., 2003) making them excellent candidates as carrier 
molecules  or  presentation  platforms  for  the  delivery  of  epitopes  targeted  at  other 
diseases.  The  formation  of  chimeric  VLPs  as  such  is  possible  through  the  genetic 
engineering of the VLP gene sequence to include genes of the foreign vaccine epitope 
and fusion proteins so that these proteins are co-expressed and assembled onto the VLP 
during synthesis. The development of chimeric VLPs significantly expands the niche of 
VLPs in preventative medicines beyond disease conditions in which VLPs are naturally 
formed (Grgacic and Anderson, 2006; Noad and Roy, 2003). The same principles may 
also  be  applied  in  the  production  of  multivalent  vaccines  targeting  more  than  one 
unrelated diseases simultaneously (Netter et al., 2001; Michel et al., 2007). [The full 
account of the range of chimeric vaccines, vaccine status in the developmental pipeline, 
the advantages and disadvantages and technical considerations are outlined elsewhere 
(Grgacic and Anderson, 2006; Boisgerault et al., 2002).] Another possibility for future 
use of VLPs lies in the ability of VLPs to assemble and disassemble when induced by 
changes in the chemical environment. This feature could be exploited for carrying either 
foreign genes or chemical agents into cells (Goldmann et al., 1999; Goldmann et al., 
2000).      
It has been reported that in spite of the unique properties of VLPs, the number of 
licensed  VLP  vaccines  remains  low  for  the  reason  that  sophisticated  and  expensive 
technologies are required in manufacture as compared to the lower costs incurred in the 
production of live attenuated vaccines (Pattenden et al., 2005; Boisgerault et al., 2002). 
The higher production costs for VLP vaccines would translate to significantly more 
expensive vaccination programmes and thus are viewed less favourably by health care 18 
 
providers.  Specific  challenges  in  VLP  process  development  and  the  associated 
regulatory constraints have been reviewed (Buckland, 2005). To achieve lower costs in 
VLP  manufacturing  and  rapid  delivery  to  the  market,  bioprocess  manufacturing 
research is as critical as the product development itself (Pattenden et al., 2005). As 
discussed previously, it is the focus of this project to study various means of improving 
the bioprocessing of VLPs to complement the enhanced capacity for the development of 
novel VLP vaccines.  
 
 
1.3 Introduction to the hepatitis B disease and the hepatitis B 
surface antigen (HBsAg) vaccine    
 
1.3.1 Hepatitis B disease 
Hepatitis B is the most serious liver infection in the world and can lead to liver 
failure, cirrhosis or cancer of the liver (Hepatitis B Foundation). It is often characterised 
by jaundice, abdominal pain, liver enlargement and fever. According to the WHO, it is 
estimated  that  400  million  people  worldwide  are  already  chronically  infected  with 
hepatitis B and this disease leads to over 1 million deaths per  year. This disease is 
transmitted by blood and body fluids, frequently during sexual intercourse. Treatment, 
is generally ineffective (Hepatitis B Foundation) and thus prevention and vaccination 
remain the best alternatives for this disease.   
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1.3.2 Hepatitis B virus 
Hepatitis  B  is  caused  by  the  hepatitis  B  virus  (HBV),  an  envelope  virus 
containing a partially double stranded, circular DNA genome and classified within the 
family hepadnavirus (Shepard et al., 2006). The virus interferes with the function of the 
liver in replicating hepatocytes causing the immune system to be activated leading to 
liver inflammation.  
The Hepatitis B virus is a spherical particle with a diameter of 42 – 47 nm and 
circulates in the blood in concentrations as high as 10
8 virions per mL (Shepard et al., 
2006). The particles are composed of  an outer  shell or envelope,  which consists of 
proteins  known  as  HBs  or  surface  proteins.  These  self-assembling  units  form  non-
infectious spherical or tubular particles (Robinson and Lutwick, 1976) containing the 
surface antigens (HBsAg) which are responsible for eliciting the immune response. The 
HBsAg  particles  contain  only  envelope  glycoproteins  and  host-derived  lipids  and 
outnumber virions by 1000:1 to 10,000:1 (Ganem and Prince, 2004). The surface coat 
surrounds an inner protein shell, composed of HBc proteins. Finally, the viral DNA and 
enzyme  DNA  polymerase  can  be  found  in  the  inner  most  region  of  the  particle.  A 
schematic of the cross section of the hepatitis B virus is as shown in Figure 1.1(a) while 
Figure 1.1(b) shows the 3D structure of the virus resolved from X-ray crystallography 
studies (Srgo, 2004). 
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Figure 1.1: (a) shows a schematic of the cross section of a hepatitis B virus. (b) shows 
the structure of the hepatitis B virus as solved by x-ray crystallography, image by Sgro 
(2004) (taken from http://www.virology.wisc.edu/virusworld/covers.php).  
 
When  the  virus  invades  the  host,  the  virus  binds  to  the  cell  surface  and 
penetrates with the help of its envelope proteins. The virus is not degraded inside the 
cell but is transported to the nucleus (Ganem and Prince, 2004). The partially circular 
DNA of HBV is initially made into covalently closed circular DNA (Tuttleman et al., 
1986),  which  functions  as  a  template  for  RNA  synthesis.  The  RNA  is  then  reverse 
transcribed into open circular DNA which is packaged into viral envelopes in the ER 
Central core: containing 
nucleocapsid core, HBcAg 
(insoluble protein) and the e 
antigen, HBeAg (soluble) 
Virus DNA: 
double stranded  
Enzyme: 
polymerase 
 
External envelope: containing 
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and transported out of the cell, potentially leading to a new round on infection. Viral 
replication continues inside the host’s liver cells.  
 
1.3.3 Brief history of treatment for the Hepatitis B disease 
Hepatitis B vaccines have been available since the early 1980s. The first vaccine 
(HEPTAVAX
®), licensed in 1981, was a subunit vaccine isolated from the blood of 
hepatitis B infected donors (Prince, 1982). In hepatitis B patients suffering from acute 
infection and in hepatitis B carriers, 22nm particles containing HBV surface antigen 
subunits  of  the  virus  are  found  expressed  in  copious  amounts.  These  particles 
themselves are not infectious but are effective in stimulating a strong immune response 
(Dekleva, 1999). Since these particles are derived from blood, extensive purification is 
critical to ensure that the final product exceeds 99% purity and is free from extraneous 
infectious viruses.  
Historically, there have been many limitations in the manufacture of plasma-
derived hepatitis B vaccines. Primarily, a constant limitation exists in the supply of 
human plasma. Due to the intensity of the manufacturing process, more than 1 year is 
required to produce just one batch (Dekleva, 1999). During the 1980s there was also 
growing concerns about AIDS infection through blood derived products (Francis et al., 
1986)  which  led  to  pressures  to  develop  a  recombinant  vaccine  for  human  use. 
RECOMBIVAX HB
® from Merck was the first recombinant hepatitis B VLP vaccine. 
GlaxoSmithKline (GSK) has produced a recombinant hepatitis B vaccine, ENGERIX 
B
®, which is also currently in the market. In addition, there is now a vaccine for both 
hepatitis  A  and  B  together,  known  as  TWINRIX
®,  which  is  bivalent  in  nature, 
containing antigenic components used in producing HAVRIX
® (Hepatitis A inactivated 22 
 
vaccine) and ENGERIX-B
® (Hepatitis B, recombinant vaccine), by GlaxoSmithKline 
(GSK).  
 
1.3.4 Hepatitis B Surface Antigen (HBsAg) VLP vaccine 
The first commercially manufactured recombinant hepatitis B VLP licensed in 
1984 (Hilleman, 2001; Hilleman, 2003; McAleer et al., 1984; Valenzuela et al., 1982) 
was cloned and expressed in S. cerevisiae (McAleer et al., 1984; Miyanohara et al., 
1983). The VLP is assembled from up to 100 copies of the hepatitis B surface antigen 
monomer  and  host-derived  lipids  forming  highly  immunogenic  spherical  particles 
measuring ~ 22nm in diameter. A cross-sectional representation of a HBsAg particle is 
shown  in  Figure  1.2  (a).  The  VLP  is  widely  referred  to  as  the  hepatitis  B  surface 
antigen (HBsAg) after its origins. Comparison of the HBsAg produced by recombinant 
yeast to HBsAg of human blood plasma has been reported (Yamaguchi et al., 1998).  
In S. cerevisiae, the assembly of the recombinant HBsAg particles is initiated by 
the insertion of the hydrophobic segments of the HBsAg monomer into the endoplasmic 
reticulum (ER) (Zhao et al., 2006) which then bud into the lumen of the ER as 20-nm 
lipoprotein  particles  using  host-dervied  machinery  and  lipids  (Eble  et  al.,  1986).  In 
humans, the HBsAg maturation process will proceed through the Golgi and the HBsAg 
particles are subsequently secreted. In yeast cells however, due to the lack of protein 
transport  machinery  (Biemans  et  al.,  1992),  the  HBsAg  particles  are  permanently 
localised in the ER.  
 
Figure 1.2: (a) shows the cross
(1980) while (b) illustrates the interaction between a p24s protein monomer and the 
lipid bilayer on the surface of the HBsAg 
Kane, 1999).  
 
The  recombinant  HBsAg  particles  are  cysteine
evolvement and maturation depends on the level of disulphide formation. The formation 
of correct intra- and intermolecular disulphide
conformational stability and immunogenicity o
Zhao et al., 2006). HBsAg derived from human blood plasma are already in the mature 
form but in recombinantly expressed HBsAg, the disulphide bond formation and the 
cross-linking process continues during purification. Additional steps of treatment with 
potassium thiocyanate (KSCN) and storage at elevated temperatures have been included 
at the end of the purification chain to 
HBsAg (Zhao et al., 2006). 
HBsAg characterisation studies have revealed that the particle is comp
75% protein and ~ 25% lipid by mass (Dreesman 
The lipid-protein interactions are responsible for the formation of the desirable helical 
structures of the proteins formi
(a) 
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shows the cross-section of an HBsAg particle adapted from Koistinen 
illustrates the interaction between a p24s protein monomer and the 
lipid bilayer on the surface of the HBsAg particle (image taken from Mahoney and 
The  recombinant  HBsAg  particles  are  cysteine-rich  and  the  structural 
evolvement and maturation depends on the level of disulphide formation. The formation 
and intermolecular disulphide bonds are critical as they determine the 
conformational stability and immunogenicity of HBsAg vaccines (Guerrero 
, 2006). HBsAg derived from human blood plasma are already in the mature 
form but in recombinantly expressed HBsAg, the disulphide bond formation and the 
linking process continues during purification. Additional steps of treatment with 
cyanate (KSCN) and storage at elevated temperatures have been included 
at the end of the purification chain to complete the maturation process 
, 2006).  
HBsAg characterisation studies have revealed that the particle is comp
5% lipid by mass (Dreesman et al., 1972; Gavilanes 
protein interactions are responsible for the formation of the desirable helical 
structures of the proteins forming the epitopes (Gavilanes et al., 1990
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bonds are critical as they determine the 
f HBsAg vaccines (Guerrero et al., 1988; 
, 2006). HBsAg derived from human blood plasma are already in the mature 
form but in recombinantly expressed HBsAg, the disulphide bond formation and the 
linking process continues during purification. Additional steps of treatment with 
cyanate (KSCN) and storage at elevated temperatures have been included 
the maturation process of recombinant 
HBsAg characterisation studies have revealed that the particle is composed of ~ 
, 1972; Gavilanes et al., 1982). 
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schematically in Figure 1.2(b). Sterol accounts for 30% of the lipid constituent of the 
HBsAg  particle  while  phospholipids  account  for  the  remaining  70%,  of  which 
phosphatidylcholine  (PC)  is  the  most  abundant.  Negatively  charged  phospholipids, 
phosphatidylserine (PS) and phosphatidylinositol (PI), in particular, have been shown to 
have significant influence on HBsAg activity (Gomez-Gutierrez et al., 1994). A full 
account of the role of lipids in maintaining the structure and antigenicity of HBsAg and 
the effects of lipid reconstitution is available elsewhere (Gavilanes et al., 1990; Gomez-
Gutierrez et al., 1994).   
The intrinsic characteristics of the HBsAg particles, outlined above, are critical 
considerations  in  ensuring  product  quality  and  potency.  Like  other  VLPs,  HBsAg 
particles are large macromolecular entities which are difficult to characterise and are 
susceptible to conformational and biological changes in different microenvironments. 
As previously discussed, the process of producing the vaccine itself often defines the 
end product (Buckland, 2005) and regulatory demands are stringent considering that the 
vaccine products are administered to healthy individuals. It is required that  assurance of 
the  identity  and  composition  of  the  administered  dosage  is  provided  to  meet  the 
demands  of  product  safety  and  efficacy.  Hence,  in  this  study,  the  biological  and 
physiochemical aspects of the HBsAg system are carefully considered alongside the 
purification  process  development  efforts.  Ultra-scale  down  (USD)  techniques  are 
particularly  valuable  here  in  simulating  industrial  scale  conditions  to  allow  the 
characterisation of the biochemical and biophysical responses of the HBsAg particles to 
different processing environments.    
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1.3.5 Hepatitis B Surface Antigen (HBsAg) platform for novel vaccines  
In  addition  of  their  use  as  direct  immunogens,  VLPs  have  shown  enormous 
potential  as  platforms  for  the  development  of  future  generation  vaccines  based  on 
hybrid or chimeric VLP. VLPs are highly efficient in stimulating cellular and humoral 
responses as they provide the spatial structure for the display of conformational epitopes 
that mimic the native viral structure leading to enhanced antibody production (Grgacic 
and Anderson, 2006).  
The hepatitis B surface antigen (HBsAg), with the ability to self-assemble with 
host-derived lipids into empty non-infectious VLPs (Cheong et al., 2009), is attractive 
as a delivery platform for foreign epitopes. The efficiency of the HBsAg particles in 
priming cellular and humoral responses even in the absence of an adjuvant has been 
reported (Boisgerault et al., 2002). Chimeric vaccines for Hepatitis C (Netter et al., 
2001), dengue (Bisht et al., 2001) and HIV (Michel et al., 2007; Greco et al., 2007) 
have been developed using this platform.  
The HBsAg particles are composed of a lipid bilayer surrounded by external 
hydrophobic  loops  which  could  be  genetically  engineered  to  carry  the  heterologous 
antigens for delivery (Delpeyroux et al., 1986; Netter et al., 2001; Phogat et al., 2008). 
The  ability  of  the  hydrophobic  loops  to  accept  peptides  facilitates  the  insertion  of 
selective epitopes against diseases including HIV-1 and hepatitis C (Lee et al., 1996; 
Schlienger et al., 1992; Boisgerault et al., 2002). 
The lipid-envelope structure of the HBsAg is an attractive attribute as it allows 
the incorporation of foreign antigens requiring the support from a lipid bilayer structure. 
This aspect is particularly relevant in the development of HIV vaccines where a lipid 
membrane  environment  is  necessary  to  orientate  the  antigenic  epitopes  for  efficient 26 
 
induction of broadly neutralising antibodies (Grunder et al., 2002). Preliminary studies 
showed that the HIV epitopes could be appended to the C-terminus of the HBsAg S-1 
protein and the lipid environment provided the support necessary for effective antibody 
binding (Phogat et al., 2007). Similarly, the chimeric VLP for dengue virus envelope 
protein  showed  enhanced  immunogenicity  when  assembled  on  the  HBsAg  platform 
(Bisht et al., 2002).  
HBsAg particles have a hollow core with an encapsulation space of 900-8000 
nm
3 (Reimann et al., 2006) and access to the interior is mediated by pores in the bilayer. 
The  hollow  structure  of  the  HBsAg  particles  could  also  be  employed  for  the 
encapsulation  or  entrapment  of  antigenic  proteins  and  peptides,  oligonucleotides  or 
cytokines which would be exposed to the surface by virtue of the pores. Early proof-of-
concept studies for this HBsAg application have been demonstrated (Reimann et al., 
2006).      
 
 
1.4. Overview of production and purification methods for HBsAg 
1.4.1 HBsAg expression in S. cerevisiae 
The HBsAg particles used as the VLP model in this study was developed by 
Merck (West Point, PA, USA) using S. cerevisiae as the host cell expression system. 
Details of the plasmid and strain construction are reported elsewhere (Carty et al., 1989; 
Hinnen et al., 1978). 
The crucial starting point in the development of a VLP vaccine is the design of a 
cell based system which is stable over many generations and produces high titres of the 27 
 
VLP  product  (Buckland,  2005).  The  choice  of  the  expression  system  is  particularly 
important for lipid-envelope VLPs for the reason that the lipid constituents are derived 
from the host cell (Betenbaugh et al., 1995;  Buonaguro et al., 2005).  Although the 
production  of  HBsAg  has  also  been  achieved  using  bacteria  (Shu  et  al.,  2006), 
transgenic plants (Kumar et al., 2005) and mammalian cells (Diminsky et al., 1997), S. 
cerevisiae  remains  a  highly  attractive  host.  Yeast  fermentation  is  well  established, 
highly  reproducible  and  amenable  to  large  scale  fermentation  (Buckland,  2005). 
Additionally, yeast cells have the ability of performing complex eukaryotic-like post-
translational modifications producing proteins similar to those of the mammalian origin 
and a wealth of  genetic information is  available for this strain  which  facilitates the 
engineering of the desired cell metabolism and expression characteristics for the VLP.  
Fermentation  conditions  for  VLP  production  would  depend  on  the  host 
expression system chosen. The recombinant HBsAg used as the VLP  model in this 
study is transcribed under the control of the GAL-10 promoter in S. cerevisiae. Hence, 
HBsAg expression is regulated by the levels of glucose and galactose in the culture 
media.  Fermentation  conditions  and  glucose-galactose  interactions  in  HBsAg 
expression have been reported previously (Carty et al., 1987; Carty et al., 1989). For 
plasmid selection and maintenance, the Merck HBsAg strain also carries a Leu
+ gene in 
the same plasmid as the HBsAg gene. This allows the use of a leucine-free basal media 
for fermentation which would select for cells containing the plasmid with the Leu
+ and 
HBsAg genes. Fermentation for HBsAg production is typically carried out in a batch 
process  (Carty  et  al.,  1987)  but  the  use  of  continuous  fermentation  has  also  been 
reported (Fu et al., 1995).  
An issue for consideration when developing yeast fermentation media is that 
yeast cells are susceptible to catabolite repression, a condition where cell growth is 28 
 
hindered when excess sugars such as glucose are present (Gancedo, 1998). Oura (1974) 
developed a fully defined media for yeast fermentation using glucose that has minimal 
catabolite repression effects. Yau (2005), in her MEng research project in Biochemical 
Engineering (UCL), proposed a media for HBsAg production which has the combined 
advantages of the Oura (1974) and the Fu et al. (1995) media. This media was shown to 
be successful for the fermentation of wild type S. cerevisiae cells but was not tested for 
the recombinant HBsAg strain due to time constraints. Joyce et al. (1998) reported on a 
recombinant S. cerevisiae fermentation media which is semi-defined for the production 
of the human pappilomavirus (HPV) vaccine. It is known that the S. cerevisiae host 
expression system for this vaccine is similar to that for hepatitis B and hence the media 
may be employed for HBsAg production.  
In this research, the recombinant S. cerevisiae for HBsAg was donated by Merck 
(West Point, PA, USA) in the form of a master seed stock. Fermentation is not a key 
element  in  this  project  however  it  is  crucial  to  produce  sufficient  feed  material  for 
subsequent purification studies which were representative of material in an industrial 
process.  There is limited information in the public domain on fermentation media for 
HBsAg production using the Merck recombinant S. cerevisiae strain. To minimise time 
and research effort in generating feed stock for purification studies, prior knowledge 
from  the  Yau  (2005)  and  Joyce  et  al.  (1998)  studies  were  used  as  the  basis  for 
fermentation development.  
 
1.4.2 Recovery and purification of HBsAg from S. cerevisiae 
HBsAg is expressed in S. cerevisiae as an intracellular product and the typical 
recovery and purification process is summarised in Figure 1.3.  For recovery of the 29 
 
intracellular  HBsAg  product,  the  yeast  cells  following  fermentation  are  harvested, 
concentrated  and  washed  with  buffer  for  the  removal  of  media  components  and 
antifoam. This is usually accomplished using centrifugation or microfiltration and the 
cells are stored as cell paste at -70 
oC (Sitrin and Kubek, 1992). 
Product recovery is performed by suspending a batch of frozen cells in a buffer 
containing phenylmethylsulfonyl fluoride which is a protease inhibitor (Dekleva, 1999), 
and the suspension is subjected to cell disruption by homogenisation. Following cell 
breakage, the crude extract is treated with a phosphate buffer containing a detergent, 
usually Triton X-100 (Wampler et al., 1985). This is a critical step in the recovery of 
HBsAg as the detergent facilitates the liberation of the HBsAg from tightly associated 
endoplasmic reticulum (ER) membrane components (Dekleva, 1999). Removal of cell 
debris can be performed by centrifugation (Wampler et al., 1985) or  microfiltration 
(Deklava, 1999). Residual detergent is removed by recirculation through polystyrene 
XAD-4 beads and the product stream can be ultrafiltered through a 100-kDa membrane 
to clear small molecular weight contaminants and for product concentration.  
Purification  is  typically  accomplished  by  chromatography-based  operations 
(Dekleva,  1999;  Wampler  et  al.,  1985;  Belew  et  al.,  1999)  although  the  use  of 
precipitation and density ultracentrifugation has been reported (Deml et al., 1999). The 
HBsAg  product  is  initially  purified  via  adsorption  and  elution  from  colloidal  silica 
(Aerosil) (Wampler et al., 1985). Conditions for this process are reported elsewhere 
(Pillot  et  al.,  1976;  Sitrin  and  Kubek,  1992).  Final  polishing  is  performed  using 
hydrophobic interaction chromatography using butyl agarose (Dekleva, 1999).  
As highlighted by Zhao et al. (2006), the HBsAg produced in S. cerevisiae is not 
in the fully disulphide-bonded form as found in blood-derived HBsAg. The maturation 30 
 
process  for  recombinant  HBsAg  progresses  through  the  purification  process.  To 
facilitate the  formation  of disulphide cross-linkages in the mature form, the HBsAg 
particles are treated with thiocyanate and incubated at an elevated temperature of 37 
oC 
prior to product formulation (Zhao et al., 2006). The product is finally adjuvanted by 
co-precipitation with aluminium hydroxide (Dekleva, 1999).  
In  the  complex  multistage  operations  involved  in  HBsAg  production  and 
purification,  product  yield  is  dictated  by  the  efficiency  of  the  detergent-mediated 
HBsAg liberation step while the purification performance of membrane filtration and 
chromatographic operations are influenced by the level of contaminants such as yeast 
proteins and lipids. This thesis investigates the development of an improved primary 
purification strategy to achieve higher HBsAg recovery and a cleaner output to reduce 
the burden on downstream operations.   
Figure 1.3: Typical process flowsheet for HBsAg production and purification adapted 
from Dekleva (1999). The 
study is highlighted (-
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: Typical process flowsheet for HBsAg production and purification adapted 
from Dekleva (1999). The primary purification stage which is of specific interest in this 
study is highlighted (- - - -). 
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1.5 Areas of focus in improving primary recovery and purification 
1.5.1 Detergent-mediated HBsAg liberation 
The HBsAg product remains permanently localised on the yeast endoplasmic 
reticulum (ER) following protein translation as transport through the secretion pathway 
is blocked (Biemans et al., 1992). A detergent is required to facilitate the liberation of 
HBsAg from tightly associated ER membrane components (Dekleva, 1999). Typically 
Triton X-100, a non-ionic detergent, is employed for this purpose although alternative 
detergents such as polysorbate 20 and 80 (PS 20 and PS 80) and variants of Triton such 
as  Triton  X-101,  CHAPS  (3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate) and glycol ether solvents have been reported for similar applications 
(Wijnendaele et al., 1987; Kniskern and Hagopian, 1997; Allen et al., 2007).   
The  key  feature  to  a  detergent’s  function  is  in  its  amphipathic  structure 
comprising  a  hydrophilic  “head”  region  and  a  hydrophobic  “tail”  region  which  can 
associate with the hydrophobic surfaces of proteins. Detergents facilitate the recovery of 
membrane proteins by disrupting the bipolar lipid membrane of cells and by forming 
protein-detergent complexes which are soluble. Of the detergents commonly employed 
for the recovery of lipid-envelope VLPs, Triton and polysorbate, both fall under the 
non-inonic detergent class. Their difference lies in the polymer type and length of the 
hydrophobic “tails”. Triton detergents are made from ethyleneglycoether polymers and 
have shorter hydrocarbon chains and higher CMC values than polysorbate detergents 
which  contain  oxyethylene  polymers  (Caligur,  2008).  Detergents  with  lower  CMC 
values are more stable however the interaction between the detergent and the protein is 
also stronger which could be an issue for subsequent detergent removal efforts. CHAPS 
in contrast is a zwitterionic detergent which may have the added benefit of being more 33 
 
effective for disrupting protein-protein bonds in reducing aggregation due to its ionic 
nature although having a net neutral charge. In general, anionic or cationic detergents 
are less preferred for biological applications as their charge characteristics could modify 
protein structure leading to increased risks of protein denaturation.     Specifically for 
HBsAg  liberation,  there  are  several  hypotheses  as  to  how  the  detergent  functions, 
mechanistically.  Chi  et  al  (1994)  proposed  that  detergents  weaken  the  hydrophobic 
interactions that exist between the VLP and the membrane components. According to 
Sitrin and Kubek (1992), detergents facilitate the disassociation of the HBsAg from the 
ER  by  promoting  the  separation  of  the  yeast  ER  membrane  from  other  unwanted 
cellular  debris.  A  study  by  Smith  and  co-workers  suggests  that  detergent  may  also 
promote VLP vesicle formation by inward budding of the ER membrane (Smith et al., 
2002; Kreibich et al., 1982).  
From  the  above,  it  appears  that  high  detergent  concentrations  would  favour 
HBsAg  liberation  based  on  reaction  kinetics.  However,  to  be  taken  also  into 
consideration,  is  the  physiochemical  nature  of  the  HBsAg  particles  which  are  75% 
protein  and  25%  lipid  by  mass  (Gavilanes  et  al.,  1982).  There  has  been  a  lack  of 
consensus as to the optimal concentration of detergent for this purpose. Other groups 
have reported that excess detergent could lead to HBsAg particle delipidation (Skelly et 
al., 1981; Howard et al., 1982; Sanchez et al., 1983) which in turn could result in a loss 
of antigenic activity. This is unsurprising given that the lipid moiety has significant 
roles  in  the  maintenance  of  the  structural  and  antigenic  properties  of  the  protein 
components of the HBsAg (Gavilanes et al., 1990).    
The  amount  of  detergent  could  also  have  indirect  implications  on  the 
contamination  profile  of  the  resulting  process  stream.  Large  amounts  of  lipid  are 
produced by yeast cells over extended periods of cell culture (Wijnendaele et al., 1987) 34 
 
which in the case of HBsAg production is necessary to achieve the desired product 
titres. The majority of these lipids are associated with membranous organelles which 
also contain some proportion of proteins for specific metabolic functions. During the 
detergent  step,  it  is  likely  that  the  membrane  associated  lipids  and  proteins  are  co-
released alongside the HBsAg product and the extent of co-liberation is also a function 
of detergent concentration.  
Based  on  the  factors  highlighted  above,  it  is  critical  to  identify  a  suitable 
detergent and its optimal range of operating concentrations for effective recovery of 
HBsAg,  preservation  of  its  antigenic  properties  and  minimal  co-release  of 
contaminating host lipids and proteins.  
 
1.5.2 Precipitation for partial purification 
  Precipitation is a traditional protein purification method and is examined here as 
a  means  of  achieving  partial  purification  and  enrichment  of  HBsAg  prior  to  higher 
resolution  chromatographic  operations.  Polyethylene  glycol  (PEG)  and  ammonium 
sulphate are the most widely cited precipitating agents for VLPs and are assessed for the 
primary purification of  HBsAg based on the degree of  contamination reduction and 
product yield.      
  Polyethylene glycol (PEG) is attractive as a precipitating agent owing to its low 
potential for protein denaturation even when present at high concentrations (Ingham et 
al., 1990; Tsoka et al., 2000) and its high fractionation efficiency when purifying large 
size proteins such as VLPs (Juckes et al., 1971). The application of PEG precipitation 
for HBsAg purification is not entirely new. Purification of the first generation hepatitis 
B vaccine based on HBsAg from plasma of carriers relied on multiple PEG precipitation 35 
 
“cuts”. Since the recombinant HBsAg examined here is not identical to the human form 
due to differences in disulphide cross-linking, these recombinant particles may have 
different solubility behaviours in the presence of PEG. There is also a difference in the 
role  of  the  PEG  precipitation  step.  In  the  1970s  process  for  human  HBsAg,  PEG 
precipitation  was  the  purification  workhorse  and  multiple  “cuts”  were  necessary  to 
achieve the desired final purity, often at the expense of significant product loss. As a 
primary purification process for future-generation vaccines, its role would be to reduce 
the  contamination  burden  and  process  volume  entering  downstream  operations  in  a 
single “cut” with minimal product loss. For PEG precipitation as a primary purification 
step product yield is critical and this relies on the effectiveness of precipitate recovery 
from  the  liquor.  Although  PEG  has  a  low  intrinsic  viscosity  (Polson  et  al.,  1964), 
concentrations above 10% w/v PEG may have substantial effect on the viscosity of the 
process stream. The effect of this on the performance of the centrifugation or filtration 
step for the precipitate recovery would need to be evaluated.           
The  use  of  ammonium  sulphate,  another  popular  precipitating  agent,  is  also 
investigated. It is generally known that the ammonium sulphate salt is less selective 
compared  to  PEG  which  results  in  larger  quantities  (>  40%  w/v)  of  the  salt  being 
required for protein precipitation (Wijnendaele et al., 1987) which could create waste 
disposal issues. Lipid solubility, in contrast, is more sensitive to ammonium sulphate 
and  lower  concentrations  of  the  salt  are  typically  sufficient  for  their  precipitation. 
Bracewell et al. (2008) demonstrated an inverse purification strategy using ammonium 
sulphate precipitation. In the study, lipid contaminants were precipitated out of solution 
whilst protein products are retained in the soluble phase. This strategy would be more 
suitable  for  large-scale  VLP  purification  owing  to  the  lower  levels  of  ammonium 
sulphate consumption which would pose less waste disposal issues.    36 
 
1.5.3 Selective product release for primary purification 
  For expression of recombinant proteins in S. cerevisiae, there are three main 
regions in the cell where the product of interest is likely to be located: (1) the space 
between the cytoplasmic membrane and the outermost mannan-protein layer of the cell 
wall, (2) in the cytosol, or (3) embedded in subcellular organelles or particles (Huang et 
al.,  1991).  It  is  within  the  third  category  that  the  production  of  recombinant  lipid-
envelope  VLPs  such  as  the  HBsAg  falls.  The  natural  localisation  of  the  product  of 
interest in a specific region of the cell can provide a powerful means of recovering the 
product separately from bulk contaminants originating from the host cell. This approach 
has been demonstrated previously in the recovery of proteins from the periplasmic space 
of E.coli cells using osmotic shock or enzymes (French et al., 1996; Witholt et al., 
1976) and from specific regions in yeast using detergent and enzymes (Chi et al., 1994; 
Huang et al., 1991; Asenjo et al., 1993). Using these methods, several-fold product 
enrichment was reported with product yields of up to 90%.  
As highlighted previously, HBsAg particles in yeast are permanently localised 
on the endoplasmic reticulum (ER) because transport through the secretion pathway is 
blocked (Biemans et al., 1992). It is for this reason that a detergent is typically added to 
the cell lysate following homogenisation to release the HBsAg from the associated ER 
components. The ability to separate ER particles containing the HBsAg product from 
bulk cell contaminants prior to the addition of detergent would be invaluable as this 
would allow the HBsAg product to be recovered later and in a cleaner process stream. 
The endoplasmic reticulum which is slightly hydrophobic (Chi et al., 1994) and denser 
than the cell cytosol would be sedimented together with solid debris particles when 
centrifuged whilst bulk cytosolic material would be in the supernatant. By discarding 
the supernatant fraction and treating only the solids fraction with detergent, HBsAg 37 
 
would be released into a process stream with significantly reduced host lipid and protein 
contaminants. The efficiency of this process would rely on the relative partitioning of 
the  HBsAg  product  and  host  contaminants  across  the  cytosol  and  the  membranous 
components. 
It is possible to enhance further the selective recovery process by fine-tuning the 
cell  disruption  conditions.  Characterisation  of  the  size  distribution  of  yeast  debris 
generated as a function of the homogenisation conditions revealed that the release of 
intracellular proteins is often accompanied by fragmentation and micronisation of the 
cell wall (Siddiqi et al., 1995). Conditions of the homogenisation step could have a 
major influence on the efficiency of the selective recovery process at three different 
levels: (1) the extent of cell disruption would influence the accessibility of detergent to 
the ER during the HBsAg liberation step and this would impact product yield, (2) the 
population size of the ER components following homogenisation would influence the 
effectiveness of their recovery by sedimentation during the initial centrifugation step 
and  this  would  also  impact  product  yield,  and  (3)  the  particle  size  distribution  of 
membranous debris would influence the rate of co-extraction of contaminating lipids 
and proteins during the detergent step and this would impact the level of purification 
achieved. Thus, a trade-off study on the impact of homogenisation conditions would be 
warranted in developing any approach to selective product release.     
 
1.5.4 Scalability of selective product release  
  In process development, USD  techniques are invaluable as they are capable of 
predicting  industrial  scale  performance  of  biopharmaceutical  protein  downstream 
processing in a rapid fashion using as little as millilitres of material (Titchener-Hooker 38 
 
et al., 2008). Identification of process challenges and prediction of performance of large 
scale  protein  precipitation  operations  using  ultra  scale-down  techniques  has  been 
demonstrated (Boychyn et al., 2000). Hence, the focus here was on the scale-up of a 
selective product release method.  
The selective product release methodology investigated in this work relies on a 
twin centrifugation operation. The role of the first centrifugation step is to allow the 
elimination  of  bulk  cytosolic  contaminants  whilst  retaining  the  solids  fraction 
containing  the  HBsAg  product.  The  second  centrifugation  step  which  is  performed 
following detergent treatment recovers the HBsAg product in the supernatant whilst 
solid contaminants are discarded. Different centrifuge designs such as the tubular bowl, 
multichamber bowl and disc-stack centrifuge have been reviewed (Salte et al., 2006; 
Boychyn et al., 2004). The CARR Powerfuge
TM centrifuge, which is a tubular bowl 
variant, is most suited for inclusion in the selective product release process sequence 
due  to  its  good  solids  compaction  and  high  clarification  features.  The  level  of 
dewatering  and  clarification  attained  would  dictate  the  selectivity  and  product  yield 
from this approach. 
The Sigma  concept (Ambler, 1959) allows the comparison and prediction of 
centrifuge  performance  across  scales  and  centrifuge  designs  by  the  introduction  of 
correction factors which account for differences in flow patterns. USD models have 
been developed from the Sigma theory (Tustian et al., 2008; Boychyn  et al., 2004; 
Boychyn et al., 2000; Salte et al., 2006) and are useful here to predict the clarification 
performance of an industrial CARR Powerfuge
TM operating at different feed flow rates 
and rotational speeds. Having determined the optimal operating conditions of the CARR 
Powerfuge
TM centrifuge for the selective recovery process, a pilot-scale validation study 39 
 
can be performed to verify that the purification potentials of any methodology are not 
compromised upon scale-up.   
 
 
1.6 Research Aims 
The  fundamental  goal  of  this  project  is  to  investigate  a  series  of  potential 
improvements for primary purification processes for future generation lipid-envelope 
VLP vaccines from Saccharomyces cerevisiae with the purpose of reducing the burden 
on  higher  resolution  operations  downstream  and  to  achieve  better  overall  process 
performance. The critical response factors applied here when measuring the efficiency 
of  primary  purification  are:  (1)  product  yield  from  primary  purification;  and  (2) 
effective reduction of host-derived contaminants, specifically yeast lipids and proteins. 
These studies will be carried out using the hepatitis B surface antigen (HBsAg) as the 
lipid-envelope model to achieve the following objectives: 
 
1.6.1 Identification of suitable detergent and range of operating conditions 
The importance of the detergent-mediated VLP liberation step is unparalleled in 
setting the benchmark for VLP yield and antigenicity and the contamination profile of 
the  process  stream  entering  subsequent  purification.  To  identify  the  detergent  most 
suited for this purpose, the effectiveness of a range of commonly employed detergents 
will  be  compared.  Following  this,  a  trade-off  study  will  be  performed  to  identify  a 
suitable operating range for the detergent step. Factors including the effects of detergent 
concentrations  on  HBsAg  yield,  antigenic  activity,  physical  characteristics  of  the 40 
 
HBsAg,  the  level  of  release  of  host  cell  contaminants  (lipids  and  proteins)  and  the 
potential impact on the performance of a downstream ultrafiltration operation will be 
taken into account in this evaluation.  
 
1.6.2  Investigating  the  potentials  of  PEG  and  ammonium  sulphate 
precipitation for primary purification   
  PEGs with molecular weights of 6000 and 8000 have been reported (Tsoka et 
al.,  2000)  to  be  most  effective  for  VLP  precipitation.  To  establish  the  suitable 
precipitating conditions, different concentrations of PEG 6000 and PEG 8000 will be 
compared  in  terms  of  their  effectiveness  in  promoting  HBsAg  precipitation  and  the 
resulting degree of product enrichment. The use of centrifugation and filtration will be 
compared to determine their suitability for precipitate recovery. Finally, the practical 
and  economical  feasibility  of  PEG  precipitation  as  a  primary  purification  will  be 
assessed based on the overall step yield and the purification factor achieved.  
  Ammonium  sulphate  is  known  to  be  less  selective  than  PEG  and  higher 
concentrations (> 40% w/v) are typically required for protein precipitation (Wijnendaele 
et  al.,  1987).  Its  application  at  lower  concentrations  however  could  facilitate  lipid 
aggregation and removal (Bracewell et al., 2008). An inverse strategy is investigated 
here  in  which  low  concentrations  are  employed  to  precipitate  and  remove  lipid 
contaminants  while  maintaining  the  HBsAg  product  in  solution.  Hence,  screening 
studies  would  be  performed  to  identify  ammonium  sulphate  concentrations  which 
achieved highest lipid precipitation with maximum HBsAg solubility. The degree of 
HBsAg enrichment and product yield will be evaluated to determine the practical and 
economical feasibility of this process.  41 
 
1.6.3 Investigating the potential of selective product release for primary 
purification      
  To establish the effectiveness of any improved method an analysis of the relative 
partitioning  of  the  HBsAg  product  and  yeast-derived  contaminants  between  the 
supernatant and solids fraction immediately following cell disruption and centrifugation 
would be required. As previously discussed, homogenisation pressure conditions could 
impact the effectiveness of contaminant removal. Hence a subsequent study could be 
performed  to  identify  disruption  pressure  conditions  which  afford  the  best  trade-off 
between  product  yield  and  effective  reduction  of  contaminants.  To  provide  a 
quantitative  demonstration  of  the  value  of  this  process,  a  HIC  chromatography 
challenge could be performed to analyse the effects of a cleaner feed stream on product 
binding and chromatography yields. 
 
1.6.4 Scale-up study of selective product release process 
  A tubular bowl CARR Powerfuge P6
TM shall be employed for the pilot-scale 
demonstration of the selective product release methodology which is based on a twin 
centrifugation strategy. To predict centrifugation conditions for a pilot-scale process, 
ultra-scale down (USD) methods developed previously (Tustian et al., 2008; Boychyn 
et al., 2004; Boychyn et al., 2000; Salte et al., 2006) will be adopted. Using optimal 
conditions predicted using the USD methods, the process will be demonstrated at pilot-
scale  to  evaluate  its  efficiency  upon  scale-up.  Comparison  of  USD  and  pilot-scale 
results will also provide an assessment on the reliability of USD predictions. 
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1.7 Organisation of thesis 
  The first chapter provides an introduction to the project and discusses the current 
development and challenges facing VLP production and purification. The relevance of 
studying the purification of the hepatitis B surface antigen (HBsAg) as a VLP model 
and how this project could benefit the development of future generation lipid-envelope 
VLPs were described here. A literature review on the history, biology and downstream 
processing methods for VLPs in general and specifically the HBsAg particle were also 
presented.  
  The  second  chapter  provides  a  compilation  of  the  materials  and  methods 
employed in this study. This chapter will serve as the reference point for discussions of 
experimental and analytical procedures in all of the subsequent results chapters.  
  The  third  chapter  describes  how  fermentation  development  studies  were 
conducted to design a suitable protocol for pilot-scale production of recombinant S. 
cerevisiae cell stock for purification studies. Comparison studies on two different media 
compositions  previously  developed  (Yau,  2005  and  Joyce  et  al.,  1998)  as  well  as 
fermentation scale-up from 20 L to 75 L are described here. 
  The fourth chapter reports on fundamental studies performed to characterise and 
improve  the  performance  of  detergent-mediated  HBsAg  liberation  from  the 
endoplasmic reticulum (ER). Screening studies comparing the effectiveness of different 
detergents  followed  by  a  trade-off  analysis  to  determine  the  optimal  detergent 
concentration  range  are  presented  here.  Key  discussion  points  include  the  effect  of 
detergent on HBsAg yield, antigenic activity, level of co-extraction of contaminating 
host proteins and lipids and the potential impact on the performance of a downstream 
ultrafiltration operation.    43 
 
  The  fifth  chapter  investigates  the  potentials  of  polyethylene  glycol  (PEG)  or 
ammonium sulphate precipitation as a primary purification step to reduce the level of 
lipid  and  protein  contaminants  entering  downstream  operations.  Different 
concentrations of PEG 6000 and PEG 8000 and ammonium sulphate were analysed 
based  on  their  purification  potentials  and  step  yields.  For  PEG  precipitation, 
centrifugation  and  filtration  were  compared  as  separation  options  for  precipitate 
recovery. 
  The  sixth  chapter  explores  the  potentials  of  primary  purification  using  a 
selective product release approach which is based on a twin centrifugation strategy. The 
relative  partitioning  of  the  HBsAg  product  and  host  lipid  and  protein  contaminants 
across the supernatant and solids fractions immediately following cell disruption and 
centrifugation  are  characterised.  The  impact  of  varying  homogenisation  pressure 
conditions to drive the selectivity of the process higher is also demonstrated here. The 
purification  potential  of  this  methodology  was  assessed  based  on  HBsAg  product 
enrichment and yield as well as the benefits to a downstream chromatographic step.  
  The seventh chapter follows from the successful demonstration of the selective 
recovery  methodology  and  is  aimed  at  evaluating  its  amenability  to  scale-up.  The 
application  of  USD  techniques  for  predicting  suitable  operating  conditions  for  key 
centrifugation  operations  for  a  pilot-scale  process  are  detailed  here.  Discussion  also 
includes a comparison of the performance at pilot-scale against USD predictions and an 
overall evaluation of the selective product recovery methodology upon scale-up. 
The eighth chapter summarises the findings from this study and concludes on 
the contributions of this thesis. Areas of focus for future work are also outlined here.  
The final chapter contains the inventory of references accessed in this thesis. 44 
 
Chapter 2: Materials and Methods 
Materials and Methods 
 
 
Materials 
All chemicals employed were purchased from Sigma-Aldrich (Dorset, UK) and were of 
analytical grade unless stated otherwise.  
 
 
2.1 Fermentation development studies 
2.1.1 S. cerevisiae cell lines  
Wild type S. cerevisiae ATCC 26786 (ATCC, Middlesex, UK) was employed 
for a trial fermentation run. Subsequent studies were performed using a recombinant S. 
cerevisiae strain (Merck & Co. Inc, West Point, PA, USA) which produced the HBsAg 
product. 
 
2.1.2 Fermentation media evaluation  
Two  previously  reported  fermentation  media  were  investigated  here  for  the 
production  of  HBsAg  from  recombinant  S.  cerevisiae.  Media  composition  and 
preparation methods are detailed in the following sections. 
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2.1.2.1 Media developed by Yau (2005) 
Shake flask seed cultures stages were prepared using a complex media containing 20 - 
40 g/L glucose, 10 g/L glycerol, 10 g/L yeast extract, 0.4 g/L adenine and 0.2 g/L uracil. 
The HBsAg production stage was carried out using defined media adapted from Oura 
(1976) and Fu et al. (1996) containing 20 g/L glucose, 10 g/L succinic acid, 30 g/L 
monosodium glutamate, 0.4 g/L adenine and 0.2 g/L uracil as the main components. 
These  components,  other  than  glucose  which  was  sterilised  in  an  autoclave,  were 
sterilised  in-situ  in  the  fermenter.  Vitamins  containing  0.125  mg/L  biotin,  5  mg/L 
thiamine, 6.25 mg/L panthothenic acid, 125 mg/L meso-inositol, 6.25 mg/L pyridoxine 
and 5 mg/L nicotinic acid and trace elements of 120 mg/L potassium chloride, 60 mg/L 
sodium  chloride  dehydrate,  90  mg/L  calcium  chloride  pentahydrate,  3.8  mg/L 
manganese  sulphate  monohydrate,  0.003  mg/L  sodium  molybdate  dehydrate,  0.002 
mg/L  cobalt  sulphate  heptahydrate,  0.002  mg/L  cobalt  sulphate  heptahydrate,  0.002 
mg/L zinc sulphate heptahydrate, 0.007 mg/L boric acid, 0.002 mg/L potassium iodide 
and 0.003 mg/L nickel sulphate hexaphydrate were filter sterilised into the fermenter. 
An  iron  –  phosphate  source  containing  31  mg/L  iron  (II)  sulphate  heptahydrate 
dissolved in diluted phosphoric acid was also added. At the HBsAg production stage, 20 
g/L galactose, prepared and autoclaved separately, was added for induction.   
 
2.1.2.2 Media developed by Joyce et al. (1995) 
This is a semi-defined media originally for the production of the HPV vaccine in 
S.  cerevisiae.  Media  compositions  were  identical  for  both  the  seed  and  the  HBsAg 
production stages, containing 20 - 40 g/L glucose as the main carbon source, 8.5 g/L 
Difco yeast nitrogen base without amino acids and ammonium sulfate; 0.2 g/L adenine; 46 
 
0.2 g/L uracil; 10 g/L succinic acid; 5 g/L ammonium sulfate; 40 g/L glucose; 0.25 g/L 
L-tyrosine; 0.1 g/L L-arginine; 0.3 g/L L-isoleucine; 0.05 g/L L-methionine; 0.2 g/L L-
tryptophan; 0.05 g/L L-histidine; 0.2 g/L L-lysine; 0.3 g/L L-phenulalanine. For the 
VLP production stage, 40 g/L galactose was added at the start of fermentation to induce 
HBsAg expression.    
 
2.1.3 Cell expansion and cell banking methods 
Cell expansion for wild type S. cerevisiae ATCC 26786 (ATCC, Middlesex, 
UK) was carried out by adding 1 mL of the master cell bank into 50 mL of media 
containing 10 g/L succinic acid, 20 g/L galactose, 30 g/L monosodium glutamate and 
10.4 g/L glycerol in a 250 mL shake flask. This was left overnight in a shaker incubator 
at 28 
oC with agitation of 250 rpm to achieve  OD > 2 Au. 50% glycerol was added to 
the media in a 1:2 v/v ratio and the culture was aliquoted in 1 mL volumes for storage at 
-80 
oC. For the recombinant S. cerevisiae producing HBsAg (Merck & Co. Inc, PA, 
USA), cell expansion was carried likewise but in the media described by Joyce et al. 
(1995) and without glycerol addition prior to storage.  
 
2.1.4 Development of fermentation protocol for HBsAg production 
The seed stage involved growing a frozen vial (1 mL) of the cell bank in 50 mL 
of media in a 250 mL shake flask for 24 h in a shaker incubator at 28 
oC with agitation 
of 250 rpm. 4 mL of this culture was subsequently transferred to 396 mL of media in 2 
L shake flasks and grown for a further 24 h under the same conditions. [To seed a 20 L 
fermenter, 3 of these 2 L shake flasks would be required while at the 75 L scale, 12 
would be required.]  47 
 
Fermentation studies were performed at 20 L scale using the LH 2000 Insitu 
Inceltech  fermenter  (Inceltech  UK  Ltd,  Slough,  UK)  which  has  the  following 
dimensions: vessel height = 510 mm, vessel diameter = 230 mm, shaft height = 490 
mm, shaft diameter = 12.7 mm, number of impellers = 3, impeller diameter = 68.7 mm, 
and baffle dimensions = 355 x 22 x 1.8 mm. The successful fermentation was scaled-up 
to 75 L using the Inceltech High Contamination fermenter (Inceltech UK Ltd., Slough, 
UK) which has the following dimensions: vessel height = 925 mm, vessel diameter = 
327 mm, shaft height = 595 mm, shaft diameter = 26 mm, number of impellers = 3, 
diameter  of  impeller  =  105.5  mm,  and  baffle  dimensions  =  612  x  32  x  3.5  mm. 
Fermentation working volumes were set at 60-80% and inoculation was performed with 
10%  working  volume  of  the  fermenter.  For  timed-based  induction,  pre-autoclaved 
galactose of the same initial concentration as glucose was added for induction when the 
glucose  level  had  depleted.  For  auto-induction,  galactose  was  added  together  with 
glucose at the start of fermentation. Fermentation was carried out for a total of 48 to 90 
h with pH maintained at 5.5 ± 0.1 with automated additions of 2 M H2SO4 and 4 M 
NaOH. Fermentation level was monitored using a foam probe with automated additions 
of  antifoam.  Measurements  of  temperature,  pH,  agitation  speed,  dissolved  oxygen 
tension (DOT) and airflow rate were recorded automatically using the ProPack data 
logging and acquisition software (Acquisition Systems, Hampshire, UK) integrated to 
the fermenter. Regular samplings were performed to allow off line analysis of optical 
density (OD) measurements at 600nm, dry cell weight analysis and glucose analysis. 
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2.2 Pilot-scale production of HBsAg feed stock for purification 
studies 
Following  from  the  fermentation  studies,  a  protocol  was  established  for  the 
production  of  HBsAg  feed  stock  for  subsequent  purification  investigations.  This 
protocol is based on growing the S. cerevisiae strain for HBsAg (Merck & Co. Inc, 
West Point, PA, USA) using the Joyce et al. (1995) method described in Section 2.1.2. 
To  generate  sufficient  material  for  purification  experiments,  multiple  fermentation 
batches were carried out at the 75 L scale using the protocol described in Section 2.1.4.    
 Following fermentation, cells were harvested using a CARR Powerfuge
TM P6 
(Pneumatic Scale Corporation, Florida, USA) tubular bowl centrifuge which has a 1 L 
bowl  volume  and  is  operated  in  a  batch  mode.  For  cell  harvesting,  the  centrifuge 
rotational speed was set at 15,000 rpm and feed flowrate at 1 L/min. Cells recovered in 
the form of a solid paste were stored in polyethylene bags at -80 
oC. 
 
 
2.3 Pilot-scale homogenisation for cell disruption  
Homogenisation  was  performed  using  a  Gaulin  Micron  Lab  40  homogeniser 
(APV Gaulin GmbH, Lubeck, Germany), which has a 40 mL capacity, for all studies 
unless  specified.  Prior  to  homogenisation,  the  cell  paste  was  resuspended  in  0.1  M 
sodium phosphate, pH 7.2, with 0.5 M NaCl containing phenylmethylsulfonyl fluoride 
(PMSF), a protease inhibitor, prepared in to a concentration of 0.2M in isopropanol and 
added to the phosphate buffer to achieve a final concentration of 2 mM of PMSF. Cell 
paste to buffer ratio for resuspension was 1:3 (w/v). The temperature of the machine 49 
 
was maintained at below 6 
oC by flowing  glycol coolant through the external coils 
throughout  the  process.  Homogenisation  was  performed  for  3-4  passes  at  1200  bar 
unless stated otherwise.  
 
 
2.4 Detergent treatment for HBsAg liberation  
In  experiments  for  comparing  the  efficiency  of  different  detergents  and 
chemicals for HBsAg liberation, solutions of Triton X-100, Triton X-101, Polysorbate 
20  and  80  (PS20  and  PS80)  and  CHAPS  were  prepared  in  their  typical  operating 
concentrations of 0 – 1% v/v and ethyl butyl ether (EB) in the range of 0 – 30% w/v in 
0.01 M phosphate buffer (pH 7.5). Yeast cell homogenate was added to 2 volumes of 
the  solutions  prepared  and  these  were  allowed  to  mix  for  4  h  on  an  Eppendorf 
Thermomixer  (Eppendorf,  Cambridge,  UK).  The  removal  of  cellular  material  was 
performed subsequently by centrifugation (Eppendorf Centrifuge 5415R, Cambridge, 
UK) at 13,000 rpm for 15 min. The supernatant samples were recovered for analysis.  
For  all  other  studies,  Triton  X-100  detergent,  which  was  found  to  give  the 
highest degree of HBsAg liberation, was employed. For screening studies to determine 
the optimal working concentration of Triton X-100, solutions of Triton X-100 in 0.01 M 
phosphate buffer (pH 7.5) were prepared in the range of 0 – 10% v/v. The Triton X-100 
solutions were added to the yeast cell homogenate in a 2:1 volume ratio to achieve 
resulting Triton X-100 concentration of 0 – 6.7 % v/v. Incubation with Triton X-100 
and centrifugation for the removal of cell debris were carried out as described above. 
Prior  to  analysis,  to  prevent  interference  of  Triton  X-100  with  the  assays,  excess 
detergent was removed by incubating the samples with Amberlite XAD-4 beads in a 50 
 
batch mode  (Supelco,  Dorset, UK) for 2 h. [The amounts of  XAD-4 required were 
based  on  0.5  g  XAD-4  per  g  Triton  X-100  determined  from  the  Sigma  product 
information sheet. The efficiency of Triton X-100 removal was verified using control 
experiments.] The XAD-4 beads are larger than the tip of a 200 µL pipette tip, hence 
following the XAD-4 step, samples were recovered by careful pipetting avoiding the 
XAD-4 beads.   
To generate larger amounts of HBsAg feed material required for purification 
studies, the detergent process was scaled up accordingly. Samples were prepared in 50 
mL  BD  Falcon
TM  tubes  (BD  Biosciences,  CA,  USA)  and  centrifugation  was 
accomplished using a Beckman C6-6R centrifuge (Buckinghamshire, UK), operated at 
3,000 rpm for 15 min. The XAD-4 step was also performed as a batch process and the 
separation  of  the  sample  form  XAD-4  beads  was  by  using  either  a  solid-phase 
extraction column which retains the XAD-4 beads or by filtration via a 0.2 µm filter 
(Millipore, Watford, UK). Details of the detergent step performed at pilot-scale for the 
centrifugation validation study are provided in Section 2.12.  
 
 
2.5  Ultrafiltration  study  comparing  effects  of  Triton  X-100 
concentrations  
The ultrafiltration (UF) study was performed using the Akta Cross Flow system 
(GE Healthcare, Amersham, UK) driving an ultra scale-down UF rig designed at UCL. 
In this study, the USD device was operated with 1.5 mL of feed material. Biomax disc 
membranes  (Millipore,  Watford,  UK)  with  100  kDa  molecular  weight  cutoff  and 
effective filtration area of 3.46 cm
2 were employed. Fresh membranes were used for 51 
 
each study. Flux versus TMP curves were generated in total recycle mode, by recording 
steady-state  permeate  flowrates  at  gradual  pressure  increments.  For  all  samples, 
viscosity  was  measured  using  a  Brookfield  Cone  and  Plate  DVII+  Programmable 
Viscometer (Brookfield, Stoughton, MA) as described in Section 2.13.11.  
 
 
2.6 PEG precipitation study 
Equal  volumes  of  cell  lysate  and  PEG  solutions  prepared  in  0.01  M  sodium 
phosphate, pH 7.5, were added to achieve final PEG concentrations of 0% w/v to 25% 
w/v. The samples were allowed to incubate for 2 h with gentle agitation on a Eppendorf 
Thermomixer  (Eppendorf,  Cambridge,  UK).  The  use  of  centrifugation  and  filtration 
were explored for the separation of the resultant precipitate from the mother liquor. For 
centrifugation, the samples were set up using 2 mL Eppendorf tubes and sedimentation 
of the precipitates was achieved via centrifugation at 12,000 rpm for 20 min (Eppendorf 
Centrifuge, 5415R, Cambridge, UK). For filtration, the samples were set up in 96-well 
Multiscreen  filter  plates  (Millipore,  MA,  USA)  and  filtration  was  driven  by 
centrifugation (Eppendorf Centrifuge 5810, Hamburg, Germany) at 900 rpm for 20 min. 
For precipitate resolubilisation, 0.01 M sodium phosphate buffer, pH 7.5, equalling the 
total volume of cell lysate and PEG solution at the start of precipitation was employed. 
To improve resolubilisation, a 0.2% v/v Triton X-100 buffer prepared in 0.01 M sodium 
phosphate, pH 7.5 was investigated. 
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2.7 Ammonium sulphate precipitation study      
Equal volumes of cell lysate and ammonium sulphate solutions prepared in 0.01 
M  sodium  phosphate,  pH  7.5  were  added  to  achieve  final  ammonium  sulphate 
concentrations of 0% w/v to 25% w/v. The samples in eppendorf tubes were allowed to 
incubate  for  2  h  under  gentle  agitation  on  the  Eppendorf  Thermomixer  (Eppendorf, 
Cambridge,  UK)  and  subsequently  centrifuged  (Eppendorf  Centrifuge,  5415R, 
Cambridge, UK) at 12,000 rpm for 20 min. The lipid precipitates formed a floatation 
layer above the soluble phase. The soluble phase was recovered by careful pipetting for 
analysis.  
 
 
2.8 Investigating the selective product recovery methodology  
  The selective product recovery methodology is based on a twin centrifugation 
strategy.  Following  cell  disruption  by  homogenisation,  the  yeast  homogenate  was 
diluted with 2 volumes of a 0.01 M phosphate buffer with a pH of 7.5 and the mixture 
was  centrifuged  using  a  Beckman  C6-6R  centrifuge  (Beckman  Coulter  Inc., 
Buckinghamshire,  UK)  for  15  min  at  3000  g  to  separate  the  cell  solids  from  the 
cytosolic  components.  To  investigate  the  partitioning  of  the  HBsAg  product  and 
contaminants across the supernatant and solids fraction following centrifugation, both 
fractions were treated with a 0.01 M sodium phosphate buffer (pH 7.5) containing 0.6% 
v/v  Triton  X-100  of  a  volume  equivalent  to  that  used  for  the  dilution  of  the  yeast 
homogenate prior to the first centrifugation step. The detergent step was performed as 
described in Section 2.4. Material from the solids fractions was subjected to a second 
centrifugation step operated under identical conditions to the first centrifugation step for 53 
 
the removal of contaminating solids. Prior to analysis, a Triton X-100 removal step 
using Amberlite XAD-4 was performed on all samples as previously described. 
 
 
2.9 Investigating impact of homogenisation pressure on selective 
product recovery 
  Material was prepared for the homogenisation study as described in Section 2.3. 
The homogenisation study was performed on a Gaulin Micron Lab 40 (APV Gaulin 
GmbH,  Lubeck,  Germany).  The  samples  were  homogenised  for  4  passes  at  various 
operating pressures between 100 to 1200 bar and a control sample of undisrupted cells 
was prepared. Temperature was maintained below 6 
oC throughout cell disruption. The 
homogenate samples were subjected to the selective product recovery methodology as 
described in Section 2.8 prior to analysis. 
 
 
2.10 Investigating impact on hydrophobic interaction 
chromatography 
  Chromatographic  separations  were  carried  out  using  1  mL  Hi-trap  Butyl-
Sepharose
® columns (GE Healthcare, Amersham, UK). Sample preparation involved 
adding to the samples 3 M ammonium sulphate solution in a 4:1 ratio to give a final 
concentration of 0.6 M. New columns were employed for each sample and the flowrate 
was maintained at 1 mL/min throughout the operation and separation was performed at 54 
 
room temperature. For all samples, the columns were initially loaded with 2 mL of 
material in the equilibration buffer containing 20 mM sodium phosphate buffer with 0.6 
M ammonium sulphate at pH 7. This was followed by washing using the same buffer to 
remove any unbound material. For elution, a buffer containing 10mM sodium phosphate 
at pH 7 was applied to the column. A second elution in 30% (v/v) isopropanol dissolved 
in 10 mM sodium phosphate at pH 7 was performed to desorb more tightly  bound 
proteins.  Fractions  were  collected  at  regular  intervals  with  volumes  of  0.3-0.5  mL 
during sample loading, early wash stage and product elution.         
 
 
2.11 Ultra-scale down (USD) centrifugation study 
The  two  key  centrifugation  operations  in  the  selective  product  recovery 
methodology were evaluated independently based on the method described in Section 
2.8. Feed material was prepared by homogenisation at 400 bar for 4 passes using the 
Gaulin  Micron  Lab  40  homogeniser  (APV  Gaulin  GmbH,  Lubeck,  Germany).  The 
centrifugation  studies  were  performed  using  the  Eppendorf  Centrifuge  5810R 
(Eppendorf, Hamburg, Germany) and tempearature was maintained at 4 
oC. To study 
the first centrifugation operation, pre-weighed Eppendorf tubes were filled with 1.5 mL 
of the homogenate and centrifuged for different lengths of time and at rotational speeds 
in the range of 3000 – 13,000 rpm to achieve Q/C∑ conditions of 1.3 x 10
-9 to 1.8 x 10
-7 
m/s in 6 replicates. A well spun sample used as the reference for solids recovery and 
dewatering  was  prepared  by  centrifugation  for  40  min  at  13,000  rpm  to  achieve  a 
corresponding Q/C∑ value of 1.1 x 10
-9 m/s. All supernatant fractions were carefully 
removed by pipetting. Residual liquid and lipid layer remaining on the wall of the tubes 55 
 
were removed with the aid of a tissue. The Eppendorf tubes containing wet cells were 
weighed. For each centrifugation condition, a set of 3 wet pellet samples were kept for 
detergent-mediated  HBsAg  liberation  while  the  other  3  were  left  to  dry  in  an  oven 
overnight at 100 
oC and reweighed after the drying process. Following the detergent 
step  (described  below),  a  second  centrifugation  step  was  performed  for  recovery  of 
soluble product and this was at constant Q/C∑ of 1.1 x 10
-9 m/s for all samples.  
To study conditions of the second centrifugation step, the first centrifugation 
step was performed for all samples at the optimal Q/C∑ condition determined above. 
Following the discard of the supernatant from the first centrifugation step, Eppendorf 
tubes containing wet cells were weighed and treated with a phosphate buffer containing 
0.6% v/v of Triton X-100 detergent as described previously in Section 2.8. The second 
centrifugation operation was carried out under a range of Q/C∑ values (1.3 x 10
-9 to 6.5 
x 10
-7 m/s) in 6 replicates. The supernatants from this second centrifugation step were 
recovered and the Eppendorf tubes containing the wet sediment weighed, left to dry and 
then reweighed.  
 
 
2.12 Pilot-scale centrifugation study for USD validation  
  The pilot-scale centrifugation validation study was performed using the CARR 
Powerfuge
TM P6 to compare the use of the optimal conditions predicted from the USD 
studies  (Batch  A)  against  the  worst  case  scenario  (Batch  B).  Due  to  the  lack  of 
availability of recombinant S. cerevisiae expressing the HBsAg product, baker’s yeast 
(Craftbake High Activity, DCL Yeast Ltd, Surrey, UK) was employed for this study.  
Material for the first centrifugation step was prepared as previously described in Section 56 
 
2.8 at a 10L scale using diluted cell homogenate produced at 400 bar for 4 passes using 
the  Gaulin  Micron  Lab  60  homogeniser  (APV  Gaulin  GmbH,  Lubeck,  Germany).  
Temperature was maintained at 4 
oC for all centrifugation studies. For Batch A, the first 
centrifugation step was performed at a feed flowrate of 1 L/min with a rational speed of 
5,000 rpm (Q/C∑ = 1.67 x 10
-7) while for batch B this was carried out at a feed flowrate 
of 0.1 L/min with a rotational speed of 15,000 rpm (Q/C∑ = 1.9 x   10
-9). The solids 
fraction from both Batch A and B were recovered and resuspended with ~ 7 L of a 0.6% 
v/v  Triton  X-100  buffer  and  mixing  was  accomplished  in  a  20L  LH  2000  Insitu 
Inceltech fermenter (Inceltech UK Ltd, Slough, UK) with mixing at 200 rpm at room 
temperature.  The  second  centrifugation  step  was  performed  for  Batch  A  at  a  feed 
flowrate of 0.1 L/min with a rotational speed of 15,000 rpm (Q/C∑ = 1.9 x 10
-9) and for 
Batch B at a 1 L/min feed flowrate and 5,000 rpm in terms of rotational speed (Q/C∑ = 
1.67 x 10
-7). Samples of the supernatant and solid fractions from Batch A and B for both 
centrifugation  stages  were  analysed  to  determine  the  levels  of  dewatering,  solids 
recovery, clarification and the amounts of host protein and lipid contaminants present.         
 
 
2.13 Analytical techniques 
2.13.1 Optical density measurements 
Optical  density  (OD)  measurements  were  performed  on  a  BioMate3 
spectrophotometer  (Thermo  Spectronic,  Rochester,  NY,  USA)  at  a  wavelength  of 
600nm.  Sarstedt  cuvettes  (Sarstedt,  Numbrecht,  Germany)  were  employed  and  the 
machine was blanked with DI water prior to analysis. The linear range for detection was 57 
 
between 0 and 1 Au. Samples with OD values > 1 Au were diluted and re-measured.  
[Coefficient of variance from duplicate samples ≤ 5%.] 
 
2.13.2 Dry cell weight analysis 
Dry cell weight analysis was performed by filtering a known volume of sample 
through  a  pre-weighed  Whatman  Glass  Microfibre  Filter  Grade  GF/F  (Whatman, 
Maidstone, UK) and rinsed with DI water. The filter was then dried overnight in an 
oven at 100 
oC and re-weighed. Dry cell weight, which is a reflection of the cell density 
achieved in fermentation, was calculated as shown in the Equation 2.1 below where 
DCW represents dry cell weight, Ff, mass of the filter containing cells before drying, Fo, 
mass of an empty filter and V, the volume of sample filtered through. [Coefficient of 
variance from duplicate samples ≤ 10%.] 
    = 
     
        (Equation 2.1) 
 
2.13.3 Glucose analysis   
Offline  glucose  analysis  was  performed  using  a  YSI  bioanalyser  (YSI  Life 
Sciences, Yellow Springs, Ohio, USA). The method has a linear detection range from 0-
5 g/L. Samples with glucose concentrations above this range were diluted accordingly 
prior to analysis. [Coefficient of variance from duplicate samples ≤ 2%.] 
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2.13.4 HBsAg determination by ELISA 
HBsAg concentration was determined using the Murex HBsAg ELISA assay kit 
from  Abbott  Laboratories  (Maidenhead,  Beckshire,  UK).  Recombinant  HBsAg  (1 
mg/mL) from Serotec (Oxford, UK) was used as the standard and calibration curve was 
generated from serial dilution of the standard. Due to the narrow linear range of the 
assay (linear range observed for concentrations below 3 x 10
-4 mg/mL), samples were 
diluted  1000-fold  with  buffer  (0.01  phosphate,  pH7.5).  This  assay  functions  on  a 
sandwich format whereby 75 µL of diluted samples were added along with 25 µL of 
sample diluent from the kit containing detergents and bovine and goat proteins to a 96-
well plate coated with mouse monoclonal antibody to HBsAg. The plate was incubated 
for 1 h at 37 
oC and following this, 50 µL of conjugate horseradish-peroxidase labeled 
goat antibody to HBsAg buffered in bovine and goat proteins were added to each well. 
A second incubation period of 30 min at 37 
oC followed this. The plate was then rinsed 
5  times  using  wash  buffer  of  glycine/borate  solution  diluted  5-fold  in  RO  water. 
Subsequently, 100 µL of  a substrate solution containing 3,3’,5,5’-tetramethylbenzidine 
(TMB) was added and during this stage, for wells containing the HBsAg product, a 
colour  change  from  pink  to  blue  /  purple  would  be  observed.  The  plate  was  again 
incubated for 30 min at 37 
oC. The enzyme-substrate reaction responsible for the colour 
change was quenched by the addition of 50 µL of 2 M sulphuric acid which resulted in a 
second colour change from blue / purple to yellow. Detection was performed using the 
Tecan  Safire  II  microplate  reader  (Tecan  Group  Ltd,  Mannedorf,  Switzerland)  at  a 
wavelength  of  450  nm  using  690  nm  as  the  reference  wavelength.  [Coefficient  of 
variance for triplicate samples of ≤ 17%.] 
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2.13.5 Total protein assay by Bicinchoninic acid assay (BCA) 
Total soluble protein was determined using a bicinchoninic acid assay (BCA) kit 
(Sigma,  Dorset,  UK.)  Calibration  was  performed  by  7  steps  of  serial  dilution  using 
bovine  serum  albumin  (BSA)  of  2  mg/mL  which  accompanied  the  kit  to  achieve  a 
protein  range from 0.15 – 2 mg/mL. Samples were diluted 2 – 8 fold depending on their 
starting  concentration  to  ensure  that  the  final  concentrations  fell  within  the  linear 
detection range. 20 µL of sample or standard was added with 200 µL of BCA reagent 
on  a  96-well  plate  (Sarstedt  AG  &  Co,  Leicester,  UK  or  Nunc,  Thermo  Fisher 
Scientific, Leicester, UK). The samples were incubated at 37 
oC for 30 min and a colour 
change from green to blue was observed for samples containing protein. Detection was 
performed using the Tecan Safire II microplate reader (Tecan Group Ltd, Mannedorf, 
Switzerland)  at  an  absorbance  wavelength  of  562  nm.  [Coefficient  of  variance  for 
triplicate samples ≤ 10%.] 
 
2.13.6 Lipid analysis by HPLC 
Sample preparation for HPLC was carried out by adding 70 µL of sample to 930 
µL sample buffer containing chloroform, TFA in methanol (TFA:methanol = 1:285) and 
methanol in 50:3:40 v/v ratio. The mixture was then centrifuged at 13,000 rpm for 2 
min to remove precipitated proteins from solution. Supernatant containing soluble lipids 
was decanted into vials for HPLC analysis. The HPLC lipid assay used a Jordi Gel 
Glucose DVB 500 column (Alltech, Deerfield, IL, USA) and operated at a flowrate of 1 
mL / min, with a run time of 25 min under an isocratic mode of separation. Absorbance 
was monitored at 254 nm to detect for ergosterol which is the major lipid contaminant 
in yeast cells (Veen & Lang, 2004). Running buffer contained chloroform, methanol 60 
 
and 0.15% TFA in water at a ratio of 50:42:7 (v/v). Ergosterol standard of 10 µg/mL 
was analysed in order to identify the major lipid peak. The minor peaks, however, were 
unidentifiable and to account for these, results were presented in terms of total peak 
area. [Coefficient of variance (for peak area) for duplicate samples ≤ 4%.] 
 
2.13.7 Protein analysis by size exclusion chromatography (SEC) 
Samples of 100 µL were loaded onto a Superose 6 10/300 GL  column (GE 
Healthcare, Amersham, UK) which was operated at 0.5 mL/min for a total run time of 
90 min using 0.5 M phosphate running buffer, pH 7. Absorbance was monitored at 280 
nm. Protein profiling using this method was based on the elution time of the peaks with 
larger  proteins  eluting  earlier.  [Coefficient  of  variance  for  peak  area  for  duplicate 
samples ≤ 4%.] 
 
2.13.8 Nucleic acid determination 
Prior to analysis, the nucleic acids were extracted using a QIAprep kit (Qiagen, 
West  Sussex,  UK),  following  the  protocol  accompanying  the  kit.  Nucleic  acid 
determination was carried out using a NanoDrop
® ND-1000 (NanoDrop
®, Delaware, 
USA) where the measurements of nucleic acid contents are determined by the software 
based  on  the  absorbance  measurements  of  the  samples  at  260  nm.  [Coefficient  of 
variance for triplicate samples ≤ 10%.] 
 61 
 
2.13.9  VLP  fractionation  by  size  exclusion  chromatography  for  particle 
size analysis 
Samples filtered using a 0.2 µm hydrophilic filter (Millipore, Watford, UK) were 
loaded  onto  a  Superose  6  10/300  GL  column  (GE  healthcare,  Amersham,  UK). 
Separation was carried out at a flowrate of 0.5 mL / min for a total run time of 90 min. 
The running buffer was 0.5 M phosphate buffer, pH 7. Fractions of 1 mL were collected 
and the active peak identified using an ELISA based method detailed in Section 2.13.4. 
 
2.13.10 Particle size analysis by dynamic light scattering  
Particle size analysis was carried out using a Malvern Zetasizer Nano S (Malvern 
Instruments  Ltd.,  Worcestershire,  UK)  which  operates  based  on  dynamic  light 
scattering. This equipment allows size measurements in the nanometer range. Prior to 
sample analysis, 70 µL of samples were filtered through a 0.2 µm hydrophilic filter 
(Millipore,  Watford,  UK).  Data  presented  are  based  on  particle  size  /  volume 
distribution. DLS volume distribution was chosen over intensity distribution since the 
latter  is  more  susceptible  to  signal  domination  by  large  sized  particles  which  may 
provide misleading representation of the population, and DLS volume distribution was 
favoured over number distribution to minimise the error in data conversion (User Guide, 
Malven  Instruments). Samples were measured in triplicate and the number of scans 
taken  was  set  to  automatic  (instrument  determines  the  number  of  measurements  to 
achieve  good  quality  data  taking  into  account  sample  polydispersity)  and  the 
measurement errors are denoted on the histogram generated by the software, showing an 
average coefficient of variance of 10%.       
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2.13.11 Viscosity measurement 
  Viscosity  measurements  were  performed  using  a  Brookfield  Cone  and  Plate 
DVII+ Programmable viscometer (Brookfield, Stoughton, MA, USA). The machine was 
initially autozeroed and a check was performed to ensure the pin on the cone and cup 
were correctly positioned by running the machine at 10 rpm and monitoring the display 
for jumps or unsettled readings. A sample of 1-2 mL was then  added to the chamber 
and the shear stress and shear rate measurements were recorded at a range of rotational 
speeds of 40-200 rpm. Shear stress values were then plotted against shear rates and the 
viscosity  of  the  sample  determined  by  the  slope  of  the  stress-strain  relationship.  A 
control was performed using RO water. [Average coefficient of variance ≤ 10%]  
 
2.13.12 Microscopy analysis 
Cell homogenate generated at different pressures together with the undisrupted 
sample  as  a  control,  were  studied  under  a  Leica  DM  light  micrcoscope  (Leica 
Microsystems  Ltd,  Heerbrigg,  Switzerland).  For  sample  preparation,  10  µL  material 
was  added  to  a  microscope  slide  and  a  cover  slip  was  lowered  gently  to  avoid  the 
formation of air bubbles. Initial focusing was carried out at 400 X magnification using 
the  40  X  objective.  For  1000  X  magnification,  oil  was  added  to  the  cover  slip  for 
immersion using the 100 X objective. The software on the Leica system allows the 
microscope images to be captured and saved. A scale was drawn using the Image J 
programme  (National  Institute  of  Health,  USA,  1997)  based  on  the  correlation  of 
number of pixel to length information from the Leica and this provided a capacity to 
record the key dimensions of the visible cell homogenate components.  
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2.13.13 Analysis of solids recovery or clarification level 
For centrifugation studies, Eppendorf tubes were weighed initially empty and at 
the end of the experiment when they contained solid fractions dried in an oven at 100 
oC 
overnight.  The difference in weight equals the dry cell weight. A reference for 100% 
(w/w) solids recovery was setup using a well spun sample prepared by centrifugation at 
13,000  rpm  for  40  min  (Q/C∑  =  1.1  x  10
-9  m/s).  For  all  other  samples,  the  solids 
recovery level were calculated proportional to the reference data as shown in Equation 
2.2. [Average coefficient of variance ≤ 10%.] 
%                 = 
                         
                             x 100%    (Equation 2.2) 
 
2.13.14 Analysis of dewatering level 
The  dry  cell  weight  was  measured  as  above,  determined  as  the  difference 
between the weights of the Eppendorf tubes when containing wet solid fractions and 
when empty. A well spun sample prepared under the conditions described in Section 
2.11 was used as the reference and denoted as 100%. The ratio of the dry cell weight to 
the  wet  cell  weight  (dwr)  was  calculated  and  this  constant  used  to  account  for  the 
amount  of  intracellular  water  removed  by  the  drying  process  (Salte  et  al.,  2006). 
Percentage dewatering for all samples can be calculated as shown in the Equation 2.3 
below whereby WWsed and DWsed respectively denote the wet and dry weights of the 
sedimented cells. [Average coefficient of variance ≤ 10%.] 
%            = 100% −  
      
     
   
     
 x 100%     (Equation 2.3) 
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2.14 Application 
This chapter provides a compilation of the main experimental and analytical procedures 
in this research and serves as a point of reference for discussions in the following results 
chapters on materials and experimental methods employed. Specific modifications to 
the  procedures  reported  here  for  individual  studies,  if  any,  are  described  in  the 
corresponding results chapters.   
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Chapter 3: Fermentation development for recombinant S. cerevisiae  
Fermentation Development  
 
 
3.1 Introduction  
Saccharomyces  cerevisiae  is  an  attractive  host  strain  for  the  large-scale 
expression of recombinant proteins as it is non-pathogenic for humans, relatively free of 
endotoxins  and  has  favourable  fermentation  characteristics  such  as  high  protein 
productivity, reproducibility and amenability to scale up (Carty et al., 1989; Buckland, 
2005). Yeast cells have the added ability of performing complex eukaryotic-like post-
translational modifications producing proteins similar to those of the mammalian origin. 
A wealth of genetic information on S. cerevisiae is available and this facilitates the 
engineering  of  the  desired  cell  metabolism  and  expression  characteristics  using  this 
strain.  
The hepatitis B surface antigen (HBsAg) from Merck & Co Inc. (West Point, 
PA,  USA)  examined  in  this  study  is  expressed  recombinantly  in  S.  cerevisiae.  For 
plasmid maintenance and to confer a competitive advantage over wild type cells, the 
plasmid containing the HBsAg gene has also been inserted with a Leu+ gene (Carty et 
al., 1989). This allows the use of a leucine-free selective media for fermentation in 
which  the  recombinant  strain  capable  of  synthesising  the  amino  acid  leucine  would 
thrive whilst the growth of wild type cells would be hindered.   66 
 
The HBsAg gene is expressed under the control of the GAL-10 promoter (Fu et 
al.,  1996)  and  is  regulated  by  the  levels  of  glucose  and  galactose  present  during 
fermentation (St. John and Davis, 1981). When glucose becomes depleted during cell 
culture, the cells switch to galactose metabolism which induces the HBsAg gene and the 
product is synthesised. Composition of the culture media and feeding strategy has an 
enormous  impact  on  cell  growth  and  protein  expression  characteristics.  Glucose  is 
employed as the main carbon source for HBsAg fermentation however high glucose 
levels in yeast could cause catabolite repression which impairs cell growth. A synthetic 
medium  containing  glucose  but  with  minimal  catabolite  repression  effects  was 
developed by Oura (1974). Galactose is another vital media component in fermentation 
for the regulation of the HBsAg gene. The interactions between glucose and galactose in 
the regulation of HBsAg expression has been reported (Carty et al., 1989). Galactose 
could be added when glucose has been depleted for time-based induction which could 
minimise  the  effects  of  catabolite  repression  due  to  the  use  of  overly  rich  media 
(Gancedo,  1998)  or  at  the  start  of  fermentation  for  auto-induction  which  serves  to 
reduce process monitoring requirements.  
In this study, the master cell bank of the recombinant yeast cells was donated by 
Merck & Co. Inc (West Point, PA, USA). To generate material for purification studies, 
fermentation  was  carried  out  at  pilot-scale  at  the  Advanced  Centre  for  Biochemical 
Engineering at UCL. Although fermentation itself was not the focus of this thesis, the 
production of a realistic feed stock for subsequent purification studies was critical.  
This chapter therefore describes fermentation development studies performed to 
determine the suitable media composition and feeding strategy for the recombinant S. 
cerevisiae cells.  Two different fermentation media compositions were investigated: (1) 
a  fully  defined  media  developed  by  Yau  (2005)  which  was  adapted  from  previous 67 
 
studies by Oura (1974) and Fu et al. (1996) and has been successfully demonstrated for 
wild type yeast fermentation; and (2) a semi-defined media reported by Joyce et al.  
(1998)  for  the  production  of  the  human  papillomavirus  (HPV)  vaccine  from 
recombinant  S.  cerevisiae.  Trial  fermentations  at  20L  scale  was  initially  performed 
using wild type S. cerevisiae to provide an understanding of growth characteristics and 
requirements of yeast cells. For the recombinant strain, a similar protocol was adopted 
but with modifications in terms of the media composition, galactose addition time and 
the  length  of  fermentation.  Fermentation  performance  was  evaluated  based  on  cell 
growth characteristics as indicated by dissolved oxygen levels, glucose consumption, 
cell density measurements and the HBsAg productivity levels targeted at 100 mg/L 
based on Merck process recommendations. The suitable media composition and feeding 
strategy were then scaled up to 75 L to generate material for the subsequent HBsAg 
purification studies.    
 
 
3.2 Materials and Methods 
Fermentation development studies were performed using two different strains of 
S. cerevisiae. A wild type S. cerevisiae strain, ATCC 26786 (ATCC, Middlesex, UK) 
was initially employed for a trial fermentation and subsequent studies were performed 
using the recombinant S. cerevisiae strain (Merck & Co. Inc, West Point, PA, USA) 
which produces the HBsAg product. Two different fermentation media were evaluated 
for HBsAg production and the media composition are detailed in Section 2.1.2. Cell 
banking  methods  were  described  in  Section  2.1.3.  Fermentation  experiments  were 
conducted initially at a 20 L scale and the developed process was subsequently scaled 68 
 
up  to  75  L  as  reported  in  Section  2.1.4.  The  pilot-scale  process  employed  for  the 
production of HBsAg feed stock for purification studies is described in Section 2.2.   
Analytical  techniques  for  fermentation  process  monitoring  include  online 
measurements of pH, temperature, dissolved oxygen tension (DOT), agitation speed and 
air  flow  rate  (Section  2.1.4),  determination  of  cell  density  by  optical  density 
measurements  (Section  2.13.1)  and  dry  cell  weight  analysis  (Section  2.13.2), 
measurement  of  glucose  levels  (Section  2.13.3)  and  determination  of  HBsAg 
productivity via an ELISA assay (Section 2.13.4).  
 
 
3.3 Results and Discussions 
Fermentation  studies  were  carried  out  to  develop  a  suitable  protocol  for  the 
production of a realistic feed stock for HBsAg purification research. Initial studies were 
carried out at 20 L and the developed process was subsequently scaled up to 75 L. The 
media previously reported by Yau (2005) and the Joyce et al.  (1998) were assessed in 
terms of their ability to support growth of recombinant S. cerevisiae cells and HBsAg 
productivity titres that are representative of the industrial process.   
 
3.3.1 Wild type S. cerevisiae fermentation in the Yau (2005) media  
A trial fermentation was carried out using wild type S. cerevisiae from ATCC 
with the aim of gaining better understanding on yeast cell growth characteristics and 
media requirements. The fermentation was performed at 20 L scale with 12 L working 
volume using the Yau (2005) media which was developed based on previous works by 69 
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Fu  et  al.  (1996)  and  Oura  et  al.  (1974).  20  g/L  glucose  was  added  at  the  start  of 
fermentation  as  the  main  carbon  source  and  when  this  had  depleted,  galactose  was 
added to induce HBsAg production.  
The  fermentation  profile  recorded  is  as  shown  in  Figure  3.1.  A  drop  in  the 
dissolved oxygen tension (DOT) was observed from the start of fermentation due to 
increased oxygen consumption which is indicative of increased cell growth rate. The 
DOT level plateaued at the minimum DOT set point of 30% maintained by the feedback 
regulation  of  the  agitation  rate  to  compensate  any  further  increase  in  oxygen 
consumption.  At  approximately  18  hours,  a  rise  in  the  DOT  level  was  detected 
suggesting a decrease in the cell growth rate. Off-line glucose measurement indicated 
that  the  glucose  level  was  near  depletion  at  this  stage.  Galactose  was  added  for 
induction. A dip in the DOT level was observed at approximately 25 hours and this is 
likely due to the switch to galactose metabolism. 
  
 
 
 
 
 
 
 
Figure 3.1: Fermentation profile obtained for wild type S. cerevisiae grown in media 
adapted from Oura (1974) and Fu et al. (1996) showing variations in DOT ( ), 
OD600 ( ) dry cell weight (DCW) ( ) and glucose levels ( ) over 
the culture period.  70 
 
Offline measurements of OD600 and dry cell weight followed the trends in the 
DOT profile. D600 and dry cell weight plateaued after approximately 20 hours when the 
glucose supply had been depleted and galactose metabolism begun. The fermentation 
lasted 48 hours achieving a maximum OD600 of 27 Au and maximum dry cell weight 
of 22 g/L.  
The  results  from  the  wild  type  S.  cerevisiae  fermentation  showed  that  the 
adapted media could support cell growth and may be employed for the production of 
HBsAg. Assuming that the growth characteristics of the recombinant strain were similar 
to the wild type, glucose level would be expected to deplete after ~ 23 hours after which 
galactose  induction  would  commence.  Subsequent  studies  were  performed  with  the 
recombinant strain to verify this.  
 
3.3.2 Recombinant S. cerevisiae fermentation using the Yau (2005) media 
  Following from the promising fermentation performance of the wild type S. 
cerevisiae cells, the Yau (2005) media was investigated for culturing the recombinant 
strain. During the seed stage, low OD600 measurements were observed. After 24 hours 
of culture OD600 of < 0.3 Au was achieved in comparison to the wild type strain which 
showed OD600 > 1 Au at the same time point. OD600 values correlate to the number of 
cells detected. Hence the low OD600 values recorded could be due to poor cell growth 
or increased cell aggregation due to the mnn mutation in yeast which renders the cells 
clumpy during growth (Mendez-Vilas et al., 2004). A reddish tint was also detected in 
the shake flask cultures. This may have been caused by an ade1 mutation which leads to 
the  accumulation  of  an  adenine  precursor  which  later  polymerises  into  a  pigment 
(Ugolini & Bruschi, 1996; Crowley & Kaback, 1984).  71 
 
Despite the low OD levels, the shake flask cultures were used to inoculate a 20 
L fermenter. Galactose was added together with glucose at respective concentrations of 
20 g/L at the start of fermentation for auto-induction and the culture was maintained for 
~ 90 hours. The DOT level decreased only slightly and remained above 80% over the 
fermentation period. The low oxygen consumption indicated that the rate of cell growth 
was low. A maximum OD600 of 7 Au and dry cell weight of 8 g/L were obtained but 
only towards the end of the ~ 90 hour culture period. Offline glucose analysis by HPLC 
further confirmed that cell metabolism was slow. For the wild type fermentation, the 
glucose level was depleted after ~ 20 hours, however this did not occur until after 60 
hours  for  the  recombinant  strain  investigated  here.  Due  to  the  poor  growth 
characteristics and the late galactose induction (after 60 hours), a low HBsAg titre of ~ 
12 mg/L was measured.    
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Figure 3.2: Fermentation profile obtained for recombinant S. cerevisiae grown under 
the same conditions and media composition as the wild type strain showing variations 
in DOT ( ), OD600 ( ), dry cell weight (DCW) ( ) and glucose levels 
( ) over the culture period.  72 
 
It is evident that the media previously shown to be successful for the wild type 
fermentation did not achieve the same cell growth characteristics for the recombinant 
strain.  Galactose  addition  at  the  start  of  fermentation  for  auto-induction  could  have 
contributed to the poor cell growth observed, hence further studies to investigate this 
would be required if such a media were to be used as the basis for large scale HBsAg 
production.  
In view of the poor cell growth observed using the Yau (2005) media, a second 
media originally developed for the large scale  production of the HPV  VLP vaccine 
(Joyce et al., 1998), was investigated for HBsAg production.   
 
3.3.3 Recombinant S. cerevisiae fermentation in media from Joyce et  al.  
(1998) 
The  fermentation  protocol  described  in  Joyce  et  al.  (1998)  originally  for 
producing the HPV vaccine employs a culture media which is semi-defined and leucine 
free both for the seed stages and for HBsAg production. An improvement in cell growth 
over that achieved with the earlier Yau (2005) media was observed during the seed 
stages. After a 24-hour period, OD600 values of > 2 Au were attained and the cultures 
did not show the reddish colouring previously observed for the Yau (2005) media.  
Fermentation for HBsAg production was carried out also with additions of 20 
g/L glucose and 20 g/L galactose for auto-induction.  The fermentation profile is shown 
in Figure 3.3. A rapid drop in the DOT profile was observed at the start of fermentation 
reaching the minimum DOT set point of 30% at ~ 10 hours at which point the DOT 
plateaud  at  this  level  for  a  further  20  hours.  The  DOT  profile  was  similar  to  that 
obtained  for  the  trial  fermentation  with  the  wild  type  strain  in  which  high  oxygen 73 
 
consumption  rates  indicated  healthy  cell  growth.  Off-line  glucose  measurements 
suggested that galactose induction occurred before ~ 22 hours which again was similar 
to that from the wild type fermentation.  
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Figure 3:3: Fermentation profile obtained for recombinant S. cerevisiae grown in the 
Joyce et al. (1998) media originally for HPV production. Variations in DOT ( ), 
OD600 ( ), dry cell weight (DCW) ( ) and glucose levels ( ) are 
shown over the culture period.  
 
Fermentation  was  carried  out  for  a  total  of  72  hours  achieving  a  maximum 
OD600 of 5.5 and maximum dry cell weight of 6 g/L which was slightly lower than the 
9.5 – 9.7 g/L range reported by Joyce et al. (1998). Although the maximum OD and dry 
cell weight were similar to those from the Yau (2005) media for the recombinant strain, 
these values were achieved earlier at ~ 22 hours. This was beneficial as high cell density 
achieved earlier in fermentation would increase the productivity level of HBsAg over 
the culture period.  ELISA assay results showed that an overall HBsAg titre of ~ 60 74 
 
mg/L was attained from this fermentation, significantly closer to the range expected for 
this Merck strain.  
 
3.3.4 Scale up of recombinant S. cerevisiae fermentation to 75 L scale 
Based on the promising fermentation performance using the Joyce et al. (1998) 
media, the fermentation was scaled up in terms of volume, from 20 L to 75 L and in the 
supply  of  glucose  and  galactose  which  were  doubled  to  40  g/L  respectively.  The 
fermentation profile obtained is as shown in Figure 3.4. From the start of fermentation, 
a rapid decline in the DOT level to a minimum of ~ 40% was observed. Unlike that 
observed at the 20 L scale, the DOT level did not plateau but instead increased after the 
initial drop. [Further studies may be required to investigate if this was due to differences 
in oxygen transfer characteristics which are related to the design of the fermenters but 
these aspects were deemed to be beyond the scope of this thesis].   
The scaled up process was maintained for an equal length of culture time of 72 
hours.  In spite of the higher supply of  glucose  at the start of fermentation, glucose 
depletion and galactose induction occurred around the same time point as of the 20 L 
batch. Maximum OD600 and dry cell weight measurements of ~ 6 respectively were 
similar to those previously attained however higher HBsAg titres were achieved with a 
maximum of 100 mg/L recorded at ~ 48 hours. Off-line HBsAg measurements over the 
course of fermentation are shown in Figure 3.5. The drop in HBsAg levels towards the 
end of fermentation corresponded to the decrease in dry cell weight measurements and 
may suggest that some level of cell death and proteolysis might have occurred. Based 
on this, the optimal harvest point would be ~ 50 hours to ensure that maximum HBsAg 
yield is achieved.  75 
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Figure 3.4: Recombinant S. cerevisiae fermentation scaled up to 75 L using the Joyce et 
al. (1998) media with 40 g/L glucose and galactose additions. Profiles of DOT ( ), 
OD600 ( ), dry cell weight (DCW) ( ) and glucose levels ( ) are 
shown over the culture period.  
 
 
 
 
 
 
 
 
Figure 3.5: HBsAg expression per litre of fermentation broth measured off-line for the 
recombinant S. cerevisiae fermentation at 75 L scale with 2-fold increase in additions of 
glucose and galactose over the 20 L fermentation.    76 
 
  A total of ~ 400 g of wet cells were harvested from this fermentation with an 
estimated total HBsAg yield of 5 g. The cell biomass from fermentation based on a 
maximum dry cell weight of 6 g/L and the HBsAg productivity level of 80-100 mg/L 
broth are within the target values expected from an industrial process. Based on this, it 
was deemed that the 75 L scale process demonstrated here was capable of generating 
feed stock that was sufficiently realistic for subsequent purification studies.      
 
 
3.4 Conclusions 
The HBsAg protein is recombinantly expressed in S. cerevisiae and to generate 
sufficient material for purification studies, the development of a suitable fermentation 
method was critical. Although fermentation itself was not the focus of this research 
project,  it  was  important  that  the  feed  stock  generated  was  representative  of  that 
obtained from an industrial process to ensure that results from subsequent purification 
studies  were  relevant.  Fermentation  performance  can  be  assessed  based  on  the  cell 
biomass and HBsAg productivity levels achieved. Fermentation developmental studies 
were performed at 20 L scale based on two previously reported fermentation media 
compositions.  The  first  was  a  defined  media  developed  by  Yau  (2005)  based  on 
previous studies by Oura (1974) and Fu et al. (1996). Although this media had shown 
promising results for wild type S. cerevisiae fermentation, the rate of cell growth was 
very low when used for the recombinant HBsAg producing strain. This was reflected by 
the low oxygen consumption levels as DOT measurements remained > 80% over the 
cell  culture  period  and  the  low  final  HBsAg  productivity  titre.    The  second  media 
investigated was originally developed by Merck & Co. Inc for the production of the 77 
 
HPV vaccine in recombinant S. cerevisiae (Joyce et al., 1998). Fermentation using this 
media for the production of HBsAg was successful. Healthy cell growth was evident 
from the oxygen consumption and cell density profiles. Significantly  higher HBsAg 
titre was achieved. This fermentation was scaled up to 75 L and the supply of glucose 
and galactose were doubled. Similar cell growth characteristics and an improvement in 
HBsAg productivity titre were observed upon scale up. The cell densities and HBsAg 
titres were comparable with those achieved in industry (Joyce et al., 1998). Having 
fulfilled these criteria the scaled up process was deemed suitable for the production of 
HBsAg for purification studies which formed the next stage of the investigations.  78 
 
Chapter 4: Detergent-mediated HBsAg liberation 
Detergent-mediated HBsAg liberation 
 
 
4.1 Introduction  
Although  production  of  HBsAg  has  been  achieved  using  bacteria,  transgenic 
plants (Kumar et al., 2005) and mammalian cells (Diminsky et al., 1997), expression in 
S. cerevisiae remains an attractive option. Yeast fermentation is well established, highly 
reproducible  and  amenable  to  large  scale  operation  (Buckland,  2005).  However,  as 
previously discussed, the HBsAg is a lipid-envelope protein and its expression using S. 
cerevisiae as the host cell could raise specific challenges in the recovery of the product. 
The p24s monomers of the HBsAg are secreted cotranslationally into the endoplasmic 
reticulum (ER) and bud into the lumen as 20-nm lipoprotein particles using host lipid 
(Eble et al., 1986). Since the protein is permanently localised within the ER (Biemans et 
al., 1992), cell disruption using high pressure homogenisation followed by a detergent 
step is necessary to release the VLP from the tightly associated membrane components. 
The multistage process for the recovery and purification of HBsAg from yeast cells is 
shown  in  Figure  4.1.  Following  release  of  HBsAg  into  the  process  stream,  cell 
membrane  debris  and  other  contaminating  solids  are  removed  by  centrifugation. 
Subsequently,  detergent  is  removed  from  the  process  stream  by  recirculation  of  the 
material  through  an  XAD-4  column.  Purification  of  HBsAg  is  typically  achieved 
through  a  series  of  chromatographic  stages  (Dekleva,  1999;  Belew  et  al.,  1999) 79 
 
although the use of precipitation and density ultracentrifugation (Deml et al., 1999) has 
also been reported.  
 
 
Figure  4.1:  Typical  process  flowsheet  for  recovery  of  HBsAg  from  S.  cerevisiae. 
(Adapted from Dekleva, 1999).  (---) highlights unit operations focused on in this study. 
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Detergent-mediated  liberation  of  VLP  is  a  critical  step  in  the  recovery  of 
HBsAg. Detergent facilitates recovery of HBsAg by weakening interactions that exist 
between  the  VLP  and  membrane  components  (Chi  et  al.,  1994)  and  by  promoting 
separation  of  yeast  cell  membrane  from  other  unwanted  cellular  debris  (Sitrin  and 
Kubek, 1992), allowing better access of the detergent to the ER. A study by Smith and 
co-workers on extraction of HBsAg from recombinant plant systems further suggested 
that detergent may also promote VLP vesicle formation by driving the inward budding 
of the ER membrane (Smith et al., 2002; Kreibich et al., 1982) 
Based on the above, it is likely that increases in detergent concentration would 
favour VLP recovery. However, it may also be necessary to take into consideration the 
fact that the HBsAg particle is essentially a lipoprotein, composing of 75% protein and 
25%  lipid  by  weight  (Gavilanes  et  al.,  1982).  The  lipid  moiety  has  been  shown  to 
perform  critical  roles  in  the  maintenance  of  native  structure  and  antigenic  activity 
(Gavilanes et al., 1990; Sevcsik et al., 2007). Excess detergent could have detrimental 
effects  on  the  lipid  constituents  of  the  HBsAg  particle  leading  to  a  decrease  in 
immunogenic activity.  
The yeast endoplasmic reticulum and other membranous organelles are rich in 
lipid and protein. Lipid production in yeast cells increases during extended cell cultures 
(Wijnendaele et al., 1987), which is necessary in the production of VLPs to achieve the 
desired  protein  expression  levels.  It  is  likely  that  the  addition  of  detergent  would 
promote the release of membrane associated host proteins and lipids and that the level 
of these contaminants would be a function of detergent concentration. Any increase in 
the extent of host lipid and protein contamination would consequently have implications 
for the performance of subsequent downstream operations. 81 
 
Triton X-100 is the most commonly employed detergent for the liberation of 
HBsAg from the ER although the use of other detergents such as variants of Triton-X, 
CHAPS and polysorbate (PS) and glycol ether solvents has been reported for similar 
applications  (Wijnendaele  et  al.,  1987;  Kniskern  and  Hagopian,  1992;  Allen  et  al., 
2007). [Properties of these detergents were discussed in Section 1.5.1.] For Triton X-
100, there is also no consensus as to the level of detergent requirements reported. For 
example, Wampler et al. (1985) treated cell lysate with 4 volumes of 0.1% v/v Triton 
X-100 solution whereas Sitrin & Kubek (1991) proposed a concentration of 0.5% v/v. 
The different amounts of detergent reported could be due to variations in the process 
and linked to differences in cell culture and cell disruption conditions.  
This  chapter  aims  to  investigate  the  influence  of  the  detergent  step  on  key 
process parameters in order to facilitate the development of a framework which could 
benefit the process design of future generation lipoprotein vaccines. A detergent screen 
was  initially  carried  out  to  compare  the  performance  of  Triton  X-100  to  other 
commonly employed detergents and chemicals to determine if indeed Triton X-100 was 
the superior agent for HBsAg liberation. Having determined the most suitable detergent 
for this purpose, its effects on HBsAg recovery were analysed at three different levels: 
(1)  the  direct  impact  of  the  amount  of  detergent  employed  on  the  level  of  HBsAg 
recovery and product quality, (2) characteristics of the process streams resulting from 
the  use  of  different  detergent  concentrations  in  terms  of  the  level  of  host  lipid  and 
protein  contamination,  and  (3)  the  indirect  impact  of  the  detergent  step  on  the 
performance  of  the  ultrafiltration  step  immediately  following  primary  recovery.  The 
results from this study would assist in the identification of best trade-off conditions for 
HBsAg recovery which can be adopted as a reference point when designing the process 
for future generation vaccine candidates.  82 
 
4.2 Materials and Methods 
The  experiments  reported  in  this  chapter  were  performed  using  HBsAg  feed 
stock  generated  from  fermentation  as  detailed  in  Section  2.2  and  disrupted  by 
homogenisation as described in Section 2.3. The primary recovery process adopted for 
the screening studies to compare chemical agent for HBsAg liberation and subsequently 
to determine the optimal concentration range are discussed in Section 2.4.   
The  study  to  characterise  the  impact  of  detergent  concentrations  during  the 
HBsAg liberation step on the performance of a downstream ultrafiltration operation is 
described  in  Section  2.5.  Viscosity  measurements  to  support  the  analysis  of  mass 
transfer resistance during ultrafiltration were conducted as described in Section 2.13.11.  
Analyses  performed  for  HBsAg  particle  characterisation  and  the  profiling  of 
contaminants  in  the  product  stream  include  an  ELISA  assay  to  measure  HBsAg 
antigenicity  (Section  2.13.4),  HBSAg  particle  size  measurements  by  dynamic  light 
scattering  (DLS)  (Section  2.13.10),  total  protein  concentration  determination  by  a 
Bicinchoninic  (BCA)  assay  (Section  2.13.5)  and  lipid  analysis  by  HPLC  (Section 
2.13.6). Sample fractionation by size using size exclusion chromatography was carried 
out prior to DLS analysis as reported in Section 2.13.9.   
 
 
4.3 Results and discussions 
The objective of this study  was to identify optimal conditions for detergent-
mediated HBsAg liberation, which could be adopted in the process design for future 
generation  lipid-envelope  VLP  vaccines.  In  this  study,  the  criteria  chosen  for 83 
 
determining  optimal  conditions  for  the  detergent  step  include  VLP  yield,  product 
quality and the level of host cell protein and lipid contaminants in the resulting process 
stream. Since VLP vaccines are to be administered to healthy patients, product quality is 
of  paramount  importance.  Step  yield  and  the  degree  of  contamination  are  also 
considered since these parameters could have implications for the overall throughput 
and production costs.  
 
4.3.1  Investigating  the  efficiency  of  a  range  of  chemicals  for  HBsAg 
liberation  
Although Triton X-100 is most commonly employed agent for the recovery of 
HBsAg following cell disruption, other detergents and solvents have been reported for 
similar applications (Wijnendaele et al., 1987; Kniskern and Hagopian, 1992; Allen et 
al., 2007). Hence, the first set of studies was performed to assess if indeed Triton X-100 
was optimal for this purpose. The effectiveness of Triton X-100 for the liberation of 
HBsAg from the ER was compared to that of Polysorbate (PS) 20 and 80, Triton X-101, 
CHAPS and ethyl butyl ether (EB). The maximum achievable HBsAg recovery levels 
within the typical operating range of 0 – 1% w/v for the detergents (Wijnendaele et al., 
1987; Kniskern and Hagopian, 1992) and 0 – 30% w/v for EB (Allen et al., 2007) were 
determined by an ELISA assay and are shown in Figure 4.2. The results demonstrate 
that the highest HBsAg yield was obtained using Triton X-100 thus verifying that this 
detergent was optimal for HBsAg recovery.  84 
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Figure 4.2: Comparison of the HBsAg yield obtained from the use of different agents 
for the extraction of HBsAg product from the ER. The data has been normalised against 
the highest HBsAg yield measured (~18 mg HBsAg / g cell) and the error bars represent 
the standard deviation from triplicate samples.    
 
4.3.2  Investigating  impact  of  Triton  X-100  concentration  on  HBsAg 
recovery & activity 
Having determined that indeed Triton X-100 was superior for the recovery of 
HBsAg, subsequent studies were performed to characterise the potential impact of the 
operating  concentrations  on  the  level  of  HBsAg  recovery  and  product  antigenicity.  
Different concentrations of the detergent were screened. An ELISA assay was again 
employed to measure the level of HBsAg activity in the samples at the end of primary 
recovery and the results are as shown in Figure 4.3. 85 
 
 
 
Figure 4.3:  Recovery of HBsAg per gram of wet cell under different Triton X-100 
concentrations determined by an ELISA activity assay. Negative control with no Triton 
X-100  gave  a  recovery  level  of  1.7  mg  HBsAg  /  g  cell.  Error  bars  correspond  to 
standard deviation from triplicate samples. 
 
Improvement  in  HBsAg  activity  in  the  product  stream  was  observed  when 
Triton X-100 concentrations were increased from 0% to 0.5% v/v. This trend correlated 
with what is understood from the literature of the role of detergent in VLP liberation. 
Increasing the amount of detergent would result in more effective disassociation of the 
HBsAg particle from the ER (Chi et al., 1994) and promote dispersion of membrane 
material (Sitrin and Kubek, 1992) thereby increasing the surface area for disassociation 
of HBsAg to occur and, at a molecular level, facilitate inward budding of the VLP from 
the ER membrane (Smith et al., 2002; Kreibich et al., 1982).  
However, when Triton X-100 concentrations were increased above 0.5% v/v, the 
HBsAg activity levels appeared to decrease. Since the ELISA technique correlates to 
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HBsAg activity, the decrease in recovery level observed is most likely to be a reflection 
of a decline in HBsAg antigenicity. The loss of activity observed is consistent with the 
findings  of  Gavilanes  et  al.  (1990)  and  is  attributed  to  HBsAg  delipidation.  Excess 
Triton X-100 present when its concentration is increased above  a specific threshold 
could react with and remove lipid constituents from the HBsAg particle. Since the lipid 
moiety  plays  a  critical  role  in  maintaining  the  structural  properties  of  the  HBsAg, 
delipidation  would  lead  to  conformational  changes  which  are  antigenically 
unfavourable. [The HBsAg delipidation study to provide further evidence for this is 
discussed in the following section.] 
In  a  separate  study,  to  investigate  if  such  a  loss  of  antigenic  activity  were 
reversible, samples after the detergent step were diluted such that the resulting detergent 
concentration  was  equal  to  0.1%  v/v  Triton  X-100.  If  indeed  the  loss  of  antigenic 
activity due to the action of the detergent were reversible, the overall product yield 
estimated would be expected to increase when the detergent content in the sample were 
diluted down. A mass balance was carried out on the estimated HBsAg concentration 
before and after dilution. The results did not show any improvement in HBsAg yield 
after dilution, suggesting that the detrimental effect of the detergent on HBsAg is most 
likely irreversible. 
The results in Figure 4.3 indicate an apparent increase in HBsAg recovery at 
Triton X-100 concentrations above 2% v/v. It is likely that the species formed at Triton 
X-100  concentrations  above  2%  v/v  are  non-native  VLP  particles.  As  previously 
described, a mature HBsAg particle is assembled from ~ 100 copies of the 24 kDa 
monomeric  proteins  (p24s)  (Peterson,  1987).  Following  complete  delipidation  it  is 
likely  that  the  p24s  monomeric  proteins  form  thermodynamically  stable  micelles  in 
excess Triton X-100. [Triton X-100 has a low critical micelle concentration of 0.013% 87 
 
v/v Triton (Sigma Product Information Sheet).] This species, as a result of its antigen 
orientation could show improved antigenicity as has been previously reported (Howard 
er al, 1982; Sanchez et al., 1983; Skelly et al., 1981).  
Further studies to investigate the formation of antigenic polypeptide micelles 
and  also  the  possibility  of  controlled  disassembly  and  reconstitution  of  HBsAg  to 
improve the homogeneity of the HBsAg particles may be warranted. However, these are 
beyond the scope of this study. In this study, the recovery of native HBsAg is of interest 
and the results clearly indicate that there is an optimal range of detergent concentrations 
necessary  to  ensure  high  levels  of  recovery  and  without  compromising  particle 
antigenicity.    
 
4.3.3 Further investigation into HBsAg delipidation 
HBsAg  delipidation  due  to  the  effect  of  high  Triton  X-100  concentrations 
(>0.5% v/v) was further investigated. The motive of this study was to detect constituent 
lipid components which may have been removed from the native HBsAg due to the 
action of the detergent. The HPLC technique employed for this analysis detects lipids 
primarily on the basis of their functional groups.  
In  this  study,  cell  homogenate  was  initially  treated  at  a  low  Triton  X-100 
concentration of 0.1% v/v to ensure recovery of native HBsAg particles. Centrifugation 
was carried out  following HBsAg liberation for the removal of membrane material. 
XAD-4,  a  polyaromatic  absorbent  specifically  for  small  hydrophobic  compounds 
(Sigma  product  information  sheet),  was  employed  for  the  removal  of  Triton  X-100 
detergent. The efficiency of the XAD-4 step is shown in Figure 4.4(a). The subsequent 
chloroform-methanol  precipitation  step  removed  protein  components  prior  to  HPLC 
analysis.  Both  the  centrifugation  and  XAD-4  steps  were  important  to  prevent  any 88 
 
further contribution of host lipid into the process stream and the potential interference of 
Triton X-100 with the lipid analysis. The product stream from this step was denoted as 
Sample  I.  The  chloroform-methanol  precipitation  step  preceding  HPLC  analysis 
removed  protein  components  so  that  only  soluble  lipids  were  analysed.  Lipid 
components in Sample I that were detected are shown in Figure 4.4(b). Based on the 
previous HBsAg activity analysis, no HBsAg delipidation was expected at 0.1% v/v 
Triton X-100. Hence, peaks A, B and D would represent host lipid components released 
into the process stream.  
Sample I was divided into three aliquots. The first aliquot was kept at 0.1% v/v 
Triton X-100 as the control. The second and third aliquots were treated with Triton X-
100  stock  solution  to  mimic  medium  (0.7%  v/v)  and  high  (7%  v/v)  Triton  X-100 
concentrations and these were denoted as samples II and III, respectively. Since cell 
membrane material had been removed by centrifugation, excess Triton X-100 present in 
samples II and III could not lead to further release of lipid contaminants from the host 
membrane. However, if the HBsAg particles were susceptible to delipidation, excess 
Triton X-100 present in samples II and III could release the lipid constituent from the 
native HBsAg into the process stream. As previously, following a period of incubation, 
an XAD-4 step was carried out for removal of Triton X-100.  
HPLC lipid profiles for samples II and III are shown in Figures 4.4(c) and (d). 
Peaks A, B and D observed from samples II and III were similar to those from sample I 
which  was  as  expected  since  all  three  samples  were  originally  from  the  same  VLP 
liberation  step  using  0.1%  v/v  Triton  X-100.  However,  at  a  retention  time  of  14 
minutes,  a  baseline  shift  was  observed  for  the  medium  Triton  X-100  concentration 
mimic (sample II) and a distinct peak, Peak C, was present only for the high Triton X-
100 concentration mimic (sample III). Peak C was not an artifact from Triton X-100 as 89 
 
the retention times are different. In fact, the retention time of peak C suggested that the 
species  involved  is  a  phospholipid.  [The  presence  of  phospholipids  and  the  role  of 
phospholipids in HBsAg has been reported (Vanlandschoot et al., 2003).] Furthermore, 
the source of this lipid could not be a contaminant from host cell membrane material 
since, as noted earlier, this had been effectively removed by centrifugation. Pure native 
VLP which comprises proteins and lipids when precipitated by chloroform-methanol 
would yield a lipid-free material as shown in Figure 4.4(a). It follows therefore that in 
this case of HBsAg material, liberation of lipid from the  antigen itself must be the 
source of lipid peak C seen in Figure 4.4(d). [Repeats of the delipidation study with 
purified  HBsAg  may  have  proven  helpful  to  provide  further  evidence  for  this 
delipidation  phenomenon  although  that  was  not  performed  here  due  to  the  lack  of 
material availability.] 
 90 
 
 
  
Figure 4.4: Chromatogram (a) shows the efficiency of Triton X-100 removal by XAD-4. (
____) 
and (- - - -) represent the profiles for 7% (v/v) Triton X-100 in phosphate buffer before and after 
the  XAD-4  step,  respectively.  (
…...)  was  obtained  when  pure  native  HBsAg  was  analysed. 
Chromatogram (b) shows the lipid profile for the process stream recovered using 0.1% v/v 
Triton X-100 (Sample I). Chromatograms (c) and (d) were obtained when the process stream 
was  spiked  with  Triton  X-100  stock  solution  to  mimic  0.7%  v/v  and  7%  v/v  Triton  X-100 
(Samples II and III). Peaks A, B and D correspond to host lipid contaminants and are similar 
for all samples. Peak C is only observed at high Triton X-100 concentrations and is attributed 
to HBsAg delipidation.  
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4.3.4 Exploring the role of Triton X-100 in maintaining HBsAg liberation 
Understanding the role of detergent in maintaining HBsAg liberation is crucial if 
potential product loss due to re-association of HBsAg to membrane components is to be 
minimised. This issue is likely to be most significant during the centrifugation step for 
removal of cell debris. Sedimentation of cell debris and the forces involved are likely to 
enhance the entrapment of HBsAg in the cell pellet. In this study the role of Triton X-
100 in preventing HBsAg product loss during centrifugation was investigated.    
  In a typical primary recovery process, as shown in Figure 4.1, Triton X-100 is 
present during the centrifugation step for clarification of the stream from membrane 
debris. To investigate the role of Triton X-100 during this step, the process sequence 
shown in Figure 4.1 was altered such that the XAD-4 step was carried out to remove 
Triton X-100 prior to the recovery of  HBsAg  product from cellular components by 
centrifugation.  The  level  of  HBsAg  in  the  supernatant  after  centrifugation  was 
compared  to  the  level  of  product  recovery  at  the  end  of  primary  recovery  if  the 
conventional route shown in Figure 4.1 were adopted. From Figure 4.5 it is evident 
that  the  recovery  of  HBsAg  was  lower  when  centrifugation  was  carried  out  in  the 
absence of Triton X-100. The result suggests that the Triton X-100 played an important 
role  during  centrifugation  in  preventing  re-association  of  HBsAg  to  the  membrane 
components. Thus in terms of process design it is vital to ensure that the removal of 
cellular material and contaminating solids precedes the XAD-4 step.  
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Figure 4.5: Comparison of recovery level of HBsAg when Triton X-100 was absent 
( ) during the centrifugation and when Triton X-100 was present ( ). Error bars 
correspond to standard deviation from triplicate samples. 
 
 
4.3.5  Investigating  the  effect  of  Triton  X-100  on  particle  size 
characteristics 
From this delipidation study and findings reported by others (Smith et al., 2002; 
Kreibich et al., 1982), it is likely that the detergent employed impacts recovery at a 
molecular level, specifically the degree of HBsAg release from the ER. Particle size 
analysis using dynamic light scattering (DLS) was carried out to probe further the role 
of Triton X-100 in this. The samples after primary recovery were highly impure. The 
challenges  associated  with  the  use  of  DLS  in  the  presence  of  large  contaminating 
particles  have  been  discussed  elsewhere  (Holwill  et  al.,  1995;  Madani  et  al.,  1991; 
Tsoka et al., 1999). To prevent potential interference from larger-sized contaminants, 
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such as residual cell debris and lipid aggregates, a degree of size-based separation prior 
to DLS analysis was necessary.  
  In this study, the size of HBsAg populations recovered using 0.1% v/v, 0.4% v/v 
and 0.7% v/v Triton X-100 were investigated. Separation was carried out using size 
exclusion chromatography (SEC) and the fractions containing HBsAg were identified 
by an ELISA assay. These fractions were filtered using a 0.22 µm membrane filter prior 
to  DLS  analysis.  Triton  X-100  in  the  process  stream  could  act  as  a  surfactant 
minimising protein aggregation but in this study this was expected to be minimal since 
excess TritonX-100 would have been removed by the XAD-step.  
  DLS  analysis  for  early  antigenically  active  fractions  from  SEC  showed  no 
significant  difference  in  particle  size  distribution.  Native  HBsAg  particles  were 
expected to be within the 20-30nm size range based on the diameter of HBsAg reported 
in literature (Zhou et al., 2006). The early fractions for all samples showed mean values 
of approximately 100nm. This is likely to be caused by HBsAg aggregation which may 
have  been  aggravated  by  the  SEC  separation  step.  However,  for  later  antigenically 
active  fractions,  differences  in  particle  size  distribution  between  the  samples  were 
observed. Figure 4.6 shows that higher mean values were obtained for the low Triton 
X-100 sample (0.1% v/v Triton X-100). This result suggests that at low Triton X-100 
concentrations,  residual  ER  material  may  still  be  attached  to  the  HBsAg  particles, 
making  them  appear  large.  Furthermore,  this  species  may  also  be  more  prone  to 
aggregation owing to the hydrophobicity of the residual ER. These ideas concur with 
earlier hypotheses (Smith et al., 2002; Kreibich et al., 1982) that detergent may have a 
role in promoting inward budding of the HBsAg from the ER. Residual ER obstructing 
the  antibody  binding  epitopes  on  the  HBsAg  may  also  explain  the  low  antigenicity 94 
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measurements at 0.1% v/v Triton X-100. In order to verify these hypotheses, electron 
microscopy studies may be useful.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.6:  Comparison  of  particle  size  distribution  (PSD)  obtained  using  DLS 
analysis. Histograms (a), (b) and (c) correspond to PSDs of samples recovered using 
0.1% v/v, 0.4% v/v and 0.7% v/v Triton X-100 respectively. The PSDs above were for 
later  active  fractions  from  SEC.  The  earlier  active  fractions  from  SEC  gave  mean 
particle size of approximately 100nm and no statistically significant differences were 
observed between the different Triton X-100 samples. 95 
 
4.3.6 Determination of the impact of Triton X-100 on characteristics of the 
process stream 
The effects of the Triton X-100 conditions employed during the liberation step 
on the levels of host protein and lipid contaminants were investigated. The yeast ER, as 
well as other membranous organelles, is rich in lipid and contains various membrane 
proteins for cell metabolism. During the detergent step, recovery of HBsAg is likely to 
be  accompanied  by  release  of  host  lipids  and  proteins.  Increasing  the  Triton  X-100 
concentrations  employed  in  this  step  could  result  in  higher  levels  of  contamination. 
Characterisation  of  the  process  stream  is  therefore  important  since  the  level  of 
contamination could affect the performance of subsequent downstream operations.  
The lipid content in the process streams at the end of primary recovery under 
different  Triton  X-100  concentrations  was  determined  using    HPLC  lipid  analysis. 
Inclusion of the XAD-4 step in primary recovery process was important for the removal 
of excess Triton X-100 to prevent its interference with the analyses. In Figure 4.7, 
chromatograms (a) and (b) correspond to the lipid profile when 7% v/v and 0.1% v/v 
Triton X-100 were used respectively. The retention time for peak X is similar to that for 
ergosterol which has been observed in wild type S. cerevisiae strains. Peak Z is likely to 
be a phospholipid component while peak Y, which was observed at high Triton X-100 
concentrations was attributed to delipidation of HBsAg as discussed previously. The 
total peak area determined from HPLC was plotted against the different concentrations 
of Triton X-100 employed (Figure 4.8). The results clearly suggest that the level of 
lipid contamination is significantly influenced by the Triton X-100 concentration.  
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.7:  Chromatograms 
recovery  when  7%  v/v  and  0.1%  v/v  Triton  X
HBsAg liberation step.
Figure 4.8: The total peak area from HPLC lipid analysis under different Triton X
concentrations employed during the HBsAg liberation step. Y
normalised by denoting total peak area for 7% v/v Triton X
96 
:  Chromatograms  (a)  and  (b)  show  lipid  profiles  at  the  end  of  primary 
recovery  when  7%  v/v  and  0.1%  v/v  Triton  X-100,  respectively,  were  used  for  the 
HBsAg liberation step. 
: The total peak area from HPLC lipid analysis under different Triton X
concentrations employed during the HBsAg liberation step. Y-axis 
ed by denoting total peak area for 7% v/v Triton X-100 as 100%.
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The process streams following primary recovery were also analysed in terms of 
total protein. Total protein concentration was higher when more concentrated Triton X-
100 solutions were employed.  In Figure 9, protein purity is expressed as the ratio of 
HBsAg to total protein. Initially an apparent increase in HBsAg purity was observed 
with increasing Triton X-100 concentration and this is most likely due to improved 
recovery  of  HBsAg.  However  at  Triton  X-100  concentrations  above  0.2%  v/v,  a 
decrease in the level of HBsAg purity was observed. This is due to the combined effect 
of the increase in host protein contamination and the decrease in antigenic HBsAg at 
high Triton X-100 concentrations. [Attempts were also made to analyse HBsAg purity 
using SDS-PAGE. This however proved unsuccessful due to the poor resolution of the 
bands obtained which was a result of the crude nature of the cell lysate samples.]  
 
 
Figure 4.9: Recovery of HBsAg as a percentage of total protein under different Triton 
X-100  concentrations  ( )  is  plotted  on  the  primary  axis.  The  proportion  of 
HBsAg reflects protein purity. The secondary axis shows total protein concentration at 
the end of primary recovery ( ) with increasing Triton X-100 concentrations. 
Error bars correspond to standard deviation from triplicate samples. 
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The  combined  protein  and  lipid  results  indicate  that  higher  levels  of 
contamination  resulting  from  the  use  of  excess  Triton  X-100  could  raise  specific 
challenges for subsequent downstream operations. Examples might include fouling of 
membrane filtration (Maartens et al., 1998) and chromatographic stages (Pampel et al., 
2007) due to high levels of lipid in the process stream. The presence of contaminants in 
the  process  stream  could  also  affect  the  purification  performance    achieved  during 
downstream operations.  
 
4.3.7  Investigating  the  indirect  impact  of  the  detergent  step  on  UF 
performance  
As demonstrated, the amount of host lipid and contaminating proteins present in 
the process streams could vary depending on the amount of Triton X-100 used in the 
VLP liberation step.  With reference to Figure 4.1, the process stream after primary 
recovery is normally subjected to an ultrafiltration (UF) step to achieve the appropriate 
buffer conditions required for chromatography. Thus,  the sensitivity of UF performance 
to processing streams resulting from the use of different concentrations of Triton X-100 
was investigated. The study was carried in an ultra-scale down (USD) device to mimic 
actual processing conditions. The relationship describing a membrane filtration process 
derived from Darcy’s law is shown in Equation 4.1 below. 
 
m R
P
dt
dV
A µ
∆
=
1
            (Equation 4.1) 
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where A is the effective membrane area (m
2), V the permeate volume (m
3), t filtration 
time  (s),  P  the  transmembrane  pressure  drop  (N  m
-2),  µ  dynamic  viscosity  and  Rm 
membrane resistance (m
-1). The term 
dt
dV
A
1
 represents flux. Flux and transmembrane 
pressure (∆P) are important parameters.  
Flux versus TMP curves for process streams originally generated using 0.1% 
v/v,  0.4%  v/v  and  0.7%  v/v  Triton  X-100  are  shown  in  Figure  4.10.  The  samples 
investigated were obtained at the end of primary recovery where Triton X-100 had been 
removed  from  the  process  stream  by  the  application  of  the  XAD-4  step.  This  was 
important to ensure that the filtration performance was not influenced by the presence of 
the detergent.  
No significant difference in critical flux was observed for all three Triton X-100 
concentrations but the transmembrane pressure required to achieve the critical flux was 
lowest  for  the  process  material  prepared  using  0.1%  v/v  Triton  X-100.  In  order  to 
understand better the possible reasons for these observations, the direct impact of host 
contaminants on membrane resistance during filtration was investigated. Equation 4.1 
can be rearranged to give Equation 4.2 shown below.   
m R
dt
dV
A
P
µ =
∆
]
1
[
              (Equation 4.2) 
 
The flux versus TMP curves in Figure 4.10 show very linear correlations (R
2 > 
0.98) below the critical flux points. The left hand term of Equation 4.2 is the reciprocal 
of the gradient of the flux versus TMP curve. Determination of the viscosity of the 
samples showed that each of these to be close to the theoretical value for water, 0.0091 
kgm
-1s
-1 (T = 297K) indicating that impact of contaminants on viscosity was small.  By 100 
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application of Equation 4.2, the membrane resistance (Rm) for the different samples 
was calculated and a summary of the results is provided in Table 4.1.  
 
Figure 4.10: Comparing flux versus TMP curves for process streams recovered using 
different concentrations of Triton X-100: 0.1% v/v Triton X-100 ( ), 0.4% v/v 
Triton X-100     ( ) and 0.7% v/v Triton X-100 ( ). 
 
 
Table 4.1: Comparing viscosity and membrane resistance for samples recovered at the 
end of primary recovery under different Triton X-100 concentrations. All experiments 
were carried out at 297 K. 
 
Triton X-100 
concentration [% v/v] 
TMP / Flux 
[x10
7 Pa / ms
-1] 
Viscosity 
[x10
-3 Pa s] 
Membrane resistance 
[x10
10 m
-1] 
0.1  1.69  0.96  1.76 
0.4  2.47  1.03  2.39 
0.7  2.57  1.04  2.48 
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As expected, Rm is influenced by the Triton X-100 concentration employed in 
the liberation step. Higher membrane resistances for samples recovered using 0.4% v/v 
and 0.7% v/v Triton X-100 reflect more severe membrane fouling and were consistent 
with the earlier lipid contamination analysis (Figure 4.8). The levels of contaminating 
protein also differed across this range of Triton X-100 (Figure 4.9) but vary to a much 
lower extent than did the lipid content which was probably therefore the major source of 
the membrane fouling. It is not clear why the level of increase in Rm was small from 
0.4%  to  0.7%  Triton  X-100.  This  may  be  due  to  the  nature  of  the  fouling  or  cake 
formation that occurred on the membrane surface at these concentrations. Such analysis 
was however considered to be beyond the scope of this study.  
Lower  membrane  resistance  was  encountered  when  HBsAg  liberation  was 
carried out using lower Triton X-100 concentrations. Based on filtration performance 
alone, low Triton X-100 conditions are thus favoured. The reduced extent of membrane 
fouling as a result of minimal release of host lipid would allow the use of lower pressure 
operations and could result in an improvement in membrane lifespan. More importantly, 
the  potentially  gentler  operation  could  also  promote  HBsAg  stability  and  reduce 
problems of shear-induced protein denaturation and aggregation.  
  
 
4.4 Conclusions  
The results obtained demonstrated that the use of Triton X-100 is superior for 
the liberation of HBsAg from the ER and its operating concentration has significant 
impact on the effectiveness of the HBsAg recovery process. Operating below the range 
of effective concentrations of Triton X-100 was found to lead to incomplete HBsAg 
liberation and poorer antigenic activity. Excess detergent, on the other hand, was shown 102 
 
to cause HBsAg delipidation which also resulted in reduced particle antigenicity. From 
the perspective of process performance there is no obvious advantage in the use of high 
Triton X-100 concentrations for the process. Increasing the amount of Triton X-100 
employed would raise the level of host protein and lipid contamination which in turn 
would  have  a  negative  impact  on  the  performance  of  downstream  operations.  The 
results obtained in this study are summarised in Table 4.2.  
Based  on  the  system  investigated,  the  most  suitable  range  of  Triton  X-100 
concentrations  to  ensure  good  recovery  of  HBsAg  and  maintenance  of  its  antigenic 
properties is likely to be between 0.2% v/v and 0.5% v/v. Triton X-100 concentrations 
below 0.2% v/v showed poor yields of HBsAg. Based on the particle size analysis, it is 
likely that residual ER material remain associated with the HBsAg particle under such 
conditions.  This  could  hinder  the  immunogenic  recognition  of  the  antigen  thereby 
reducing the efficiency of the vaccine material generated. Reduced HBsAg activity was 
also observed at Triton X-100 concentrations of above 0.5% v/v and this is attributed to 
HBsAg  delipidation  as  previously  discussed.  The  raised  levels  of  host  derived 
contaminants  in  addition  to  the  loss  of  antigenic  activity  at  such  high  detergent 
concentrations are unfavourable from the perspective of process efficiency. Choosing a 
specific concentration within the 0.2% v/v – 0.5% v/v range would depend on further 
trade-off considerations between product recovery and the level of contamination that 
can be tolerated by downstream operations. As a general guideline, product yield is 
typically given precedence over purification for such an early stage recovery operation 
thus operating close to the 0.5% v/v upper limit would be ideal.     
  In conclusion, the issues presented in this study could be valuable as a guide to 
the  process  design  of  future  generation  of  lipid-based  VLP  vaccine  candidates. 
Although  the  type  of  detergent  and  the  specific  range  of  optimal  operating 103 
 
concentrations may differ from system to system, the framework and insights gained 
from this study could be employed as a platform for process selection and optimisation.  
 
Table 4.2: Schematical representation of the effect of detergent conditions on various 
process parameters  
 
 
 
Having established the trade-off conditions for the detergent-mediated HBsAg 
liberation step to ensure maximal HBsAg recovery with minimal co-extraction of host-
derived contaminants, subsequent studies were performed to improve further the purity 
of the processing stream entering later stage chromatographic operations. The use of 
precipitation methods and a strategy for selective product recovery for this purpose are 
illustrated in the following chapters.   
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Chapter 5: HBsAg precipitation with PEG and ammonium sulphate 
HBsAg  precipitation  with  polyethylene  glycol 
(PEG) and ammonium sulphate 
 
5.1 Introduction 
The purification of HBsAg expressed in yeast requires a complex and multistage 
process to deal with the high levels of host cell lipid and protein contaminants present. 
Release  of  such  contaminants  into  the  process  stream  is  exacerbated  by  the  use  of 
detergents such  as Triton X-100  for the liberation of HBsAg from the  endoplasmic 
reticulum (ER) (Kee et al., 2008). The presence of these contaminants could affect the 
performance  of  downstream  operations  (Kee  et  al.,  2008;  Pampel  et  al.,  2006; 
Bracewell et al., 2008). Furthermore, the exposure of the HBsAg product to protease 
contaminants could lead to product degradation (Chi et al., 1994). Hence the removal of 
such contaminants early in the process is favourable.  
Currently, the manufacturing process for HBsAg relies heavily on the use of 
chromatographic operations (Koen et al., 2005; Sitrin and Kubek, 1992, Dekleva, 1999) 
which  offer  high  levels  of  resolution  but  are  expensive  and  have  low-throughputs 
(Przybycien  et  al.,  2005).  The  ability  to  reduce  the  burden  and  reliance  on 
chromatography is attractive (Leser and Asenjo, 1992; Tsoka et al., 2000, Przybycien et 
al.,  2005)  and  one  of  the  means  of  achieving  this  is  by  introducing  an  additional 
separation step to achieve partial purification prior to downstream processing. 105 
 
Of  the  various  methodologies  available,  selective  protein  fractionation  by 
precipitation  remains  popular  as  it  affords  both  purification  and  concentration  in  a 
single step. Polyethylene glycol (PEG) is a commonly employed class of precipitatant 
particularly for the separation of virus-like particles because of its selectivity for larger 
size  proteins.  Other  benefits  of  PEG  include  its  low  potential  for  denaturation  of 
proteins (Polson et al., 1964) and its inert nature (Ingham et al., 1978). In fact the first 
generation hepatitis B vaccines derived from the plasma of hepatitis B carriers relied on 
PEG precipitation and centrifugation techniques (Einarsson, 1983). Low concentrations 
of PEG (typically below 5% w/v) employed for recovery of HBsAg from human plasma 
have been reported by other groups (DeRizzo et al., 1972; Vnek and Prince, 1976). In 
such cases to achieve the level of purity required, multiple fractionation “cuts” had to be 
carried out.  
The  use  of  salts,  such  as  ammonium  sulphate,  as  a  fractionation  agent  for 
HBsAg  from  blood  plasma  has  also  been  demonstrated  (Peterson  et  al.,  1981).  In 
general, salts lack selectivity and for the same level of precipitation, larger quantities of 
the precipitating agent of up to 40-50% w/v may be required for protein precipitation 
(Van Wijnendaele et al., 1987). This could potentially lead to waste disposal problems. 
An inverse strategy could be adopted in which the contaminants are precipitated out at 
lower salt concentrations leaving the protein product in solution. The benefit is that the 
protein product undergoes no phase change and the challenges of product recovery by 
precipitate resolubilisation can be avoided. An example of this has been demonstrated in 
the reduction of lipid contaminants prior to a hydrophobic interaction chromatography 
step (Bracewell et al., 2008).     
Although the use of PEG and ammonium sulphate have been successful in the 
purification of human plasma HBsAg, it may not be necessarily so for recombinantly 106 
 
expressed HBsAg particles which are not completely identical in form. In yeast, there is 
limited  cross-linking  of  the  recombinant  HBsAg  during  its  production.  Rather  it  is 
during  the  purification  process  and  KSCN  treatment  post-purification  that  the 
disulphide  bond  formation  of  the  mature  particle  is  achieved  (Zhao  et  al.,  2006; 
Wampler et al., 1985). By contrast, HBsAg recovered from serum is already in the 
mature form.  
This chapter investigates and compares the potentials of PEG and ammonium 
sulphate  precipitation  in  the  bioprocessing  of  recombinant  HBsAg,  specifically  for 
contaminant  reduction  to  reduce  the  burden  on  downstream  chromatographic 
operations. PEG 6000 and PEG 8000 were chosen for this study as PEG with molecular 
weight within this range has previously been identified to be most suitable for VLP 
precipitation  (Tsoka  et  al.,  2000).  Similarly,  different  concentrations  of  ammonium 
sulphate solutions were evaluated. Key response factors were the level of product yield, 
the amount of precipitant required and the degree of purification afforded. From the 
perspective of process feasibility, the mechanism of separation for the precipitate from 
the mother liquor is equally important and the use of centrifugation and filtration were 
evaluated and compared in this light.  
 
 
5.2 Materials and Methods 
Crude cell lysate containing HBsAg for the precipitation studies were generated 
by fermentation (Section 2.2), homogenisation (Section 2.3) and detergent-mediated 
HBsAg  liberation  (Section  2.  4).    The  precipitation  experiments  using  polyethylene 107 
 
glycol (PEG) and ammonium sulphate were conducted as in Section 2.5 and Section 
2.6, respectively.  
Sample analysis was performed using an ELISA-based assay (Section 2.13.4) 
for measuring the level of HBsAg present in the samples, a Bicinchoninic (BCA) assay 
for total protein determination (Section 2.13.5) and lipid analysis by HPLC (Section 
2.13.6). 
 
 
5.3 Results and Discussion 
This study investigates the potential of including a precipitation step in the primary 
purification of recombinant HBsAg to achieve product enrichment and contamination 
reduction  prior  to  high  resolution  chromatographic  operations.  Polyethylene  gycol 
(PEG), a type of nonionic water soluble polymer and ammonium sulphate salt were 
chosen for this study as they represent two of the most common classes of precipitants 
employed for VLP particles. As mentioned in the introduction, product yield across the 
precipitation step and the level of product enrichment were used as the key parameters 
for evaluation.   
 
5.3.1 PEG precipitation chemistry and impact on purification and yield 
PEG  6000  and  PEG  8000  were  evaluated  in  this  study  as  these  molecular 
weights  have  previously  been  identified  to  be  most  suitable  for  VLP  fractionation 
(Tsoka et al., 2000). Different concentrations of PEG were added to the cell lysate 
samples  and  following  a  period  of  agitation,  the  samples  were  centrifuged.  The 108 
 
concentration of the HBsAg product and that of total protein in the supernatant fractions 
were  analysed  by  ELISA  and  BCA  assay  respectively.  Based  on  the  results,  the 
solubility profiles of the HBsAg protein in comparison with total protein under different 
PEG concentrations were developed as shown in Figure 5.1. For PEG 8000 and PEG 
6000,  the  HBsAg  concentration  in  the  soluble  phase  dropped  below  10%  at  PEG 
concentrations  above  10%  w/v  and  15%  w/v  respectively  indicating  successful 
precipitation of the HBsAg product under these conditions. Total protein concentrations 
in the soluble phase however were relatively high which means that whilst significant 
proportions  of  the  HBsAg  were  precipitated,  the  total  protein  remained  largely  in 
solution.    The  greater  sensitivity  of  the  HBsAg  particles,  which  are  larger  than  the 
average proteins, to PEG precipitation is consistent with the findings of others (Juckes 
et al., 1971; Tsoka et al., 2000).  
The fractionation diagram as shown in  Figure  5.2 allows comparison  of the 
precipitation behaviour of PEG 6000 and PEG 8000. In the fractionation diagram, the 
percentage of HBsAg in solution was plotted against the percentage of total protein in 
solution.  The  diagonal  line  of  zero  fractionation  represents  conditions  whereby  no 
purification is achieved as the HBsAg and total protein are equally dispersed in both 
solids and soluble states. PEG 8000 appears to be the more effective agent as its curve is 
further displaced from the line of zero-fractionation. Highest HBsAg enrichment in the 
solids phase was achieved at 10% w/v PEG 8000 with an estimated product enrichment 
factor of ~ 8 fold. The highest product enrichment factor for PEG 6000 was achieved at 
a concentration of 15% w/v PEG and was ~ 5 fold.  
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Figures 5.1 (a) and (b) show the solubility profile of the HBsAg product ( ) in 
comparison to the average protein ( ) plotted against different concentrations of 
PEG 6000 and PEG 8000 during the precipitation step. Error bars indicate standard 
deviation from triplicate samples.  110 
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Figure 5.2: The degree of HBsAg fractionation from total protein in the soluble phase 
for PEG 6000 ( ) and PEG 8000 ( ) under different PEG concentrations.  
(- - - - -) is the line of zero fractionation at which the HBsAg and the average protein 
are equally partitioned in the solids and soluble phases. ( ) shows highest product 
enrichment. Error bars indicate standard deviation from triplicate samples. 
 
A lower amount of precipitant was required to achieve a given level of HBsAg 
precipitation for PEG 8000 in comparison to PEG 6000. For example, to achieve greater 
than 80% HBsAg precipitation, 10% w/v PEG 8000 was required in contrast to the 15% 
w/v required for PEG 6000. These findings are consistent with previous reports that the 
use of higher molecular weight PEGs yielded lower requirements of the precipitating 
agent (Tsoka et al., 2000) and hence from a process design perspective are preferred.  
In addition to the reduction in host protein contaminant levels, the use of PEG 
precipitation also showed potential for the removal of lipid contaminants. 10% w/v PEG 111 
 
8000, which was identified as optimal for the removal of protein contaminants, also 
achieved an approximate 65% reduction in the level of host lipids (data not shown).  
High  levels  of  product  enrichment  however  could  occur  at  the  expense  of 
product  yield. Figure 5.3 was developed to investigate the relationship between the 
level of purification afforded and the maximum achievable yield assuming complete 
recovery and resolubilisation of the precipitate. PEG conditions achieving lower than 
10% protein precipitation were not  represented  in this plot for the reason that their 
purification factors, calculated to be near infinity, were unrealistic. Based on Figure 
5.3, it is evident that 10% w/v PEG which gives the highest purification factor of 8-fold 
and maximum theoretical yield of over 90% presents the best trade-off condition.  
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Figure  5.3:  Trade-off  assessment  of  the  degree  of  purification  versus  maximum 
achievable HBsAg yield for PEG 6000 ( ) and PEG 8000 ( ) at different 
PEG concentrations. ( ) represents conditions for best trade-off.  
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5.3.2 Precipitate recovery using centrifugation or filtration 
Having  established  the  purification  potentials  of  PEG  6000  and  PEG  8000, 
subsequent studies were carried out to evaluate the precipitation step yield. Other than 
the impact of the precipitating agent in causing a phase change, step yield also depends 
on the efficiency of the separation of the precipitates from the mother liquor and the 
resolubilisation  of  the  recovered  precipitate.  The  HBsAg  yields  achieved  following 
precipitate recovery by centrifugation and resolubilisation are shown in Figure 5.4.  
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Figure 5.4: HBsAg yield following resolubilisation of the precipitate recovered from 
the mother liquor using centrifugation for PEG 6000 ( ) and PEG 8000 ( ). 
HBsAg  level  of  ~1  g  corresponds  to  100%  recovery.  Error  bars  indicate  standard 
deviation from triplicate samples. 
 
On the whole, HBsAg product recovery was very low. The optimal range of 
PEG concentrations appears to be between 10% w/v and 15% w/v PEG with respect to 
the  final  product  yield  after  the  resolubilisation  of  the  precipitate.  At  lower  PEG 113 
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concentrations, there is insufficient PEG to precipitate the HBsAg and thus the HBsAg 
remains largely in solution. At higher PEG concentrations, the increased viscosity of the 
mother  liquor  impacts  negatively  the  sedimentation  characteristics  of  the  HBsAg 
precipitates formed.  
To  circumvent  the  issue  of  low  rates  of  precipitate  sedimentation  by 
centrifugation,  the  use  of  filtration  as  an  alternative  for  precipitate  recovery  was 
investigated. As shown in Figure 5.5, significant improvement in HBsAg yield was 
observed using dead-end filtration. For PEG  concentrations of 10% w/v and above, 
average HBsAg yields of 50% were achieved. Unlike in the case with centrifugation, no 
significant drop in HBsAg yield at PEG concentrations above 15% w/v was observed. 
This  supports  the  hypothesis  that  the  drop  in  yield  observed  for  the  centrifugation 
recovery option was primarily due to viscosity effects.  
 
 
 
 
 
 
 
 
Figure 5.5: HBsAg yield following resolubilisation of the precipitate recovered from 
the mother liquor using filtration for PEG 6000 ( ) and PEG 8000 ( ). HBsAg 
level  of  ~0.2  g  corresponds  to  100%  recovery.  Error  bars  indicate  the  standard 
deviation from triplicate samples. 114 
 
Based on ELISA measurements, highest product yield of approximately 70% 
was measured at 10% w/v PEG 8000. Of the 30% product lost, an estimated 10% was 
found to be owing to unprecipitated HBsAg which remained in solution. The other 20% 
drop in ELISA activity measurement could be due to irreversible loss of antigenicity or 
incomplete  resolubilisation  of  the  precipitate.  To  investigate  the  latter,  a  buffer 
containing 0.2% v/v Triton was added to aid the resolubilisation process. However no 
improvement in the HBsAg yield was observed. Based on this, it is more likely that the 
primary cause for the drop in the HBsAg levels observed was the negative impact of 
precipitation on HBsAg antigenicity rather than the issue of poor resolubilisation.   
In the experiment, the samples were compared against a filtered control. Hence, 
the effect of material loss due to irreversible adsorption on the filter membrane is not 
reflected in these calculations. A subsequent experiment was performed to quantify the 
magnitude of the filter losses and this was found to be ~ 20% which would reduce the 
maximum yield achieved using 10% w/v PEG 8000 to ~ 50%. The level of product loss 
on the filter is a function of the protein load per unit area of membrane. Typically high 
protein loading > 20 g/m
2 is recommended to minimise adsorption losses (Millipore 
Technical Publication). The low protein load experienced on the filter plate in this case, 
may  have  led  to  the  overly  pessimistic  results  and  would  represent  the  worst  case 
scenario.  
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5.3.3  Comparison  with  historical  precipitation  data  for  human-derived 
HBsAg 
Optimal precipitation conditions and step yields reported here for recombinant 
yeast  HBsAg  were  found  to  be  different  from  those  reported  in  literature  for  the 
purification of HBsAg from human plasma. In the methodologies described previously 
(Vnek and Prince, 1976; DeRizzo et al., 1972) multiple precipitation cuts using low 
concentrations (2 - 5% w/v) of PEG 6000 were employed with step yields of 80 - 90% 
HBsAg  product.  In  our  study  however,  using  the  same  PEG  precipitating  agent, 
concentrations above 10% w/v were required and step yields obtained were lower at ≤ 
70%.  The  difference  in  performance  may  be  attributed  to  the  physiochemical 
differences  between  recombinant  HBsAg  and  the  human-derived  form.  It  has  been 
reported (Wampler  et al., 1985;  Zhao et al., 2006) that limited cross-linking of the 
HBsAg occurs spontaneously both during production in yeast and ensuing downstream 
purification and that the maturation process relies on subsequent KSCN treatment and 
incubation at 37 
oC. The human-derived HBsAg is known to be in the mature form 
whereas the recombinant HBsAg at this stage of the process would only have partial 
cross-linking.  Owing  to  the  extensive  disulphide-bond  formation  and  structural 
consolidation,  mature  HBsAg  would  have  a  more  compact  structure  and  reduced 
conformational  flexibility  (Zhao  et  al.,  2006).  This  may  also  explain  why  human-
derived HBsAg are more amenable to PEG precipitation and more resistant to losses in 
antigenicity during the process.   
 116 
 
5.3.4  Ammonium  sulphate  precipitation  chemistry  and  impact  on 
purification and yield 
Ammonium  sulphate  is  another  widely  employed  precipitating  agent.  High 
concentrations in the region of 40% w/v are typically required to precipitate proteins out 
of solution (Van Wijnendaele et al., 1987). However, the use of ammonium sulphate 
has also been demonstrated for the precipitation of lipids and this was found to occur at 
lower  concentrations,  ~20%  w/v  (Bracewell  et  al.,  2008).  Precipitation  using  low 
concentrations of ammonium sulphate for lipid removal whilst maintaining the HBsAg 
in  solution  may  represent  an  attractive  alternative  to  circumvent  the  issues  of  poor 
HBsAg precipitate resolubilisation and activity losses noted earlier with PEG.  
In this study cell lysate samples were treated with ammonium sulphate solutions 
to achieve final concentrations of 0 – 25% w/v. Following a period of incubation, the 
samples were centrifuged to promote lipid separation. It was observed that the lipid 
precipitates formed a waxy upper layer consistent with the earlier findings (Bracewell et 
al., 2008). The supernatant samples were analysed in terms of the amount of lipid and 
HBsAg in the soluble phase. Decreased lipid solubility with increasing concentrations 
of  ammonium  sulphate  is  as  shown  in  Figure  5.6.  Above  ammonium  sulphate 
concentration of 15% w/v no HBsAg product was detected in the supernatant (Figure 
5.7).  The  results  suggest  that  under  these  conditions,  the  HBsAg  becomes  almost 
completely co-precipitated with the lipid contaminants.        
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Figure 5.6: The level of lipid contaminants in the soluble phase following precipitation 
with  different  concentrations  of  ammonium  sulphate.  Error  bars  indicate  standard 
deviation from triplicate samples. 
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Figure  5.7:  HBsAg  yield  following  precipitation  with  different  concentrations  of 
ammonium  sulphate  solutions.  HBsAg  level  of ~1  g  corresponds  to  100%  recovery. 
Error bars indicate standard deviation from triplicate samples. 
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To ascertain the separation efficiency of  ammonium sulphate precipitation, a 
fractionation diagram analogous to that in Figure 5.2 was generated as shown in Figure 
5.8. Final ammonium sulphate concentration of ~ 15% w/v, indicated by “X” in the 
figure, is furthest from the line of zero fractionation and would give the highest degree 
of  product  enrichment.  Under  this  condition,  greater  than  90%  reduction  of  lipid 
contaminants was achieved with an HBsAg enrichment factor of ~ 8-fold.  
Figure 5.9 which is analogous to Figure 5.3 in the PEG precipitation study was 
developed to study the trade-off between the level of purification attained and product 
yield. The results show that the co-precipitation of HBsAg with the lipid contaminants 
could have a significant impact on product yield. The 8-fold lipid reduction achieved 
using 15% w/v ammonium sulphate was at the expense of product loss of up to ~ 50%.  
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Figure  5.8:  The  degree  of  HBsAg  fractionation  from  host  lipid  using  ammonium 
sulphate precipitation. (- - - - -) is the line of zero fractionation representing conditions 
at which the HBsAg and the host lipid contaminants are equally partitioned in the solids 
and soluble phases and (X) represents highest product enrichment. Error bars indicate 
standard deviation from triplicate samples. 119 
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Figure 5.9: Trade-off assessment between the levels of purification achieved versus 
HBsAg yield at different concentrations of ammonium sulphate.   
Precipitation of the average yeast proteins typically requires ammonium sulphate 
concentrations of above 40% w/v (Van Wijnendaele et al.; 1987, Clarkson et al., 1996).  
Hence, under the ammonium sulphate concentrations investigated here (< 25% w/v) its 
impact on host protein solubility is expected to be negligible.  
In summary, ammonium sulphate precipitation is potentially an effective method 
for the elimination of host lipid contaminants. To improve product yields, it is vital to 
reduce the extent of HBsAg co-precipitation and for this purpose, a multifactorial study 
may be employed to optimise the buffer conditions such as pH, ionic strength and the 
possibility of using surfactants for this operation. 
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5.4 Conclusions 
  The performance of HBsAg purification using PEG and ammonium sulphate as 
precipitating  agents  is  summarised  in  Table  5.1.  Precipitation  experiments 
demonstrated  that  PEG  and  ammonium  sulphate  solutions  were  both  effective  as 
fractionation agents for the HBsAg product. 10% PEG 8000 was found provide the 
optimal condition for the removal of host proteins with an HBsAg enrichment factor of 
over  8-fold  and  a  concomitant  2-fold  reduction  in  the  level  of  lipid  contaminants. 
Ammonium sulphate precipitation achieved a 8-fold purification factor relative to lipid 
contaminants. Separation of protein contaminants is unlikely under the concentrations 
examined for ammonium sulphate as host proteins would remain in the soluble phase 
with the HBsAg product. From this study, it appears that PEG would be the preferable 
precipitating agent for eliminating protein contaminant and ammonium sulphate for host 
lipid reduction.  
This  study  has  highlighted  that  the  main  challenge  with  both  precipitation 
options is in product recovery. For PEG precipitation, separation of the precipitate from 
the mother liquor using centrifugation is hindered at PEG concentrations ≥ 10% w/v due 
to the increasing viscosity of the mother liquor. This issue could be circumvented to 
some degree by the use of filtration for precipitate recovery. Some product loss owing 
to irreversible adsorption of HBsAg to the membrane surface was observed, however 
this  could  be  minimised  by  optimising  the  filtration  conditions.  The  issue  with 
ammonium sulphate precipitation is that substantial amounts of the HBsAg product co-
precipitates  with  the  lipid  contaminants.  Further  studies  to  reduce  the  extent  of  co-
precipitation would be warranted.   
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Table 5.1: Comparing best achievable precipitation performance from the use of PEG 
8000 and ammonium sulphate as precipitating agents for HBsAg purification. Step yield 
in brackets for PEG 8000 assumes 20% product loss due to irreversible adsorption 
during  filtration.  *Host  protein  reduction  is  expected  to  be  negligible  at  15%  w/v 
ammonium sulphate based on previous findings.    
 
   
PEG 8000  Ammonium sulphate 
Concentration of precipitant 
required (w/v) 
10%  15% 
Reduction in host protein 
contaminants (%) 
90± 5  Negligible* 
Purification factor  8-fold  Negligible* 
Reduction in host lipid 
contaminants (%) 
65 ± 10 
 
90 ± 5 
Purification factor  2-fold  8-fold 
Step yield (%)  70 ± 5 
(50 ±5) 
50 ± 10 
 
  Overall, the purification potentials of PEG and ammonium sulphate precipitation 
demonstrated  are  promising.  The  findings  in  this  study  could  be  employed  as  the 
foundation  for  future  optimisation  studies  particularly  to  fine-tune  the  precipitation 
conditions and to improve the efficiency of the separation techniques. Although low 
yields were observed from the precipitation methods examined, these operations may 
still be practical provided the levels of contaminant removal achieved facilitate high 
levels  of  product  yield  in  subsequent  chromatographic  steps.  Further  studies  on  the 
benefit of the precipitation steps on high resolution downstream operations would be 
warranted. 
  In view of the challenges in HBsAg purification by precipitation an alternative 
method,  which  is  based  on  the  exploitation  of  intracellular  compartmentalisation 
characteristics  of  HBsAg  particles  on  the  yeast  endoplasmic  reticulum  (ER),  was 122 
 
explored to impart selectivity to the HBsAg recovery process. This is discussed in the 
following chapter.  
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Chapter 6: Selective product recovery methodology 
Selective  product  recovery  for  primary 
purification 
 
 
6.1 Introduction 
As discussed in Chapter 1, it has been recognised that in spite of the obvious 
merits of VLP vaccines, their potentials have yet to be fully realised (Pattenden et al., 
2005). One of the main reasons for this is the higher costs of production (Boisgerault et 
al., 2002) compared to traditional vaccines. The cost in VLP manufacturing, like most 
protein recovery and purification operations is dominated by the expensive and low 
throughput  chromatographic  operations  (Przybycien  et  al.,  2004).  Although  it  is 
unlikely that the use of chromatography can be excluded entirely from the bioprocess 
route, the ability to reduce the purification burden and to improve their throughput is 
highly attractive. One of the means of achieving this is by maximizing the potentials of 
the primary purification stages to reduce contaminants such as host lipids and proteins 
entering the chromatographic operations.  
The  typical  approach  to  improving  the  efficiency  of  primary  purification  of 
VLPs  is  by  the  introduction  of  fractionation  techniques  such  as  precipitation  using 
polyethylene glycol (PEG) and ammonium sulphate (Vnek et al., 1977; Tsoka et al., 
2000, Peterson et al., 1981). However, as demonstrated in the previous chapter, HBsAg 
purification was achieved at the expense of product yield. The issue of contamination 124 
 
removal  for  lipid-envelope  VLPs  from  S.  cerevisiae  may  be  addressed  from  an 
alternative  perspective  by  drawing  upon  understandings  of  the  VLP  expression 
characteristics.  Lipid-envelope  proteins  are  formed  through  a  budding  process  from 
cellular compartments such as the ER, plasma membrane or lipid rafts (Grgacic and 
Anderson, 2006). Often as in the case of the HBsAg, the VLPs remain permanently 
localised on the membranous organelles due to the lack of protein transport machinery 
(Herbert  et al., 1956).  For product  recovery, a detergent extraction step is typically 
required  following  cell  disruption  to  release  the  VLP  from  the  membranous 
components.  The  inherent  intracellular  compartmentalisation  of  such  lipid-envelope 
VLPs may be exploited for selective product recovery and purification. This concept 
has been previously adopted in the recovery of proteins from targeted regions such as 
the periplasmic space of E.coli (French et al., 1996; Witholt et al., 1976) and from the 
cytosol or subcellular organelles in S. cerevisiae (Chi et al., 1994; Huang et al., 1991).  
This  chapter  demonstrates  how  a  twin  centrifugation  strategy  with  process 
interaction  considerations  (between  cell  disruption  and  the  detergent  step)  may  be 
applied  to  exploit  the  inherent  localisation  of  lipid-envelope  VLPs  on  membranous 
organelles  to  impart  selectivity  to  the  VLP  recovery  and  purification  process.  The 
HBsAg particle is employed as the model VLP in this study. The conventional process 
route for HBsAg production (Dekleva, 1999; Wampler et al., 1985; Sitrin and Kubek, 
1992) which provides the benchmark for the comparative study is as shown in Figure 
6.1 (a). The selective product recovery method investigated in this study involves an 
additional  centrifugation  step  following  cell  disruption  but  prior  to  the  detergent-
mediated HBsAg liberation (Figure 6.1 (b)).  125 
 
 
Figure 6.1: (a) represents the conventional process route for the production of HBsAg 
as described by Dekleva (1999) and Wampler et al. (1985). (b) represents the selective 
recovery approach investigated which incorporates an additional centrifugation step 
prior to detergent-mediated HBsAg liberation. (- - -) shows unit operations in primary 
purification.   
 
The rationale behind this is that the ER containing the HBsAg product would be 
sedimented  following  centrifugation  1  allowing  bulk  cytosolic  material  containing 
significant proportions of yeast proteins, lipid and nucleic acids to be eliminated in the 
supernatant  fraction.  Recovery  and  subsequent  treatment  of  the  solids  fraction  with 
detergent would then release the HBsAg product into an enriched product stream. A 
second  centrifugation  step  (centrifugation  2)  is  then  employed  for  the  removal  of 
membranous debris now free of the HBsAg product. The relative partitioning of the 
HBsAg product and the yeast-derived contaminants between the supernatant and solids 
fraction  following  centrifugation  1  was  initially  evaluated  to  assess  the  maximal 126 
 
achievable yield and degree of purification from this method. To enhance the selectivity 
of this approach, the impact of homogenisation pressure conditions on product yield and 
the contamination profile following the detergent step were characterised to identify a 
suitable process trade-off. Finally, to ascertain the benefits of the proposed purification 
process,  its  impact  on  the  performance  of  a  downstream  hydrophobic  interaction 
chromatography step was evaluated. The likely merits and process considerations for 
adopting such a selective product recovery process would aid the development of a 
process framework for the delivery of future generations of VLP vaccines.   
 
 
6.2 Materials and Methods 
HBsAg material for this study was prepared by fermentation as described in 
Section 2.2 and homogenisation was conducted at a range of pressures (100-1200bar) 
for 4 passes as discussed in Section 2.9. The selective product recovery methodology 
based  on  a  two-step  centrifugation  approach  proposed  in  this  study  is  detailed  in 
Section 2.8. The conventional HBsAg liberation process described in Section 2.4 was 
employed  as  the  benchmark  for  process  comparison.  The  hydrophobic  interaction 
chromatography (HIC) step for analysing the benefits of improved primary purification 
processing methods on downstream chromatography is detailed in Section 2.10.  
Sample analysis was performed using an ELISA assay for HBsAg measurement 
(Section 2.13.4), a Bicinchoninic (BCA) assay for total protein determination (Section 
2.13.5),  lipid  analysis  by  HPLC  (Section  2.13.6)  and  nucleic  acid  determination 
(Section 2.13.8). The yeast homogenate following cell disruption were characterised by 
microscopy as in Section 2.13.12. 127 
 
6.3 Results and Discussions 
The objective of this study was to develop a selective product recovery strategy 
for  the  purification  of  lipid-envelope  VLPs  so  as  to  improve  the  performance  of 
subsequent downstream chromatography operations. As highlighted in the introduction, 
the selective recovery approach under investigation is based on the exploitation of VLP 
localisation characteristics on membraneous organelles in S. cerevisiae, requiring the 
use  of  a  detergent  for  their  release.  The  method  described  by  Dekleva  (1999)  and 
Wampler et al. (1985) was used as the benchmark process and VLP yield, purification 
efficiency and impact on chromatography were used as the criteria for evaluation.  
 
6.3.1 Investigating the potentials of the selective recovery methodology 
In the recovery of HBsAg, the use of a detergent is necessary to facilitate the 
liberation of the VLP from the ER (Dekleva, 1999; Wampler, 1985; Sitrin and Kubek, 
1992). As shown in Figure 6.1(a), the detergent is typically added immediately after 
cell disruption. The HBsAg product is consequently released into a complex process 
stream containing a mixture of cell debris, host cell organelles,  yeast lipid, protein, 
nucleic  acids  and  other  yeast-derived  contaminants.  In  an  attempt  to  reduce  the 
complexity of the process stream, the use of a selective recovery approach as in Figure 
6.1(b) was investigated. 
  In this element of the study, homogenisation was carried out at 1200 bar 
for 4 passes. High homogenisation pressure conditions as such are favoured for rapid 
and efficient processing (Sitrin and Kubek, 1992). Comparison of the product stream at 
the end of primary purification generated from the solids fraction using the selective 128 
 
recovery methodology to that using the conventional method is shown in Table 6.1. For 
mass  balance  analysis,  the  level  of  product  loss  and  the  amount  of  contaminants 
eliminated in the supernatant waste stream following centrifugation 1 using the selective 
recovery methodology are also documented.  
 
Table 6.1: Comparison of the levels of the HBsAg product and major classes of 
contaminants  recovered  at  the  end  of  primary  purification  using  the  conventional 
method previously described
22-23 with the levels observed also at the end of primary 
purification  generated  from  the  solids  fraction  following  the  selective  recovery 
methodology. Product loss and the level of contaminants successfully eliminated in the 
waste  stream  following  the  selective  recovery  methodology  are  also  shown. 
Measurements reported for total protein and lipid are based on BCA assay and HPLC 
peak area analysis, respectively. *refers to solids and supernatant streams generated 
from centrifugation 1. 
 
ELISA activity measurements revealed that ~ 80% of the HBsAg product was 
recovered from the solids fraction during centrifugation 1 while the remainder was lost 
in the supernatant. In spite of some product loss, HBsAg yield from primary purification 
using the selective recovery methodology at 8 mg/g cell still matched the level attained 
using the conventional method. This reflects an improvement in the HBsAg liberation 
efficiency during the detergent step. Given that the detergent typically reacts also with 
  Conventional 
method 
Selective recovery method 
Solids* 
(Product stream) 
Supernatant* 
(Waste stream) 
HBsAg (mg/g cell)  8  8  2 
Total protein (mg/g cell)  31  9  20 
Nucleic acids (µg/g cell)  33  14  42 
Total lipid (mAu*mL)  1711  527  1091 129 
 
lipid  contaminants,  it  is  not  surprising  that  when  such  lipids  are  reduced,  enhanced 
levels of HBsAg liberation by detergent is observed.    
Total protein analysis using the bicinchoninic acid (BCA) method estimated that 
approximately  32%  of  the  total  protein  remained  in  the  product  stream  following 
primary purification. HBsAg purity based on total protein concentration following the 
selective  recovery  methodology  was  calculated  at  89%  which  was  a  significant 
improvement over the 26% recorded using the conventional process. The efficiency of 
host  protein  reduction  was  also  evident  from  the  SEC  profiles  in  Figure  6.2.  The 
HBsAg product has a molecular weight of 3.5 x 10
6 (Gavilanes et al., 1990) which is 
close  to  the  exclusion  limit  of  the  Superose  6  column  of  4  x  10
6  (GE  product 
information sheet). The earliest peak (A) in Figure 6.2 was found to contain the HBsAg 
product as well as lipids based on the collection of the fraction for ELISA assay and 
lipid HPLC analysis. Subsequent peaks (B) were due to host cell proteins and the profile 
for the solids fraction showed a dramatic reduction in these contaminants. [Analysis of 
HBsAg purity in terms of total protein was also performed. The results however were 
inconclusive due to the poor resolution of the bands attained.]    
Lipid analysis was carried out by HPLC and the profiles are as shown in Figure 
6.3. The retention time of peak Y matched that of the ergosterol standard while peaks X 
and Z, based on the chromatogram database from the column manufacturer, were likely 
due to a sterol and a phospholipid respectively. (Subsequent studies may be required to 
characterise  peaks  X  and  Z.)  The  chromatograms  showed  that  upon  centrifugation, 
lipids in peak Z were fractionated into the supernatant stream while lipids in peaks X 
and Y remained in the solids fraction. Since ergosterol or sterols are found mainly in the 
plasma membrane and secretory vessels (Zinser et al., 1993), it is not surprising that 
during centrifugation, these lipids were sedimented together with their host organelles. 130 
 
Overall,  a  ~70%  reduction  in  total  lipid  contaminants  was  achieved  in  the  solids 
fraction.  
In terms of nucleic acid contaminants from the yeast host cell, A260 analysis 
revealed that the level in samples from the solids had been reduced by over 70%. The 
nucleic acids levels detected in the product fraction and the supernatant waste stream 
following the selective recovery methodology in total exceeded the level measured from 
the conventional process. Like in the case with the HBsAg product, this may be a result 
of the increased rate of nucleic acid extraction by the detergent when a lower level of 
lipid contaminants is present.   
This initial study demonstrates that the inclusion of an additional centrifugation 
step results in a highly selective recovery methodology with significant potential for the 
reduction  of  host  contaminants  with  minimal  compromise  on  product  yield.  Having 
established this, subsequent studies were carried out to investigate if the efficiency of 
contaminant removal achieved by this operation may be further enhanced.   131 
 
 
Figure  6.2:  (a)  shows  the  SEC  profile  of  samples  at  the  end  of  primary  recovery 
following the conventional method as described by Dekleva (1999) and Wampler et al. 
(1985). (b) and (c) are profiles of samples at the end of primary recovery obtained from 
the  supernatant  and  solids  fractions,  respectively,  following  the  selective  recovery 
approach. Cell disruption for all samples was carried out at 1200 bar for 4 passes.  
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Figure 6.3: Chromatogram (a) shows lipid profile of samples at the end of primary 
recovery  following  the  “Deklava”  method.  Chromatograms  (b)  and  (c)  show  lipid 
profiles  obtained  at  the  end  of  primary  recovery  from  the  supernatant  and  solids 
fractions following the selective recovery approach. Cell disruption for all samples was 
carried out at 1200 bar for 4 passes.   133 
 
6.3.2 Evaluating the impact of cell disruption conditions on product yield 
and the level of contaminants  
The data for HBsAg recovery and purification up to this point were obtained 
using homogenisation at 1200 bar, consistent with the process described by Sitrin and 
Kubek, (1992) for 4 passes, reportedly ideal for HBsAg recovery from yeast (Milburn 
and Dunnill, 1994; Pointek and Weniger, 2002).  Cell disruption conditions, however, 
do not only impact the level of product recovery but could have an influence on the 
levels of release of host cell contaminants into the process stream. Hence, studies were 
carried  out  to  investigate  if  the  proposed  selective  recovery  methodology  could  be 
improved by the optimisation of cell disruption conditions.  
The selective recovery approach was applied to cell lysate samples generated at 
different homogenisation pressures conditions (100 – 1200 bar) with a control sample of 
undisrupted cells. Figure 6.4 shows the microscopy images of homogenate generated 
under different disruption pressure conditions. The recombinant S. cerevisiae cells for 
the control sample shows clumps of cells measuring 20 µm in average which is due to 
the tendency of this strain to aggregate due to the mnn mutation (Mendez-Vilas et al., 
2004). At 100 bar disruption pressure, some cell breakage and a reduction in the size of 
cell clumps was observed. Significant cell breakage was observed at 400 bar and above. 
At homogenisation pressures of 800 bar and 1200 bar, extensive cell fragmentation and 
aggregating micronised particles were observed.  
Figure 6.4: Microscopy images (1000X magnification) of (a) undisrupted sample, (b) 
homogenate at 100 bar, (c) homogenate at 400 bar and (d) homogenate at 800 bar
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fragmented at higher homogenisation pressure conditions and as a result the effective 
sedimentation  of  these  organelles  during  centrifugation  1  becomes  more  challenged 
leading to increased product loss in the supernatant. A substantial amount of the HBsAg 
was recovered for the control sample that was not homogenised which is surprising. 
However, this may be due to product leaching as a result of the sample freeze-thaw or 
the use of detergent which may increase membrane permeability. (Further studies may 
be required to verify and characterise this phenomenon.) 
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Figure 6.5: The impact of homogenisation pressure conditions on the level of HBsAg 
recovery  (based  on  ELISA  measurements)  from  the  solids  fraction  following  the 
selective recovery method. The y-axis was normalised by setting the highest HBsAg 
recovery level (~10 mg/g cell) to 100%. The error bars represent normalised standard 
deviation from triplicate samples with calculated coefficient of variance of ≤ 15%.  
 
Protein and nucleic acid analyses indicated that the effect of homogenisation 
pressure conditions on the level of the reduction of these contaminants was minimal 136 
 
(data not shown). Lipid analysis however, yielded interesting results as shown in Figure 
6.6. The results demonstrated that at high homogenisation pressures, particularly at 800 
bar and above,  greater release of lipids into the product stream occurred. At higher 
pressure conditions (≥ 800 bar), the extensive cell fragmentation led to the formation of 
micronised cell debris which in turn generated larger surface area for the detergent to 
extract lipids from during the HBsAg recovery step.  
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Figure 6.6: The level of lipid contaminants in the product stream (based on peak area 
from the lipid HPLC) under different homogenisation pressure conditions following the 
selective recovery method. The data was normalised by setting the lipid sample with the 
highest  peak  area  (650  mAu*mL)  to  100%.  The  error  bars  represent  the  average 
coefficient of variance from triplicate samples calculated at 4%.  
 
  The trade-off between product recovery and the efficiency of lipid contaminant 
removal  were  explored  (shown  in  Figure  6.7).  These  results  suggest  that 
homogenisation pressures in the region of 400 bar are optimal in terms of maximising 137 
 
the  product  yield  whilst  controlling  the  level  of  lipid  contaminants.  The  ability  to 
operate  at  more  moderate  homogenisation  pressure  conditions  would  also  be 
advantageous from the perspectives of lower energy consumption and reduced cooling 
requirements during the operation.  
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Figure 6.7: Trade-off considerations of the impact of different homogenisation pressure 
conditions on the degree of lipid reduction and HBsAg yield at the end of primary 
purification. ( ) shows data point which achieved the best trade-off. 
   Investigation  on  the  impact  of  homogenisation  pressure  has  so  far  been 
performed  keeping  the  number  of  passes  constant  at  4  as  reportedly  ideal  for  VLP 
recovery from yeast (Milburn and Dunnill, 1994; Pointek and Weniger, 2002) using the 
same  homogenisation  set-up.  It  is  indisputable  that  the  number  of  homogenisation 
passes and the design characteristics of the homogeniser such as valve seat geometry 
and impact distance (Miller et al., 2002) could have significant impact on the debris 
profile thus influencing the level of host protein and lipid contaminants released during 
the subsequent detergent step. An in-depth study on a range of factors that potentially 138 
 
impact homogenisation performance may be warranted in order to develop the optimal 
window of operation for selective product release.      
 
6.3.3 Impact of improved process on HIC performance 
To  demonstrate  the  value  of  the  improved  process  based  on  the  selective 
recovery  methodology  and  the  use  of  more  moderate  homogenisation  pressure 
conditions,  the  resulting  impact  on  the  performance  of  a  subsequent  hydrophobic 
interaction  chromatography  (HIC)  operation  was  investigated.  HIC  separation  is  an 
important  chromatography  operation  in  the  purification  of  recombinant  HBsAg.  Its 
successful application has been demonstrated by Belew et al. (1991). In this study, a 
HIC challenge was performed comparing three sets of material: (1) material generated 
using  the  conventional  method  (Dekleva,  1999;  Wampler  et  al.,  1985)  with  cell 
disruption at 1200 bar (sample I); (2) material generated using the selective recovery 
methodology explored in this work with cell disruption at 1200 bar (sample II); and (3) 
material  generated  using  the  selective  recovery  methodology  examined  with  cell 
disruption at 400 bar (sample III).  
Fresh  columns  were  employed  for  each  feed  material  tested.  Flow  through 
during  the  loading  stage  were  collected  and  analysed  for  HBsAg  using  ELISA. 
Significant proportion of the HBsAg product was measured in the flow through early in 
the loading stage for sample I. This was also observed for sample II although to a lower 
extent. Based on the amount of product in the flow through, total HBsAg captured as a 
proportion of the total amount loaded were calculated and the results are summarised in 
Table 6.2. This is shown graphically in Figure 6.8, where the cumulative amounts of 
HBsAg captured in relation to the cumulative amounts fed to the column at different 139 
 
time points during the loading stage are plotted. The diagonal line (slope = 1) indicates 
100% product capture. The profile for sample III which is closest to the line of 100% 
product capture suggests that this feed stream achieved the highest level of product 
binding relative to the amount loaded. This is not surprising given that this feed material 
had  the  lowest  levels  of  host  protein  and  lipid  contaminants.  Lower  levels  of 
contaminants in the chromatography feed would reduce competitive binding and non-
specific interactions with the resin thereby ensuring greater binding capacity for the 
product of interest. Consistent with this, Sample II, which was substantially cleaner than 
sample I owing to the use of the selective recovery procedure but lower in purity than 
sample  III  due  to  the  higher  homogenisation  pressure  employed,  showed  an 
intermediate level of product binding relative to the amount loaded.  
Table  6.2:  Summary  of  the  results  from  the  HIC  challenge  for  the  process  streams 
generated  using  the  different  methodologies  investigated.  Amounts  of  HBsAg  were 
measured by ELISA assay. 
 
 
Conventional method  Selective recovery method 
Homogenisation at 
1200 bar 
(Sample I) 
Homogenisation at 
1200 bar 
(Sample II) 
Homogenisation at 
400 bar 
(Sample III) 
HBsAg  captured  as  a 
proportion  of  HBsAg 
loaded (%) 
 
38 
 
56 
 
78 
HBsAg  eluted  as  a 
proportion  of  HBsAg 
captured (%) 
 
97 
 
95 
 
98 
Overall step yield (%) 
 
37 
 
53 
 
77 
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Cumulative amount of HBsAg loaded onto the column (mg)
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Figure 6.8: Cumulative amount of HBsAg product captured on the column relative to 
the cumulative amount loaded for material generated using the conventional process 
(Dekleva,  199;  Wampler  et  al.,  1985)  with  homogenisation  pressure  of  1200  bar 
(sample  I)  ( );  for  material  generated  using  the  selective  recovery  method  with 
homogenisation pressure of 1200 bar (sample II) ( ); and for material generated using 
the selective recovery method with homogenisation at 400 bar (sample III) ( ). (-----) 
indicates 100% capture of the HBsAg product loaded.   
 
Analysis of the elution fractions in Table 6.2 showed that elution conditions 
were effective as the elution step achieved almost complete recovery (≥ 95%) of the 
HBsAg material bound to the column during the product loading stage for all samples.  
As expected Sample III, which had the highest proportion of product captured by the 
column also achieved the highest step  yield at 78%. SEC and lipid HPLC analyses 
showed that the elution fractions were comparable in terms of product purity indicating 
that the HIC resolution is independent of the level of contamination in the feed stream. 141 
 
It is however important to note that in this study, new columns were employed for each 
run. The rate at which the column resolution deteriorates as a result of fouling after 
multiple cycles of usage may differ for the feed streams investigated. Further studies 
would be required to quantify this.  
 
 
6.4 Conclusions 
The  effective  recovery  and  purification  of  detergent-liberated  intracellular 
recombinant VLPs, such as the hepatitis B surface antigen (HBsAg), is exceedingly 
challenging  due  to  the  high  levels  of  co-existing  host-derived  contaminants.  In  the 
bioprocessing of such high-value low titre products, the prerequisites are high yield, 
purity and maintenance of product integrity. This work has demonstrated the potential 
of  a  selective  product  recovery  methodology  which  capitalises  on  the  inherent 
compartmentalisation of lipid-envelope VLPs on membraneous organelles for effective 
primary purification. Understanding of process interactions between cell disruption and 
detergent-mediated product recovery is vital in ensuring optimal trade-off for high VLP 
yield  with  minimum  co-extraction  of  host-derived  contaminants.  The  benefit  of  the 
proposed  primary  purification  strategy  on  a  downstream  hydrophobic  interaction 
chromatography step is evident. As a result of the elimination of bulk contaminants in 
the  process  stream,  a  significant  improvement  in  column  binding  capacity  and  a 
concomitant increase in product yield were achieved. Furthermore, the reduction in the 
level  of  contaminants,  particularly  lipids,  would  serve  to  minimise  column  fouling 
thereby  improving  column  integrity  and  lifespan.  As  such,  the  selective  recovery 142 
 
methodology  described  here  may  provide  a  platform  for  future  VLP  process 
developments.  
The unit operations employed in this selective process are essentially the same 
as for a conventional process but with the inclusion of an additional centrifugation step. 
The effectiveness of this selective recovery approach depends on the efficiency of the 
centrifugation steps in the process sequence, particularly the levels of dewatering and 
clarification  achieved.  The  feasibility  of  this  operation  for  large  scale  VLP 
manufacturing would hence be dictated by centrifugation performance upon scale-up. 
Scale-up  considerations  for  the  key  centrifugation  operations  are  discussed  in  the 
following chapter.    
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Chapter 7: Centrifugation scale-up studies for selective product recovery methodology 
Centrifugation  scale-up  studies  for  the  selective 
product recovery methodology 
 
 
7.1 Introduction 
In the previous chapter, an enhanced primary purification methodology for the 
recovery  of  the  hepatitis  B  surface  antigen  (HBsAg)  was  developed  based  on  the 
introduction of a key centrifugation step post-cell disruption but prior to the addition of 
detergent  for  HBsAg  liberation  from  the  endoplasmic  reticulum  (ER).  The  two-step 
centrifugation process is shown schematically in Figure 7.1 and the centrifugation steps 
are  denoted  as  centrifugation  “1”  and  “2”  respectively.  The  purpose  of  the  first 
centrifugation step (centrifugation 1) is to recover sedimented cell membrane material 
containing the HBsAg product of interest and to eliminate bulk cytosolic host protein 
and lipid contaminants in the supernatant. Hence, this centrifugation step influences the 
product  yield  and  degree  of  product  enrichment  achieved.  Following  this,  the 
sedimented  fraction  is  treated  with  Triton  X-100  detergent  to  release  the  HBsAg 
product into the soluble phase. A second centrifugation step (centrifugation 2) is then 
employed for the removal of cell debris, now free of HBsAg. Since the HBsAg product 
is recovered in the supernatant fraction, the degree of dewatering is critical to achieve 
the desired product yield. This twin centrifugation methodology has been successfully 
demonstrated  at  laboratory  scale.  However,  successful  translation  of  this  strategy  to 144 
 
large  scale  manufacturing  would  depend  on  the  dewatering  and  clarification 
performance of the key centrifugation operations upon scale-up. Hence, it is vital that 
the HBsAg yield and the efficiency of contaminant removal observed at laboratory scale 
are not lost in the scaled up process.  
 
Figure  7.1:  Schematic  of  two  step  centrifugation  process  adopted  in  the  proposed 
selective product recovery methodology for the primary purification of HBsAg.  
The ability to predict large scale centrifugation performance using scale down 
methods is invaluable from both the perspectives of time and costs. The concept of ultra 
scale-down (USD) centrifugation using millilitre quantities of material, developed in 
recent years has shown enormous potential in predicting the performance of large scale 
industrial operations (Tustian et al., 2007; Boychyn et al., 2004; Boychyn et al., 2000; 
Salte et al., 2006; Titchener-Hooker et al., 2008). USD predictions are based on the 
Sigma  concept  (Ambler,  1959)  which  infers  that  maintenance  of  equivalent  flow  to 
separation area ratios will result in the same level of clarification being achieved for 
different centrifuges. Correction factors are introduced to account for non-ideal flow 
patterns and these differ depending on the type of centrifuge. An additional stage is 
usually involved when modelling the recovery of delicate materials. By the inclusion of 
a shear device, it is possible to mimic the impact of high-shear regions present in the 
inlet of centrifuges which may cause cell disruption and hence lead to a carryover of 145 
 
solid contaminants (Boychyn et al., 2004; Tustian et al., 2007). This is not required 
when  dealing  with  post-homogenisation  material,  such  as  in  this  study,  where  the 
effects at high shear regions of the centrifuge would be insignificant compared to cell 
disruption conditions to which the material will have had prior exposure.  
A  wide  range  of  centrifuge  designs  are  available  for  large  scale  processing. 
Amongst these are the disc-stack centrifuge, the multichamber bowl and a tubular bowl 
variant, the CARR Powerfuge
TM. Their characteristics have been previously reported 
(Salte et al., 2006; Boychyn  et al., 2004). The CARR Powerfuge
TM is of particular 
relevance since this high-speed industrial centrifuge, being similar to the tubular bowl in 
design, provides good clarification and solids compaction but crucially is also capable 
of automated solids discharge. It thus possesses the combined advantages of the tubular 
bowl  and  disc-stack  machines  (Boychyn  et  al.,  2004).  The  CARR  Powerfuge
TM  P6 
model for process demonstration has an operating feed flow range from 0.1 to 1 L/min 
and rotational speed of 5,000 to 15,000 rpm. 
The aim of this study was two-fold. The fundamental goal was to demonstrate 
the scalability of the selective product recovery approach, specifically that its benefits 
are  not  compromised  upon  scale-up.  The  secondary  goal  was  to  investigate  if 
centrifugation  conditions  could  be  tuned  to  enhance  further  the  selectivity  of 
contaminant  removal  using  this  method.  The  first  step  to  both  goals  involves 
determining the optimal range of operating conditions for the two centrifugation steps. 
Ultra scale-down (USD) centrifugation experiments were adopted to mimic conditions 
of  feed  flowrate  and  rotational  speed  within  the  operating  range  of  the  CARR 
Powerfuge
TM P6 centrifuge. Centrifugation performance were analysed in terms of the 
degree of solids recovery, the clarification level, percentage dewatering, HBsAg yield 
and the effective removal of host protein and lipid contaminants. A pilot-scale study 146 
 
was performed to evaluate the “optimal” and “worst case” scenarios identified from the 
USD mimics. The pilot-scale study would allow the assessment of the accuracy of the 
USD  centrifugation  predictions  and  more  importantly  for  the  verification  of  the 
scalability of the selective product recovery methodology.  
   
 
7.2 Theoretical considerations 
USD centrifugation theory is based on the Sigma concept (Ambler, 1961) which 
allows  the  separation  area  of  a  centrifuge  to  be  described  independently  of  process 
parameters.  The  sigma  value,  ∑,  can  be  used  as  an  index  for  the  comparison  of 
centrifuges  of  different  types  or  for  the  prediction  of  the  performance  of  a  given 
centrifuge during scale up as shown in Equation 7.1 where Q is the feed flowrate into 
the centrifuge, ∑ the equivalent settling area and C the correction factors to account for 
nonidealities in fluid flow. 
   
  Σ 
 =
   
  Σ 
 = 
  
  Σ 
   (Equation 7.1) 
Different centrifuge designs result in different expressions for the settling areas. In this 
study,  the  performance  of  a  CARR  Powerfuge
TM  tubular  bowl  type  centrifuge  was 
modelled using a laboratory fixed angle centrifuge. The equivalent settling area, ∑, for 
the CARR Powerfuge can be calculated using the tubular bowl Equation 7.2 whereby ω 
is  the  angular  velocity,  g,  gravitational  acceleration,  L,  bowl  length,  ro,  outer  bowl 
radius and r1, radius of weir for supernatant discharge (Boychyn et al., 2000).  
Σ =  
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[The CARR Powerfuge
TM P6 centrifuge (Pneumatic Scale Corporation, Florida, USA) 
employed in this study has the following dimensions: L = 0.1273m; r0 = 0.0762m and r1 
= 0.0508 m.]      
The sigma value for the laboratory centrifuge can be calculated using Equation 
7.3  whereby  Vlab  is  the  volume  of  the  material  in  the  tube  and  R1  and  R2  are  the 
respective distances between the centre of rotation and the top of the liquid and the 
bottom of the tube (Boychyn et al., 2000).  
Σ    =         
     
   
     
 
     (Equation 7.3) 
[Using  the  Eppendorf  Centrifuge  5810R  (Eppendorf,  Hamburg,  Germany)  (with 
Eppendodf  tubes  filled  to  1.5  mL),  the  following  parameters  were  employed  for 
calculating the sigma value: R1 = 0.06875 m; R2 = 0.11307 m.]  
The laboratory centrifuge was used as the baseline for comparison hence the 
correction  factor  was  set  at  1.0.  The  CARR  centrifuge  is  reported  to  have  a 
corresponding correction factor of 0.9 (Boychyn et al., 2004).  
 
 
7.3 Materials and Methods 
Recombinant S. cerevisiae cells expressing the HBsAg product were produced 
by batch fermentation as reported in Section 2.2. For the ultra scale-down study, cell 
homogenate  was  prepared  by  cell  disruption  using  the  Lab  40  homogeniser  (APV 
Gaulin GmbH, Lubeck, Germany) at 400 bar for 4 passes as detailed in Section 2.3. 
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and  feed  flow  rate  are  described  in  Section  2.11.  Following  the  ultra  scale-down 
experiments,  a  validation  study  was  performed  at  pilot-scale.  Due  to  the  lack  of 
availability of recombinant S. cerevisiae for this study, baker’s yeast (Craftbake High 
Activity, DCL Yeast Ltd, Surrey, UK) was employed. Homogenisation for this scale of 
operation was performed using the Lab 60 homogeniser (APV Gaulin GmbH, Lubeck, 
Germany) under the same conditions as for the USD study of 400 bar and 4 passes. The 
operation of the pilot scale centrifugation experiment is discussed in Section 2.12. 
  Analytical  techniques  performed  for  characterisation  of  centrifugation 
conditions include analysis of solids recovery or clarification level (Section 2.13.13), 
analysis of the dewatering level (Section 2.13.4), HBsAg measurement via an ELISA 
assay  (Section  2.13.4),  total  protein  analysis  using  a  Bicinchoninic  (BCA)  assay 
(Section 2.13.5), and lipid analysis by HPLC (Section 2.13.6). 
 
 
7.4 Results and discussions 
The CARR Powerfuge
TM P6, which is a pilot-scale centrifuge with a 1 L bowl 
volume was employed as the basis for the assessment of the scalability of the selective 
recovery methodology. As previously mentioned, this centrifuge has an operating range 
of 5,000 to 15,000 rpm in terms of rotational speed and feed flowrate of 0.1 to 1 L/min. 
Based on these values, the Q/C∑ range for this centrifuge was calculated to be between 
1.86 x 10
-9 to 1.67 x 10
-7 m/s. Ultra scale-down experiments were conducted to mimic 
centrifugation performance within the operating range of the CARR Powerfuge
TM P6 
using  recombinant  S.  cerevisiae  homogenate.  As  previously  discussed,  the  two 
centrifugation  operations  have  significantly  different  roles  and  were  evaluated 149 
 
independently.  Having  identified  the  optimal  centrifugation  conditions  using  USD 
studies,  pilot-scale  experiments  were  performed  to  verify  the  accuracy  of  the  USD 
predictions  and  to  assess  the  overall  scalability  of  the  selective  product  recovery 
methodology. This was carried out using a parallel system with baker’s yeast due to the 
lack of availability of S. cerevisiae material containing the recombinant HBsAg product 
for this scale of operation. 
  
7.4.1 Ultra scale-down studies of centrifugation 1  
As  previously  discussed,  the  role  of  centrifugation  1  is  to  achieve  effective 
purification by driving the partitioning of HBsAg-ER material to the solids fraction and 
the  bulk  contaminants  to  the  supernatant  fraction.  In  order  to  determine  suitable 
centrifugation conditions for this step, laboratory centrifugation was carried out under a 
range of rotational speeds and centrifugation times to achieve a Q/C∑ range of 1.28 x 
10
-9  to  1.8  x  10
-7  m/s  which  encompasses  the  operating  range  of  the  pilot-scale 
centrifuge.  The  resulting  level  of  solids  recovery  and  percentage  dewatering  are  as 
shown in Figure 7.2. Higher levels of solids recovery and dewatering were observed at 
lower Q/C∑ conditions which are as expected.Lower Q/C∑ values correspond to the 
more  extreme  centrifugation  conditions  which  would  in  turn  lead  to  more  effective 
settling and compaction of cell debris particles. It was observed that even at the upper 
Q/C∑  operating  limit  of  the  CARR  centrifuge,  the  centrifugation  conditions  were 
sufficient  to  sediment  ~  80%  of  the  solids  although  the  level  of  dewatering  was 
significantly poorer at ~ 45%.   150 
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Figure 7.2: Level of solids recovery ( ) and dewatering ( ) observed for 
the  centrifugation  1  under  different  Q/C∑  conditions.  The  results  were  normalised 
based on values for the well spun sample set to 100%. Error bars represent standard 
deviation from triplicate samples with a coefficient of variance ≤ 5%. 
 
The wet pellets obtained from centrifugation 1 were subsequently treated with 
detergent for the recovery of the HBsAg product. A second centrifugation step was 
necessary for the recovery of soluble product for analysis and this was performed at a 
constant Q/C∑ (1.3 x 10
-9 m/s) conditions for all samples. An ELISA assay employed to 
detect  HBsAg  antigenicity  in  the  product  stream  following  both  centrifugation 
operations  showed  little  variation  in  its  measurements  across  the  Q/C∑  range 
investigated  for  the  first  centrifugation  step  (Figure  7.3  (a)).  The  almost  identical 
HBsAg  yields are not surprising given that there is less than 20% difference in the 
solids recovery level over the Q/C∑ range examined. Variations in HBsAg yields, if 
any, may have been undetectable using the ELISA assay which has a coefficient of 
variance of up to 17%.  151 
 
The product streams were also analysed in terms of the level of proteins and 
lipids  present.  Figure  7.3(b)  shows  the  total  protein  measurements  for  the  product 
stream  following  both  centrifugation  operations  and  that  for  the  waste  supernatant 
stream from centrifugation 1 over the range of Q/C∑ examined for centrifugation 1. 
Since the protein contribution from the HBsAg product appears to be constant over the 
Q/C∑ range from the ELISA results, variations in total protein measurements must be 
due to variations in the level of host proteins. The results indicate that higher Q/C∑ 
conditions (less extreme centrifugation) were beneficial as this lead to greater levels of 
protein contaminants being eliminated in the waste supernatant stream. As a result the 
HBsAg product was released into a cleaner process stream following the detergent step. 
In  contrast  under  low  Q/C∑  conditions  (more  extreme  centrifugation),  significant 
proportions of protein associated cell debris co-sedimented with the HBsAg product 
leading to higher levels of co-liberation of protein contaminants during the detergent 
step. Total lipid analysis of the product stream following both centrifugation operations 
is  shown  in  Figure  7.3(c).  The  results  mirror  those  obtained  for  the  protein 
contaminants.  More  effective  elimination  of  lipid  contaminants  in  the  supernatant 
fraction was achieved using higher Q/C∑ conditions for centrifugation 1.  
In summary, higher Q/C∑ values are favoured for the operation of centrifugation 
1 since more effective removal of host protein and lipid contaminants were achieved. 
Although dewatering levels were lower under these conditions, which resulted in more 
dilute  feed  streams  and  larger  processing  volumes  for  subsequent  operations,  the 
benefits of a cleaner process stream would probably outweigh this. Hence, it would be 
ideal to operate at the Q/C∑ upper limit for the CARR Powerfuge
TM which at 1.6 x 10
-7 
m/s is achieved when the machine is operated  at a feed flowrate of 1  L/min and a 
rotational speed of 5000 rpm.   152 
 
  
 
 
Figure  7.3:  (a)  shows  HBsAg  yield  following  the  detergent  step  generated  under 
different Q/C∑ conditions employed for centrifugation 1. (b) shows the protein levels 
eliminated in the waste stream following centrifugation 1 ( ) and the protein 
levels in the final product stream ( ). (c) shows the level of lipid contaminants in 
the final product stream under conditions for centrifugation 1. Error bars represent 
standard deviation from triplicate samples with average coefficient of 17% for HBsAg 
measurement  by  ELISA  and  coefficient  of  variance  of  ≤  5%  for  protein  and  lipid 
measurements. 
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7.4.2 Ultra scale-down studies of centrifugation 2  
The  role  of  centrifugation  2  is  to  recover  the  HBsAg  product  now  in  the 
supernatant  fraction.  Hence,  high  dewatering  performance  is  critical  to  maximise 
product  yield. HBsAg-enriched cell debris sediments were prepared centrifugation 1 
using  the  optimal  Q/C∑  value  of  1.6  x  10
-7  m/s  determined  previously.  Following 
detergent-mediated HBsAg liberation, centrifugation 2 was performed under a range of 
Q/C∑ conditions of 1.3 x 10
-9 to 6.5 x 10
-7 m/s.  
Figure  7.4  shows  the  impact  of  Q/C∑  on  the  level  of  clarification  and 
dewatering from centrifugation 2. As in centrifugation 1, it was observed that lower 
Q/C∑ conditions (more extreme centrifugation) led to higher levels of solids recovery 
and dewatering in centrifugation 2. Since the product of interest is recovered in the 
supernatant stream high dewatering conditions are critical and hence operating at the 
lower Q/C∑ limit of the machine (more extreme centrifugation) would be preferred.  
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Level of clarification ( ) and dewatering ( ) achieved for the 
centrifugation  2  under  different  Q/C∑  conditions.  The  results  were  normalised  by 
comparison with values for the well spun sample set to 100%. Error bars represent 
standard deviation from triplicate samples with coefficient of variance of ≤ 5%.  154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: (a) Impact of centrifugation Q/C∑ conditions on the level of HBsAg product 
recovery;  (b)  Impact  of  centrifugation  on  the  level  of  protein  ( )  and  lipid 
contaminants  ( )  in  the  final  product  stream.  Error  bars  represent  standard 
deviation from triplicate samples with an average coefficient of variance of ≤ 17% for 
HBsAg measurements and ≤ 5% for protein and lipid measurements.  
 
Improvement in HBsAg yields was evident from the higher dewatering levels 
achieved at low Q/C∑ (more extreme centrifugation) conditions as shown in Figure 7.5 
(a). This is primarily due to the larger volume of product stream recovered under such 
conditions. Analysis of the product stream centrifugation 2 in terms of total protein and 
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lipid are presented in Figure 7.5(b). The use of low Q/C∑ centrifugation conditions 
also  showed  up  to  a  20%  improvement  in  the  reduction  of  protein  contaminants. 
However it did not appear to have a statistically significant effect on the level of lipid 
contaminants.    
 
 
7.4.3 Pilot-scale evaluation of the USD predictability 
  The  ultra  scale-down  (USD)  experiments  have  allowed  the  rapid 
identification of the optimal operating conditions for each of the centrifugation steps. It 
appears that the optimal centrifugation strategy using the pilot-scale CARR Powefuge
TM 
P6 centrifuge would involve operating centrifugation 1 at the high Q/C∑ limit achieved 
at a feed flowrate of 1 L/min and rotational speed of 5000 rpm, and centrifugation 2 at 
the low Q/C∑ limit of the machine, at feed flowrate of 0.1 L/min and rotational speed of 
15,000 rpm. A pilot-scale study was subsequently performed to assess the accuracy of 
the USD predictions. In this study, two sets of centrifugation conditions representing the 
“optimal”  and  “worst  case”  centrifugation  scenarios  were  tested  and  the  results 
compared to those from a USD mimic.  
  The pilot-scale study would require up to 2 kg of wet cell paste. A fermentation 
at  450  L  scale  was  carried  out  to  generate  material  for  these  studies  however  the 
fermentation encountered contamination problems which could not be rectified within 
the time period allocated for this study. The study was performed instead using baker’s 
yeast as a parallel system. For process comparability, the USD study was also carried 
out using baker’s yeast. The degree of predictability of pilot-scale performance using 
USD methods determined here for baker’s yeast would be reflective of the predictability 156 
 
of USD methods for the recombinant yeast strain. The use of baker’s yeast would allow 
key parameters such as the level of solids recovery and percentage dewatering to be 
determined. The contamination profile in the product and waste streams observed here 
would be indicative of the levels expected in the purification of recombinant HBsAg. 
Although  it  is  not  possible  to  directly  analyse  the  level  of  HBsAg  yield  using  this 
baker’s yeast system, an estimation of this is possible from the correlation of product 
yield with the level of  solids recovery and dewatering from centrifugation 1 and 2, 
respectively.  Previous  data  on  HBsAg  recoverability  from  the  solids  fraction  is 
available from Chapter 6.  
   Comparison of the results obtained at pilot-scale and for the USD mimic for the 
“optimal” and “worst case” centrifugation strategies are as summarised in Table 7.1. In 
terms of solids recovery, it appears that for higher Q/C∑ (less extreme centrifugation) 
conditions,  the  amount  of  solids  recovered  were  significantly  lower  than  the  levels 
predicted  from  the  USD  mimic.  For  example,  in  centrifugation  1  of  the  “optimal” 
method, the actual amount of solids recovered from centrifugation discharge at 54% 
was significantly lower than the 96% solids recovery level predicted from the USD 
method. The supernatant fraction was subsequently analysed to determine if the solids 
were lost in the supernatant due to poor clarification. The level of solids which were 
carried over to the supernatant stream was found to only account for 11% of the total 
solids in the feed. It was observed during centrifugation discharge that some proportion 
of the solids escaped the centrifuge scraper mechanism and remained on the surface of 
the bowl. By mass balance, this was estimated to account for ~ 35% solids loss. If the 
scraper  mechanism  for  solids  discharge  had  been  effective  and  there  had  been  no 
product lost on the centrifuge bowl, the level of solids recovery would be ~ 90% and 
significantly closer to the USD predicted value of 96%. Similarly, if product loss due to 157 
 
ineffective  solids  discharge  was  negligible  for  centrifugation  2  for  the  “worst  case” 
scenario, the solids recovery level would be at 98%, close to the predicted value of 
100% from the USD model.  
  This effect was less pronounced for centrifugation processes at the low Q/C∑ 
(more extreme centrifugation) conditions in which the USD predictions more closely 
matched the actual amounts of solids recovered. The main reason for this is that under 
more extreme centrifugation conditions at low Q/C∑ values, the solids formed are drier, 
less  sticky  and  therefore  could  be  removed  more  effectively  from  the  bowl  by  the 
centrifuge scraper mechanism during discharge.  
  The amount of product loss due to the inefficiency of the scraper mechanism as 
a proportion of the maximum recoverable solids would be expected to vary depending 
on the scale of the process. Hence, this loss would be less significant for industrial scale 
centrifugation processes where larger throughputs are involved. The results imply that 
the USD model is able to predict accurately the degree of clarification achieved in the 
supernatant fraction but is more limited in its capacity to predict the actual amount of 
solids recovered as this depended on the efficiency of the scraper mechanism of the 
centrifuge in discharging the accumulated solids. 
  For predictions of dewatering levels, a larger discrepancy was observed between 
pilot-scale and USD data.  During the pilot-scale centrifugation runs, it was observed 
that the solids discharged were not homogenous. A wet slurry was typically released 
first followed by the discharge of drier solids. Due to the lack of homogeneity of the 
discharged material, it was difficult to recover a representative sample for the dry cell 
weight analysis required in determining the level of dewatering achieved. The driest 
portions of the solids discharged were relatively easy to sample for dewatering analysis 158 
 
and  this  is  reflected  in  the  results  obtained  (Table  1)  as  higher  dewatering 
measurements were recorded for pilot-scale centrifugation runs compared to the USD 
mimic. 
   Samples from the supernatant fractions were also measured in terms of the level 
of  protein  and  lipid  contaminants  eliminated  in  the  supernatant  fractions  from 
centrifugation  1  and  the  levels  remaining  in  the  supernatant  product  stream  from 
centrifugation 2. The results summarised in Table 7.2, clearly show that the levels of 
protein and lipid contaminants predicted for each of the process streams closely reflect 
the actual values recorded from the pilot-scale operations.  
 
 
Table 7.1: Comparison of the levels of solids recovery and dewatering obtained under 
“optimal” and “worst case” centrifugation conditions for the pilot-scale experiment 
and  the  ultra-scale  down  (USD)  mimic.  Values  of  solids  recovery  in  brackets  were 
determined assuming 100% efficiency of solids discharge.  
  “Optimal”  “Worst case” 
USD mimic  Pilot-scale  USD  mimic  Pilot-scale 
Centrifugation 1 
Condition  Q/C∑ = 1.7 x 10
-7 m/s  Q/C∑ = 1.9 x 10
-9 m/s 
Solids recovery  96%  54% 
(89%) 
100%  96% 
Dewatering  76%  96%  100%  87% 
Centrifugation 2 
Condition  Q/C∑ = 1.9 x 10
-9 m/s  Q/C∑ = 1.7 x 10
-7 m/s 
Solids recovery  97%  96%  100%  76% 
(98%) 
Dewatering  97%  100%  73%  97% 
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Table  7.2:  Comparison  of  contamination  profile  of  supernatant  streams  following 
centrifugation  1  and  2  for  the  pilot-scale  operation  and  the  USD  mimic  of  the 
“optimal” and “worst case” centrifugation scenarios. 
    “Optimal”  “Worst case” 
USD 
prediction 
Pilot-scale 
data 
USD 
prediction 
Pilot-scale 
data 
Centrifugation 1: Contaminants eliminated in supernatant 
Condition  Q/C∑ = 1.7 x 10
-7 m/s  Q/C∑ = 1.9 x 10
-9 m/s 
Total protein  (mg/mL)  5.7  5.8  5.4  5.1 
Total lipid (peak area)  1818  1862  1139  1432 
Centrifugation 2: Contaminants remaining in product stream 
Condition  Q/C∑ = 1.9 x 10
-9 m/s  Q/C∑ = 1.7 x 10
-7 m/s 
Total protein (mg/mL)  0.26  0.26  0.38  0.41 
Total lipid (peak area)  189.58  196.92  296.02  291.82 
   
   
  In comparing the “optimal” centrifugation strategy versus the “worst case” 
scenario  for  the  pilot-scale  experiments,  it  appears  from  Table  7.2  that  the  former 
method was clearly more effective in eliminating yeast protein and lipid contaminants 
in the supernatant fraction during centrifugation 1 leading to a purer supernatant product 
stream in centrifugation 2. Product yield for HBsAg recovery would be dictated by the 
level  of  solids  recovery  from  centrifugation  1  and  the  percentage  dewatering  from 
centrifugation 2. A greater level of solids loss during centrifugation 1 was observed for 
the “optimal” method due to the inefficiency of the scraper mechanism of the centrifuge 
in discharging solids which would impact product  yield negatively if applied to the 
recombinant  HBsAg  process.  The  dewatering  levels  for  centrifugation  2  appear 
comparable for both processes although the USD mimic predicts poorer performance 
for the “worst case” centrifugation.   
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7.4.4 Scale-up feasibility of the selective product recovery methodology 
   The  scalability  of  the  “optimal”  strategy  for  the  selective  product  recovery 
methodology was evaluated based on the USD and pilot-scale experiments with baker’s 
yeast. Product yield for the recombinant HBsAg system would be dictated by the level 
of  solids  recovery  from  centrifugation  1  and  the  level  of  dewatering  achieved  in 
centrifugation 2. In this parallel study with baker’s yeast, for centrifugation 1, a solids 
recovery  level  of  ~  96%  was  predicted  from  the  USD  mimic  and  based  on  the 
clarification performance at pilot-scale, a recovery level of ~ 90% would be achieved 
had solids been discharged effectively from the centrifuge. Although the pilot-scale data 
highlighted that solids loss due to the inefficiency of the scraper mechanism of the 
centrifuge  in  performing  solids  discharge  could  be  an  issue,  it  is  likely  that  the 
magnitude of this problem would be less pronounced at industrial scale due due to the 
higher overall process volumes and throughputs. Both USD and pilot-scale data show 
high levels of dewatering of above 95% for centrifugation 2 which would ensure high 
HBsAg product recovery in the final supernatant stream.  The results from the pilot-
scale study also verified that the degree of purification afforded by the selective product 
recovery methodology would be maintained upon scale-up. Pilot-scale and USD data 
concur in that over 90% of host lipid and protein contaminants are eliminated in the 
supernatant  stream  during  centrifugation  1  resulting  in  a  significantly  cleaner 
supernatant product stream in centrifugation 2.  
  Overall,  the  study  with  baker’s  yeast  verifies  that  USD  centrifugation 
experiments  were  reliable  in  predicting  large  scale  centrifugation  performance.  The 
agreement of the USD and pilot-scale data in terms of the expected product yield based 
on the solids recovery characteristics and the degree of purification potentials afforded 
demonstrates  that  the  benefits  of  the  selective  recovery  methodology  are  not 161 
 
compromised upon scale-up. Although the absolute values for these parameters may 
differ from system to system, it is reasonable to deduce from the baker’s yeast data, 
which provides a parallel comparison to the recombinant HBsAg process, that the scale-
up of the selective product recovery methodology would be equally feasible for the 
recombinant HBsAg material.     
 
 
7.5 Conclusions 
  It is evident that the effectiveness of the selective product recovery methodology 
depends crucially on the performance of both key centrifugation operations. The value 
of USD techniques is clearly demonstrated in this study as it allowed a wide range of 
centrifugation operating conditions for HBsAg S. cerevisiae homogenate to be studied 
in a rapid fashion with millilitre volumes of material. The results show that for the first 
centrifugation operation, high Q/C∑ conditions are favoured to ensure the majority of 
lipid and protein contaminants remain in the supernatant stream which is subsequently 
discarded. This however is provided that good solids recovery levels are achieved and 
HBsAg  yields  are  not  compromised.  Since  the  HBsAg  product  is  recovered  in  the 
supernatant  fraction  during  the  second  centrifugation  operation,  good  dewatering 
characteristics are vital for desirable product  yields. For this, operating at the lower 
Q/C∑ limit would be favourable. Pilot-scale studies performed using a parallel system 
with baker’s yeast demonstrated that the USD mimics were indeed reliable in predicting 
larger scale centrifugation performance. Based on the high level of solids recovery and 
the effective reduction of host-derived contaminants observed from the USD and pilot-
scale studies, we concluded that it would be feasible to scale-up the selective product 162 
 
recovery  methodology  for  commercial  manufacturing  of  recombinant  HBsAg.  The 
optimal centrifugation conditions identified from the USD mimics is expected to be 
equally effective for the scaled-up process.      
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Chapter 8: Conclusions and recommendations for future work 
Conclusions & recommendations for future work 
 
 
8.1 Review of research objective & direction in view of issues in 
VLP development 
Virus-like  particles  (VLPs)  are  an  increasingly  important  class  of  vaccines 
which may hold the answer to the development of a host of preventative medicines 
against  viral  infections  including  HIV  (Boisgerault  et  al.,  2002).  An  important 
breakthrough is in the development of chimeric and multivalent vaccines using VLPs as 
platforms for the presentation of foreign epitopes or targeting molecules (Grgacic and 
Anderson, 2006). This is especially key for disease conditions where in the natural state, 
recombinant surface proteins lack the spatial structure for eliciting a broad range of 
immune response.  
In spite of the enormous potentials of VLP vaccines, the commercialisation of 
such  vaccines  is  faced  with  immense  challenges  from  the  perspectives  of  stringent 
regulatory  oversights,  sophisticated  product  characterisation  requirements, 
manufacturing considerations and scale-up issues (Buckland, 2005). Of these, the chief 
contributing factor to the slower reception and commercialisation of VLP vaccines than 
originally anticipated is the higher costs involved in the production and purification as 
compared to traditional life attenuated viral vaccines (Boisgerault et al., 2002). Process 
development is particularly hampered by ineffective laboratory scale processes which 164 
 
are difficult or costly to scale up and by a lack of process flexibility for improvements 
or modifications at later stages (Pattenden et al., 2005). For commercial realisation of 
novel VLP vaccines, it is thus insufficient to focus research efforts on vaccine design 
and  development.  Instead,  it  is  vital  to  complement  such  efforts  with  research  in 
bioprocess manufacturing in order to develop effective and economical processes which 
can support the large-scale production and rapid delivery of the new vaccines to market.   
In line with the issues highlighted above, the goal of this thesis is to develop a 
robust  and  enhanced  primary  purification  route  for  future  generation  lipid-envelope 
VLPs  in  order  to  improve  overall  process  efficiency  and  throughput.  The  focus  on 
primary  purification  is  especially  relevant  as  early  purification  stages  are  often 
overlooked in process design. These operations could in reality be equally if not more 
important than high resolution operations as they often set the limits to the overall yield 
and levels of process performance that can be achieved.  
It has been reported that chromatographic operations are the largest cost centre 
for downstream purification (Przybycien  et al.,  2004). One of the means of driving 
down  the  reliance  and  purification  burden  on  chromatography  is  by  improving  the 
efficiency of contamination reduction and product enrichment in the operations prior to 
chromatography. In this thesis, a novel approach for the redesign of primary purification 
processes was examined which integrated understandings of the VLP expression system 
and their physiochemical attributes with more conventional engineering methodologies 
and  insights  to  process  interaction.  The  three  critical  research  milestones  for  this 
purpose  include:  (1)  characterisation  and  optimisation  of  the  conventional  primary 
recovery route to improve VLP yield and antigenicity and to minimise the level of host-
derived  contaminants;  (2)  primary  purification  process  re-design  involving  the 
introduction  of  an  additional  protein  fractionation  or  separation  step  to  improve 165 
 
purification  and  product  enrichment;  and  (3)  scale-up  considerations  and  feasibility 
assessment  of  the  process  developed  from  Stages  1  and  2.  At  all  stages  of  process 
design, an equal emphasis was placed on maintaining the biological and physiochemical 
aspects  of  the  HBsAg  system  as  on  purification  performance  which  is  vital  from  a 
regulatory  perspective.  Whenever  possible,  scaled-down  bioprocess  technologies, 
capable  of  predicting  industrial  scale  performance,  were  applied.  The  low  volume 
requirements and the shorter processing times using such scale-down mimics allow a 
wide  matrix  range  of  process  variants  to  be  evaluated  in  an  effective,  rapid  and 
inexpensive way.  
 
 
8.2 Summary of research findings 
8.2.1  Characterisation  &  optimisation  of  detergent-mediated  HBsAg 
liberation  
Specific to the inherent expression characteristics of lipid-envelope VLPs in S. 
cerevisiae, product recovery is driven by a detergent step which facilitates the liberation 
of the VLP from the host organelle. Detergent-mediated VLP liberation is a critical step 
in primary recovery as it sets the framework for product  yield, antigenicity and the 
profile of contaminants from the host cell which could impact downstream operations. 
The  study  with  HBsAg  demonstrates  that  the  Triton  X-100  detergent  was  the  most 
effective agent for the extraction of the VLP from the host endoplasmic reticulum. The 
optimal  concentration  range  for  Triton  X-100  was  between  0.2  –  0.5%  v/v. 
Concentrations below this range led to ineffective VLP recovery whereas concentration 166 
 
above led to HBsAg delipidation which resulted in decreased VLP antigenicity. The 
level of co-liberation of protein and lipid contaminants into the product stream was in 
proportion  to  the  amount  of  detergent  employed.  As  a  result,  greater  membrane 
resistance  due  to  increased  fouling  effects  was  observed  during  ultrafiltration  for 
samples generated using higher concentrations of detergent. Hence in general, a low 
detergent concentration is favourable for VLP liberation but the limiting factor in this 
would be the recovery level of active VLP.    
 
8.2.2 Process improvement for primary purification   
 The  first  approach  investigated  involved  the  introduction  of  a  protein 
fractionation  step  in  primary  purification  via  precipitation  with  polyethylene  glycol 
(PEG) or ammonium sulphate. For HBsAg purification, PEG 8000 at a concentration of 
10% w/v was found to be superior for the reduction of protein contaminants whilst 
ammonium sulphate at a concentration of 15% w/v was for lipid contaminants. In each 
case,  an  enrichment  factor  of  ~  8-fold  was  attained.  The  effectiveness  of  PEG 
precipitation was significantly influenced by the separation mechanism for precipitate 
recovery. Filtration was found to be superior to centrifugation when dealing with high 
viscosity  process  streams  at  PEG  concentrations  of  10%  w/v  and  above.  The  main 
drawback with PEG and ammonium sulphate precipitations is in the modest step yields 
(50%  -  70%)  attained.  In  spite  of  this,  the  performance  characteristics  of  the 
precipitation operations were sufficiently promising that, with further optimisation in 
terms of precipitation conditions and separation techniques, these operations may be 
practically and economically viable. 167 
 
The second approach investigated for primary purification is derived from the 
exploitation of the intracellular compartmentalisation characteristics of lipid-envelope 
VLPs in S. cerevisiae. Due to the lack of protein transport machinery in recombinant 
yeast cells, the VLPs produced are permanently localised on cellular compartments such 
as the endoplasmic reticulum (ER) as in the case of the HBsAg. To impart selectivity to 
the product recovery process, a twin centrifugation strategy was proposed in which a 
centrifugation step is introduced immediately following cell disruption but prior to the 
addition  of  detergent  for  VLP  liberation.  In  the  HBsAg  system  investigated,  the 
additional centrifugation step allowed the elimination of bulk cytosolic contaminants in 
the  supernatant  stream,  achieving  ~  70%  reduction  of  contaminating  yeast  proteins, 
lipids and nucleic acids. Recovery and subsequent treatment of the solids fraction with 
detergent released the HBsAg product into a significantly enriched product stream with 
a yield of over 80%. It was further demonstrated that the selectivity of this approach 
could  be  further  enhanced  by  operating  under  moderate  homogenisation  pressure 
conditions  (~  400  bar)  where  improvements  in  the  recovery  of  active  HBsAg  and 
greater reduction of contaminating lipids were observed. These were attributed to the 
lower shear conditions experienced by the HBsAg product and the reduced levels of cell 
fragmentation  which  led  to  lower  co-liberation  of  lipid  contaminants  during  the 
detergent step. The cleaner process stream resulted in a 40% improvement in product 
capture  and  a  concomitant  increase  in  step  yield  during  a  downstream  hydrophobic 
chromatography  operation.  Although  not  evaluated  in  this  study,  the  lower  level  of 
contaminants at the chromatography step is expected to improve column integrity and 
lifespan.  
Overall, the selective product recovery approach is expected to be more effective 
than  either  of  the  precipitation  methods  using  PEG  or  ammonium  sulphate  for 168 
 
improving  the  performance  of  primary  purification.  This  is  essentially  owing  to  the 
higher product yield (≥ 80%) achievable and its efficiency for the elimination of both 
yeast protein and lipid contaminant classes (≥70% reduction). In comparison, product 
yields from PEG and ammonium sulphate were in the range of 50% - 70% and their 
purification efficiencies were limited to proteins and lipids, respectively.   
 
8.2.3 Scale-up considerations and assessment on process feasibility  
  Since the selective product recovery approach was deemed superior for primary 
purification, the scale up studies were focussed on this operation. The effectiveness of 
this  strategy  is  dictated  by  the  performance  of  each  of  centrifugation  operation, 
specifically  in  terms  of  solids  recovery,  clarification,  dewatering  and  the  effective 
elimination  of  proteins  and  lipids  contaminants.  An  ultra  scale-down  model  was 
adopted in this study and the results demonstrated that the equivalent flow rate / settling 
area (Q/C∑) parameters were critical in determining the effectiveness of the approach. 
Operating near the upper Q/C∑ limit of the machine was found to be favourable for the 
first  centrifugation  step  to  ensure  that  the  majority  of  host  lipid  and  protein 
contaminants were discarded effectively in the supernatant waste stream and the low 
settling conditions did not affect adversely the level of solids recovery or HBsAg yield. 
For the second centrifugation operation, high centrifuge settling conditions at the lower 
Q/C∑  limit  of  the  centrifuge  were  desirable  to  achieve  maximal  dewatering 
characteristics to reduce product loss in the solids phase. Additionally, lower levels of 
protein and lipid contaminants were also measured in the supernatant product stream 
under these conditions. The scale-up studies using a parallel system with baker’s yeast 
demonstrated that largely USD predictions of large scale performance were accurate. 169 
 
The scale-up study also verified that the efficiency of the selective product recovery 
methodology in reducing the level of host-derived contaminants was not compromised 
by the increase in process scale. The single potential problem highlighted was related to 
the observation that some product loss occurred at pilot-scale due to the inefficiency of 
the  centrifuge  scraper  mechanism  in  performing  solids  discharge.  However,  this 
problem is likely to be less pronounced at large scale manufacturing as the proportion of 
product loss would be minimal relative to the larger process volumes and throughputs 
experienced.  
 
8.3 General conclusions  
  This  study  reaffirms  the  need  for  product  characterisation  to  complement 
process  design  efforts.  In  the  case  of  the  HBsAg  lipid-envelope  product,  the 
physiochemical and antigenic characteristics of the particle were shown to be sensitive 
to changes in the microenvironment for example in the level of detergent present in the 
process stream and the exposure of the particle to shear during homogenisation. In a 
commercial setting, extensive product characterisation is vital for the manufacturer to 
demonstrate complete assurance of the identity and composition of the vaccine and to 
prove equivalence between new and old processes if changes to the process route or 
scale were made (Buckland, 2005).    
  The  influence  of  primary  purification  operations  on  downstream  stages  is 
evident from this study. For detergent-mediated HBsAg liberation, it was demonstrated 
the amount of detergent employed affected the level of co-liberated yeast protein and 
lipid  contaminants  which  in  turn  affected  the  flux  characteristics  of  a  downstream 
ultrafiltration operation. In a similar study, the reduced level of contaminants, which 170 
 
resulted  from  an  improved  primary  purification  operation,  increased  the  binding 
capacity  and  throughput  of  a  subsequent  chromatographic  operation.  These  findings 
emphasise the necessity for process design and development to be approached based on 
the  bioprocess  as  an  entirety  rather  than  focussing  on  unit  operations  in  isolation. 
Characterisation of process interaction is invaluable in identifying trade-offs to drive up 
overall process efficiency.  
  As in the case of many recombinant protein processes the separation potentials 
of primary purification operations for VLP production have yet to be fully realised. The 
re-examination  of  the  primary  purification  process  for  HBsAg  revealed  that  by  the 
optimisation of detergent conditions for VLP liberation, the recovery of active product 
could be improved and the contamination profile reduced for the benefit of downstream 
operations. Alternative bioseparation technologies such as precipitation may provide an 
avenue for the reduction of processing burden and costs of chromatographic operations. 
The  challenge,  however,  when  additional  processing  steps  are  involved  is  in 
determining the level of acceptable compromise of product yield in favour of improved 
purification. For this purpose, it is vital that comprehensive economic feasibility studies 
accompany process development efforts.  
  This study has demonstrated how key understandings from cell biology can be 
implemented in the design of more effective purification methods for future generation 
VLP  products.  In  the  HBsAg  model,  the  compartmentalisation  of  the  VLP  on  the 
endoplasmic reticulum of the S. cerevisiae host was exploited to impart selectivity to 
the product recovery and purification process. This approach is increasingly pertinent 
with advances in biomolecular and cellular engineering which would enable the design 
of VLP expression systems to target the product of interest at specific sites of the cell 
for the ease of recovery and purification.  171 
 
  The future of VLP bioprocess design is integral with the use of effective scale-
down  technologies.  This  is  particularly  important  to  reduce  ineffective  process  at 
laboratory  scale  which  fail  to  deliver  at  manufacturing  due  to  their  inflexibility  for 
scale-up and process modifications. Scale-down mimics of bioprocess technologies in 
contrast  allow  the  assessment  of  process  efficiency,  robustness  and  scalability  of 
industrial scale operations from the onset of process design. The use of such scale-down 
methodologies for ultrafiltration and centrifugation operations in the HBsAg study was 
invaluable in permitting a wide matrix of processing conditions to be investigated using 
small volumes of material in a rapid and cost-effective manner. The reliability of ultra 
scale-down  centrifugation  predictions  were  verified  here  by  pilot-scale  experiment 
whereas the predictability of the ultrafiltration scale-down model has been demonstrated 
elsewhere  (Ma  et  al.,  manuscript  in  preparation).  A  range  of  other  scale  down 
technologies for downstream processing are available and these can be incorporated 
routinely for more strategic VLP process development.    
 
 
8.4 Recommendation for future work 
The overall thesis objectives have focussed on the primary purification of lipid-
envelope VLPs based on the HBsAg system. In so doing it has been possible to identify 
additional research areas which would be of interest as follow up studies to the primary 
purification work reported in the previous chapters.    
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8.4.1 Further analytical characterisation of HBsAg particles 
Characterisation of HBsAg in this study relied heavily on ELISA assays which 
are based on antigenic activity measurements. The limitation of the method is that it 
does  not  provide  indications  of  the  actual  conformation  of  the  HBsAg  particle.  In 
certain cases, as discussed in Chapter 4, non-native HBsAg particles in the form of 
polypeptide  micelles  assembled  under  conditions  of  excess  detergent  can  show 
antigenic activity measurements which are higher than the native particles. For more 
comprehensive particle characterisation, analytical techniques which probe for changes 
in structural properties of the HBsAg such as the use of circular dichroism (c.d.) and 
iodide  quenching  techniques  (Gavilanes  et  al.,  1990)  would  be  invaluable. 
Alternatively,  optical  imaging  techniques  such  as  confocal  microscopy  could  be 
employed to obtain 3D images of the HBsAg particles. This technique is particularly 
valuable in permitting the visualisation of aggregation problems or HBsAg denaturation 
and irreversible adsorption of surfaces.   
 
8.4.2 Further characterisation of HBsAg stability  
  The  structural  and  physiochemical  properties  of  VLP  particles,  due  to  their 
complex macromolecular structures, are highly influenced by their microenvironment 
and as aptly illustrated by Buckland (2005) the process of producing the VLP defines 
the  product.  The  issue  of  HBsAg  stability  and  antigenic  activity  has  been  broadly 
addressed in the study focussing on the impact of detergent condition during HBsAg 
liberation  and  the  effects  of  varying  homogenisation  pressure  conditions.  However, 
other  primary  purification  process  parameters  such  as  buffer  pH  and  ionic  strength, 
protein concentration, process and storage temperatures and the use of surfactants which 173 
 
could  impact  VLP  stability  (Shi  et  al.,  2005)  remain  to  be  analysed.  The  use  of 
microwell techniques (Aucamp et al., 2005) combined with multi-factorial experimental 
design methods would be invaluable here to allow a large matrix of such processing 
conditions to be screened in a rapid and high throughput manner.  
 
8.4.3 Optimisation studies to improve yield from precipitation operations 
  The levels of purification observed by precipitation using PEG and ammonium 
sulphate were promising however the problem lies with the low step yields attained. 
The  poor  yield  from  the  PEG  precipitation  was  attributed  to  the  difficulties  of 
precipitate  resolubilisation  and  the  loss  of  activity  during  this  step.  As  discussed  in 
Chapter 5, the structural stability of the HBsAg product can be improved by inducing 
HBsAg  maturation  through  intraparticular  disulphide  bond  formations  which  is 
typically accomplished only at the end of the purification process using thiocyanate and 
heat treatment (Zhao et al., 2006). To promote HBsAg stability during precipitation, the 
possibility of operating the HBsAg maturation step prior to PEG precipitation should be 
investigated. This however is provided that the contaminants present do not interfere 
with  the  HBsAg  oxidative  refolding  step  and  that  the  efficiency  of  subsequent 
purification processes are not affected.  
  In the case of ammonium sulphate precipitation, product loss was due to co-
precipitation of HBsAg with lipid contaminants. Further studies to reduce the extent of 
such co-precipitation would be warranted and this may be achievable by optimising the 
conditions during precipitation such as the pH, ionic strength and the use of surfactants. 
The possibility of inducing HBsAg particle maturation prior to ammonium sulphate 
precipitation for increased HBsAg stability could also be explored.   174 
 
8.4.4 Further characterisation of process interactions  
  As demonstrated in Chapter 6, the homogenisation conditions investigated have 
shown  significant  impacts  on  the  recovery  of  active  HBsAg  and  the  level  of  lipid 
contaminants. In the HBsAg study, homogenisation pressure conditions were varied but 
other homogenisation parameters such as the number of passes and the design of the 
homogeniser  such  as  the  “impact”  distance  and  the  valve  seat  geometry  were 
maintained as constants. Further studies should be extended to characterise these other 
parameters,  in  particular,  the  number  of  homogenisation  passes  which  would  have 
significant impact on the degree of cell breakage and the population size of the resulting 
cell debris. These factors would in turn affect the level of HBsAg recovery and the 
surface area available for co-extraction of membrane-derived lipids and proteins during 
the detergent step. These studies could be particularly valuable in further enhancing the 
efficiency of the selective product recovery methodology.  
  Significant levels of purification and product enrichment was attained using the 
selective  recovery  methodology.  With  the  level  of  purification  achieved  using  this 
primary  purification  strategy  it  may  be  possible  to  reduce  the  number  of 
chromatographic  operation  downstream.  To  assess  this,  further  studies  would  be 
required  to  gain  better  understanding  of  process  interactions  between  primary 
purification and chromatographic stages.  
 
8.4.5 Economic appraisal to complement process development efforts 
Improvement  in  purification  is  usually  at  the  expense  of  product  yield  as  is 
apparent from the results in Chapters 5-7. Also, the development or modification of 
processes could have significant impacts on processing times and costs especially when 175 
 
additional unit operations are incorporated. An economic evaluation is useful in such 
cases to set the boundaries for process development. Similarly, economic assessments 
should  be  extended  to  the  HBsAg  primary  purification  study  to  evaluate  more 
comprehensively the overall benefits of the proposed processes. This is especially in 
line  with  the  goal  of  developing  processes  which  are  practical  and  scalable  for 
commercial manufacturing.  
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